Methods and compositions for treating zellweger spectrum disorder by base editing

Adenine base editing corrects PEX1-p. G843D mutations in Zellweger spectrum disorders, effectively restoring peroxisome function and alleviating symptoms with minimal off-target effects.

WO2026236611A1PCT designated stage Publication Date: 2026-11-12THE BROAD INST INC +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027271
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is no cure for Zellweger spectrum disorders (ZSD) caused by PEX1-p. G843D (c.2528G> A) mutations, leading to severe symptoms such as liver abnormalities, intellectual disabilities, and progressive vision and hearing loss.

Method used

Adenine base editing (ABE) using ABE7.10, ABE8e, or ABE8e-V106W, combined with a guide RNA, is employed to correct the PEX1-p. G843D (c.2528G> A) mutation, restoring peroxisome function and alleviating associated symptoms.

Benefits of technology

Up to 60% allele correction in the liver of mouse models and over 80% correction in patient-derived fibroblasts, restoring peroxisome biogenesis and normalizing liver pathologies, with minimal off-target editing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027271_12112026_PF_FP_ABST
    Figure US2026027271_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides methods for correcting PEX1 mutations (e.g., a PEX1-G843D (c.2528G>A) mutant allele) linked to Zellweger spectrum disorder that use adenine base editors. The disclosure provides compositions and methods, including adenine base editors (ABEs), guide RNAs, complexes, nucleic acid molecules, vectors, delivery systems, and pharmaceutical compositions aimed at targeting PEX1 mutations.
Need to check novelty before this filing date? Find Prior Art

Description

METHODS AND COMPOSITIONS FOR TREATING ZELLWEGER SPECTRUM DISORDER BY BASE EDITINGRELATED APPLICATIONS

[0001] This application claims priority under 35 U. S. C. § 119(e) to U. S. Provisional Application, U. S. S. N. 63 / 803,378, filed May 9, 2025, which is incorporated herein by reference.GOVERNMENT SUPPORT

[0002] This invention was made with government support under Grant Nos. AI142756, HG009490, and GM 118062 awarded by the National Institutes of Health. The government has certain rights in the invention.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0003] The contents of the electronic sequence listing (B119570208WO00-SEQ-TNG.xml; Size: 256,390 bytes; and Date of Creation: May 6, 2026) are herein incorporated by reference in their entirety.BACKGROUND

[0004] The Zellweger spectrum disorders (ZSD) encompass a significant group of peroxisome biogenesis disorders, which are inherited in an autosomal recessive manner. These disorders are marked by extensive tissue damage, particularly affecting the nervous system. Within this spectrum, Zellweger syndrome (ZS) represents the most severe manifestation, while neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD) display progressively milder symptoms. The majority of cases within the Zellweger spectrum are linked to mutations in the PEX1 gene. This gene encodes a 143-kDa AAA ATPase protein that plays a critical role in the formation and maintenance of peroxisomes as it is an essential component of the PEX1-PEX6-PEX26 exportomer complex, which is required for peroxisome assembly. The identified mutations in PEX1 include a variety of alterations, such as insertions, deletions, nonsense mutations, missense mutations, and splice site mutations. There is no cure and treatment generally involves managing symptoms, e.g. pharmaceutical management of seizures.

[0005] A prevalent PEX1 mutation associated with ZSD is the loss-of-function mutant PEXl-p. G843D (c.2528G> A), which represents approximately 30% of all ZSD alleles10(see 1 / 149B1195.70208WO00#15198909v2FIG. 1A). Consistent with its residual activity, patients with at least one PEXl-p. G843D allele typically show milder clinical phenotypes and a more degenerative course of disease compared to patients with two null PEX1 gene alleles, who commonly do not survive beyond the first year of life10 13. Patients who are compound heterozygous for the PEXl-p. G843D allele and a null PEX1 allele commonly display hepatomegaly, coagulation defects, and liver abnormalities that can lead to frequent hospitalizations and a shortened lifespan13 L\ Additionally, they can show progressive vision and hearing loss, intellectual disabilities, osteopenia, kidney stones, adrenal insufficiency, and amelogenesis imperfecta (Al)1 17. Patients who are homozygous for the PEX7-p. G843D allele commonly show a milder course of degenerative disease that typically results in progressive vision and hearing loss and Al with hepatomegaly, coagulation defects, and adrenal insufficiency in some individuals13 18.

[0006] Given the lack of treatments, additional options for ZSD therapy would therefore represent a significant advancement in the art. In particular, a genetic therapy option for correcting PEXl-p. G843D (c.2528G> A) mutations would be particularly advantageous given its prevalence in ZSD.SUMMARY

[0007] The present disclosure relates, in part, to the discovery that adenine base editing is an effective approach for correcting PEX7-p. G843D (c.2528G> A) mutations as a treatment for Zellweger spectrum disorders (ZSD) in humans. In a particular embodiment, the present disclosure relates to the use of ABE7.10, ABE8e, or ABE8e-V106W for correcting a PEX1-p. G843D (c.2528G> A) mutation as a treatment for Zellweger spectrum disorders (ZSD) in a human. In another particular embodiment, the present disclosure relates to the use of an ABE and a guide RNA comprising a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113) and has a corresponding RNA spacer sequence of 5'-GUUGAUGGGUUACAUGAAGUU-3' (SEQ ID NO: 114) for correcting a PEX7-p. G843D (c.2528G> A) mutation as a treatment for Zellweger spectrum disorders (ZSD) in a human.

[0008] Thus, as described herein, the present disclosure provides adenine base editing compositions — including; (i) adenine base editors (ABEs), such as ABE7.10, ABE8e, and ABE8e-V106W; (ii) guide RNAs effective for targeting and correcting PEX7-p. G843D (c.2528G> A) mutations, such as a guide RNA comprising a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113); (iii)2 / 149B1195.70208WO00#15198909v2complexes comprising ABEs (e.g., ABE7.10, ABE8e, or ABE8e-V106W) and guide RNAs (e.g., a guide RNA comprising a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113)) which are effective for targeting and correcting PEX7-p. G843D (c.2528G> A) mutations; (iv) nucleic acid molecules encoding ABEs (e.g., ABE7.10, ABE8e, or ABE8e-V106W) and guide RNAs effective for targeting and correcting PEX7-p. G843D (c.2528G> A) mutations (e.g. a guide RNA comprising a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3’ (SEQ ID NO: 113)); (v) vectors and / or delivery systems comprising nucleic acid molecules encoding ABEs and guide RNAs effective for targeting and correcting PPX / -p. G843D (c.2528G> A) mutations; (vi) cells and tissues comprising ABEs (e.g., ABE7.10, ABE8e, or ABE8e-V106W) and guide RNAs targeting PE -p. G843D (c.2528G> A) mutations and / or comprising nucleic acid molecules encoding such ABEs and guide RNAs effective for targeting and correcting PE -p. G843D (c.2528G> A) mutations; (vii) pharmaceutical compositions and kits comprising ABEs (e.g. ABE7.10, ABE8e, or ABE8e-V106W) and guide RNAs effective for targeting and correcting PPX / -p. G843D (c.2528G> A) mutations or nucleic acid molecules encoding such ABEs and guide RNAs effective for targeting and correcting PPX / -p. G843D (c.2528G> A) mutations or delivery systems / vectors comprising nucleic acid molecules encoding such ABEs and guide RNAs effective for targeting PEX1-p. G843D (c.2528G> A) mutations; and (viii) methods of correcting one or more PEX1-p. G843D (c.2528G> A) mutations under in vivo, ex vivo, or in vivo conditions using the herein disclosed ABEs (e.g. ABE7.10, ABE8e, or ABE8e-V106W), guide RNAs (e.g. a guide RNA comprising a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113)), and compositions and / or vectors comprising or encoding same.

[0009] Zellweger spectrum disorder (ZSD) is a disease continuum caused by biallelic loss-of-function mutations in PEX genes, which are required for peroxisome biogenesis. The PEX1-p. G843D (c.2528G> A) allele, present in approximately 30% of ZSD patients, causes degenerative forms of disease resulting in liver abnormalities, intellectual disabilities, and progressive vision and hearing loss. Presented herein is the development and application of an adenine base editing strategy to correct PEX7-p. G843D (c.2528G> A) mutations. In one aspect, the invention was demonstrated by correcting the corresponding allele in a homozygous PE’X7-p. G844D ZSD mouse model through systemic delivery of AAV9 encoding ABE8e-V106W into both neonatal and 4-week-old mice. This approach achieved3 / 149B1195.70208WO00#15198909v2up to 60% allele correction in the bulk liver, which is consistent with the correction of the PEX7-p. G843D (c.2528G> A) mutation in the vast majority of hepatocytes. In the mouse model, this correction restored peroxisome functions, eliminated toxic C27-bile acid intermediate accumulation, rescued liver pathologies, and normalized body weights. In addition, correction of PEX7-p. G843D (c.2528G> A) mutation by base editing was demonstrated in patient-derived fibroblasts. This approach resulted in the correction of >80% of PEXl-p. G843D alleles and restored peroxisome biogenesis. In addition, genome-wide experimental and computational off-target analysis found minimal off-target editing in mouse and human genomes. These data demonstrate that base editing can therefore be viably used to correct PEX7-p. G843D (c.2528G> A) mutations, thereby benefiting ZSD patients.

[0010] Adenine base editing (ABE) is a system capable of converting A T base pairs to G-C base pairs (or T A base pairs to C-G base pairs) at specific locations in the genome without the formation of double- stranded DNA breaks. ABEs comprise a nucleic acid-programmable DNA-binding domain (such as a Cas9 nickase) fused to an adenosine deaminase, and this fusion enables modularity to expand the editor’s scope. ABEs have been used with a variety of Cas domains to change both the editing window and PAM preference. These modifications more precisely position the target base for deamination and prevent editing of unwanted bystander bases. The deaminase domain can be similarly interchanged to narrow or broaden the editing window, increase enzyme efficiency, or reduce Cas domain-independent deamination events. Presented herein is the ABE- mediated correction of PPX / -p. G843D (c.2528G> A) mutations as a genetic editing ZSD, thereby demonstrating that ABE editing may be used as a treatment for ZSD or symptoms thereof. In particular embodiments, the ABEs are ABE7.10, ABE8e, or ABE8e-V106W, and the guide RNA comprises a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113)), and compositions and / or vectors comprising or encoding same.

[0011] The present method describes a strategy for correcting a PEX1-G843D (c.2528G> A) mutant allele within the PEX1 gene. This approach involves the introduction of an adenine base editor, along with a guide RNA (gRNA) specifically designed to target the PEX1-G843D (c.2528G> A) mutant allele. The goal of this method is to convert an A T base pair to a G-C base pair, ultimately resulting in the generation of a corrected PEX1 allele. The adenine base editor employed can be ABE7.10, ABE8e, or ABE8e-V106W, and the gRNA may contain a spacer sequence of 5'-GUUGAUGGGUUACAUGAAGUU-3' (SEQ ID NO: 114).4 / 149B1195.70208WO00#15198909v2

[0012] In some embodiments, the human PEX1 gene may consist of the nucleotide sequence represented by SEQ ID NO: 127. Additionally, this gene encodes an amino acid sequence denoted by SEQ ID NO: 123. The PEX1-G843D (c.2528G> A) mutant allele may be characterized by a nucleotide sequence of SEQ ID NO: 128 and encodes the PEX1-G843D variant, which comprises an amino acid sequence of SEQ ID NO: 124. The adenine base editor can also be specified as ABE7.0, ABE8e, ABE8e-V106W, Sauri-ABE8e-V106W, SaKKH-ABE8e-V106W, eNme2-ABE8eV106W, or Cj-ABE8e-V106W, each having a sequence corresponding to SEQ ID NOs: 101-103 and 109-112.

[0013] The disclosure also provides for the utilizing of a split adenine base editor that consists of both an N-terminal and a C-terminal portion. In this context, the N-terminal portion can include an N-intein, while the C-terminal portion may consist of a C-intein. Specific examples of split adenine base editors that can be employed include split ABE7.10, split ABE8e, and split ABE8e-V106W. The N-intein and C-intein can also be defined by their respective nucleotide sequences, each corresponding to SEQ ID NOs: 133-134.

[0014] The adenine base editor and gRNA can be encoded on one or more polynucleotides, which can be delivered through various delivery systems. These systems may be viral vectors, such as AAV vectors or lentivirus vectors, or non-viral vectors, including virus-like particles (VLPs) or nanoparticles. The nanoparticles can further be categorized as lipid nanoparticles (LNPs), polymeric nanoparticles, inorganic nanoparticles, liposomes, or nano structured lipid carriers.

[0015] This method holds therapeutic potential, particularly in treating Zellweger spectrum disorder or alleviating symptoms associated with a PEX1 mutant allele in a subject.Symptoms may include liver abnormalities, intellectual disabilities, peroxisome dysfunction, vision loss, hearing loss, toxic bile acid intermediate accumulation, and increased body weight. The correction achieved through this method can be quantified, with the potential to correct at least 50%, 55%, 60%, 65%, 70%, 75%, or even 80% of the PEX1 mutant allele.

[0016] The contacting step of the method can be performed within a cell, either ex vivo or in vivo. In cases where the method is applied in vivo, the subject can be a human.

[0017] A complex designed for the correction of the PEX1-G843D (c.2528G> A) mutant allele comprises the adenine base editor and gRNA targeting the specific mutant allele. This complex is capable of converting an A T base pair to a G-C base pair, leading to the creation of a corrected PEX1 allele. Variants of the adenine base editor, including ABE7.10, ABE8e,5 / 149B1195.70208WO00#15198909v2and ABE8e-V106W, can be utilized within this complex, which may also include split adenine base editors.

[0018] The complex, along with the gRNA, polynucleotides, and vectors, can be combined into pharmaceutical compositions for therapeutic use. These may be administered in various forms, including cells containing the complex, kits with the necessary components, and as part of a medicament for treating Zellweger spectrum disorder or related conditions.

[0019] Finally, the use of the complex in the manufacture of a medicament is particularly significant for treating conditions linked to the PEX1 mutant allele, with specific emphasis on liver abnormalities, intellectual disabilities, vision loss, hearing loss, peroxisome dysfunction, toxic bile acid intermediate accumulation, and increased body weight.BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0021] FIGs. 1A-1G show an assessment of adenine base editing strategies to correct PEX1-p. G843D in cultured patient fibroblasts and PPX / -p. G844D in heterozygous mice. FIG. 1A shows a distribution of Zellweger spectrum disorder (ZSD) pathogenic variants among PEX genes10. FIG. IB shows a strategy for the use of SpCas9 adenine base editors (ABEs) to correct the human PEX7-p. G843D c.2528 G> A and the mouse PPX / -p. G844D c.2531 G> A pathogenic variants. Synonymous and non- synonymous bystander edits are shown, and protospacer sequences are underlined. FIG. 1C shows an assessment of adenine base editing in human patient-derived PEX7G843D / G843Dfibroblasts. Editing efficiency was measured 3 days after electroporation via high-throughput sequencing (HTS). FIG. ID shows a schematic of dual-AAV9 vectors for in vivo delivery of ABE8 variants. FIG. IE shows a schematic of facial vein injection of Pl PEX1G844D / +heterozygous mice with AAV9-ABE vectors to correct the PPX / -p. G844D pathogenic allele. FIG. IF shows base editing efficiencies quantified via HTS and CRISPRESSO®278analysis of liver samples from vehicle (saline, n = 10)- or ABE-treated PPX / -p. G844D heterozygous mice (ABE8e 4x1010 vg n = 7; ABE8e 4x109 vg n = 7; ABE8e-V106W 4x1011 vg n = 5; ABE8e-V106W 4x1010 vg n = 6; ABE8e-V106W 4x109 vg n = 5). The adenines within and near the protospacer are shown. Dots indicate values for n=3 independent replicates (FIG. 1C) and individual mice (>5 mice)6 / 149B1195.70208WO00#15198909v2(FIG. IF). Bars reflect the mean of individual values. Base editing efficiencies shown reflect the frequency of the intended base editing outcome with no indels. Error bars show standard deviation unless otherwise specified. FIG. 1G shows clinical analysis of PEX1 -p. G843D patients liver diseases. Patients were categorized into three groups: normal liver, liver dysfunction, and severe liver disease. 21 patients are PEX1 -p. G843D homozygotes and 31 patients are PEX7-p. G843D compound heterozygotes.

[0022] FIGs. 2A-2F show that AAV9-ABE8e-V106W treatment of PEX7G844D / G844Dneonatal mice rescues growth, peroxisome biochemical functions, and liver steatosis. FIG. 2A shows Kaplan-Meier survival curves for WT mice (n = 19; 9 females, 10 males) and PEX1G844D / G844Dmice treated with vehicle (n = 21; 12 females, 9 males), or AAV9-ABE8e-V106W at IxlO11vg (n = 18; 9 females, 9 males), 4xlO10vg (n = 13; 7 females, 6 males), or IxlO10vg (n = 18; 8 females, 10 males) per mouse. FIG. 2B shows growth curves for AAV9-and vehicle-treated mice. Growth is represented by mean + SEM of body weight for male and female mice in each experimental group. FIG. 2C shows quantification of editing efficiencies. Editing efficiencies were measured via HTS analysis for vehicle- (n = 4) or AAV9-ABE8e-V106W-treated mice at IxlO11vg (n = 5), 4xlO10vg (n = 3), and IxlO10vg (n = 4). The adenines within and near the protospacer were analyzed and plotted. FIG. 2D shows a peroxisome biogenesis assessment. Automated western blot analysis of ATP binding cassette subfamily D member 3 (ABCD3) was performed using liver tissue homogenates of six- and 16- week-old PEX1+I+mice, PEX7G844D / G844Dmicetreated with vehicle, or PEX7G844D / G844Dmice treated with ABE AAV (WT n = 5; and PEX7G844D / G844Dtreated with vehicle n = 4; IxlO11vg n = 5; 4xlO10vg n = 2; IxlO10vg n = 3) and 16 weeks (WT n = 5; and PEX7G844D / G844Dtreated with vehicle n = 5; IxlO11vg n = 4; 4xlO10vg n = 3; IxlO10vg n = 5). The peak area measured for ABCD3 was normalized to total protein levels, and the relative fold-change was calculated using wild- type (WT) PEX1+I+as reference. Statistical analysis performed by two-way ANOVA and Sidack’s multiple comparison test. FIG. 2E shows a lipid profile of liver samples. Lipids from liver samples collected at six and 16 weeks of age were quantified by GC / MS. The fold-change in observed signal for each lipid was calculated relative to the corresponding average for vehicle-treated PEX1+I+mice. The foldchange in abundance of each lipid is represented in volcano plots. The gray and dark gray dotted lines represent 2-fold lower and 2-fold higher change in lipid abundance, respectively. On the y-axis, the black dashed line represents a p-value of 0.05. P-values were calculated relative to vehicle-treated PEX1+I+samples by Dunn’s non-parametric many-to-one7 / 149B1195.70208WO00#15198909v2comparison test for Kruskal-type ranked data. FIG. 2F shows a histological analysis of lipid content in liver sections. Lipid content in liver sections was assessed by Oil-Red O (ORO) staining. Representative images of ORO staining in liver at six and 16 weeks of age in vehicle-treated PEX1+I+mice, PEX7G844D / G844Dmice, or ABE8e-V106W-treated PEX7G844D / G844Dmice injected with IxlO11vg, 4xlO10vg, or IxlO10vg per mouse (WT n = 9; and PEX7G844D / G844Dtreated with vehicle n = 10;, IxlO11vg n = 9; 4xlO10vg n = 5; IxlO10vg n = 7) and 16 weeks (WT n = 10; and PEX7G844D / G844Dtreated with vehicle n = 10;, IxlO11vg n = 7; 4xlO10vg n = 8; IxlO10vg n = 9). Representative images captured at 5x magnification, with insets at lOx magnification. The scale bar represents 100 pm. N = 9-10 mice by experimental group. Statistical analysis performed by two-way ANOVA and Sidack’s multiple comparison test. Values were considered statistically significant if p < 0.05 compared to vehicle-treated PEX7G844D / G844Dmiceforeach corresponding time point. Dots indicate values for individual mice in FIGs. 2C, 2D, and 2F. In FIG. 2E, each dot represents the value for an individual lipid. The dots in FIG. 2B represents the mean of the body weight. Bars reflect the mean of the treated samples in FIGs. 2C, 2D, and 2F. Error bars represent the standard deviation (FIG. 2C) or the standard error of mean (SEM) (FIGs. 2B, 2D, and 2F). Numbers above pairs of bars indicate p values using the statistical method specified above.

[0023] FIGs. 3A-3D show transcriptome and pathway analysis on ABE8e-V106W treated PEX7G844D / G844Dneonatal mouse liver tissues. FIG. 3A shows hierarchical cluster analysis of differentially expressed genes among vehicle-treated WT PEX1+I+mice (6 weeks n = 4; 16 weeks n = 3), vehicle-treated PEX7G844D / G844Dmice(g weeks n = 3; 16 weeks n = 4), and AAV9-ABE8e-V106W treated PEX7G844D / G844Dmice(IxlO11vg: 6 weeks n = 4, 16 weeks n = 4; 4xl010vg: 6 weeks n = 4, 16 weeks n = 4; IxlO10vg: 6 weeks n = 7, 16 weeks n = 4). Samples are from mouse livers harvested six weeks and 16 weeks post- injection. F = female mouse; M = male mouse. FIG. 3B shows the fold-change (FC) of 20 (Abcc4, Acot2, Apes, Areg, Arhgef2, Cd63, Cyp4al0, Cyp4a31, Ehhadh, Gpat3, Gstal, Gstm3, Lonpl, Mtl, Mt2, Npdcl, Nuprl, Rtn4, Sox4, and Trib3) differentially expressed genes relevant to liver injury, fibrosis, and carcinoma in a heatmap. FC was quantified using the mean value of gene expression for each treatment condition. The mean value for each gene in WT or ABE-treated PEX7G844D / G844Dwas then divided by vehicle-treated PEX7G844D / G844D. All the treatment conditions including vehicle-treated wild-type (WT) mice PEXl+,+,mice, and AAV9-ABE8e-V106W treated PEX7G844D / G844Dmice (lxl0nVg, 4xl010vg, and IxlO108 / 149B1195.70208WO00#15198909v2vg) were analyzed. FIG. 3C shows histological analysis of glycogen in liver sections.Periodic acid-Schiff (PAS) staining was performed to detect glycogen deposits.Representative images of ORO staining in liver at six and 16 weeks of age in vehicle-treated PEX1+I+mice (n = 10), PEX7G844D / G844Dmice(g weeks n = 10; 16 weeks n = 11), or ABE8e-V106W-treated PEX7G844D / G844Dmiceinjected with IxlO11vg, 4xlO10vg, and IxlO10vg per mouse (IxlO11vg: 6 weeks n = 9; 16 weeks n = 7; 4xlO10vg: 6 weeks n = 4; 16 weeks n = 8; IxlO10vg: 6 weeks n = 8; 16 weeks n = 9). Representative images captured at 20x magnification; scale bar, 50 pm. FIG. 3D shows quantification of PAS staining. The average percentage of ORO- stained area was calculated over three random regions of interest captured at lOx magnification for each liver section. Data indicate individual mice (FIGs. 3A-3D). In FIG. 3D, each dot represents individual mouse sample (>4 mice). At least four randomly selected liver samples from injected mice were used for the RNA-seq analysis in FIGs. 3A and 3B. Error bars represent SEM in FIG. 3D. Numbers above pairs of bars indicate p values using the statistical method specified above.

[0024] FIGs. 4A-4H show therapeutic base editing in young ppx / G844D / G844Dmice. FIG. 4A shows a schematic of retro-orbital injection of four- week-old PEX1G844D / G844Dhomozygous mice with AAV9-ABE8e-V106W (5xlOnvg per mouse) to correct the PEX1 p. G844D pathogenic allele. WT PEX1+I+(n = 6) and PEX7G844D / G844D(n= 5) injected with vehicle (saline), were used as controls. The dose was 5xlOnvg / mouse, equivalent to the effective dose used in previous neonatal experiments (IxlO11vg / mouse or 7xlOnvg / kg). All mice were randomized from multiple litters and assigned to each group in a N=6, mixed sex. FIG.4B shows Kaplan-Meier survival curves for all the ABE AAV9- or vehicle-treated mice, following injection of 4- week-old PEX7G844D / G844Dmice (n = 7; 4 females, 3 males) with AAV9-ABE8e-V106W (5xlOnvg per mouse) to correct the PE 7-p. G844D pathogenic allele and WT (n = 6; 3 females, 3 males) and PEX7G844D / G844D(n = 6, 3 females, 3 males) with vehicle served as controls. FIG. 4C shows growth curves for female and male AAV9-ABE-treated and vehicle-treated mice (n as in FIG. 4B). Growth is represented by mean ± SEM of body weight for female and male mice in each experimental group.PEX7G844D / G844Dtreated mice with AAV9-ABE8e-V106W and vehicle were compared by 2-way ANOVA and Sidak multiple comparison test, * p<0.05, ** p<0.01 for the comparison of the PEX7G844D / G844Dtreated with ABE8e-V106W AAV9 to the WT PEX1+I+treated with vehicle; # p<0.05, ## p<0.01 for the comparison of the PEX7G844D / G844Dtreated with vehicle to the WT PEX1+I+treated with vehicle. All mice received a gel diet supplementation during9 / 149B1195.70208WO00#15198909v2neonatal stage and were removed at 8 weeks of age for males and six weeks of age for females. FIG. 4D shows quantification of editing efficiencies. Editing efficiencies were measured via HTS and CRISPRESSO®2 analysis for vehicle- or ABE8e-V106W-treated mouse liver samples (n as in FIG. 4B). The adenines modified within and near the protospacer were analyzed and plotted. FIG. 4E shows a peroxisome assembly assessment. Automated Western blot analysis of ABCD3 was performed using liver tissue homogenates of 16-week-old PEX1+I+mice treated with vehicle (n = 5), ppx / GS44D / GS44l)mice treated with vehicle (n - 6), or p xG844D / G844Dmjcetreated with ABE AAV (n - 7). The peak area measured for ABCD3 was normalized to total protein levels, and the relative fold-change was calculated using wild-type (WT) PEX1+I+as reference. Statistical analysis performed by two-way ANOVA and Sidack’s multiple comparison test. FIG. 4F shows lipid profile of plasma and liver samples. Lipids were identified by GC / MS on plasma (collected when mice are 10-week and 16- week old) and liver samples (mice are 16- week old). The fold-change in observed signal for each lipid was calculated relative to the corresponding average for vehicle-treated PEX1+I+mice. The fold-change in abundance of each lipid is represented in volcano plots. The gray and dark gray dotted lines represent 2-fold lower and 2-fold higher change in lipid abundance, respectively. On the y-axis, the black dashed line represents a p-value of 0.05. P- values were calculated relative to vehicle-treated PEX1+I+samples by Dunn’s non-parametric many-to-one comparison test for Kruskal-type ranked data (n as in FIG. 4B). FIG. 4G shows analysis of bile acids from ABE-treated, homogenized mouse liver tissue. Measurement of the abundance of 3a,7a,12a-trihydroxycholestanoic acid (THCA), 3a,7a-dihydroxycholestanoic acid (DHCA), and 7a-hydroxy-3-oxo-4-cholestenoic acid (7-HOCA) bile acid intermediates in liver of AAV9-ABE8e-V106W-treated PEX7G844D / G844Dmice (n = 7) and controls WT (n = 6) and £X7G844D / G844D(n= 5) vehicle-treated was plotted. The moles of each bile acid intermediate were normalized by the amount of total protein. FIG. 4H shows a histological analysis of glycogen (PAS) and lipid (ORO) in liver sections. Glycogen and lipid content in liver sections was assessed by PAS and ORO staining, respectively. Representative images of PAS and ORO staining in liver at 16 weeks of age in vehicle-treated PEX1+I+, PEX1G^G^ mice, or ABE8e-V106W-treated PEX7G844D / G844Dmice injected with 5xlOnvg per mouse. Representative images captured at 5x magnification, with insets at lOx magnification. The scale bar represents 100 pm. N = 6 mice by experimental group. Statistical analysis performed by two-way ANOVA and Sidack’s multiple comparison test. Values were considered statistically significant if p < 0.0510 / 149B1195.70208WO00#15198909v2compared to vehicle-treated PEX7G844D / G844Dmiceforeach corresponding time-point. Dots indicate values for individual mice in FIGs. 4D, 4E, 4G, and 4H. In FIG. 4F, each dot represents the value for an individual lipid. The dots in FIG. 4C represent mean body weight. Bars reflect the mean of the treated samples in FIGs. 4D, 4E, 4G, and 4H. Error bars represent standard deviation (FIG. 4D) or SEM (FIGs. 4C, 4E, 4G, and 4H). Dots indicate individual mice, n as in FIG. 4A. Numbers above pairs of bars indicate p values using the statistical method specified above.

[0025] FIGs. 5A-5E show in vivo and in vitro off-target analysis of ABE8e-V106W targeting PEXUPEX1 pathogenic variant. FIG. 5A shows CIRCLE-seq nomination of candidate off-target (OT) sites with the PEY / -p. G844D- targeting guide RNA. Nominated candidate OT sites are listed in order of detected sequencing read number. FIG. 5B shows amplicon sequencing analysis of CIRCLE- seq-nominated OT sites at 6 and 16 weeks posttreatment in liver genomic DNA from EAA / GS44I) / GS44I)mice treated with AAV9-ABE8e-V106W (IxlO11vg) or vehicle (n = 3 per time point). Top 30 OT sites were amplified and sequenced using IxlO11AAV9-ABE8e-V106W treated or vehicle-treated PEX7G844D / G844Dmouse liver genomic DNA (gDNA) of four-week-old PEX7G844D / G844Dmicetreated with AAV9-ABE8e-V106W (5xlOnvg), ABE-LNP, or vehicle. Editing efficiencies were measured by HTS and analyzed with CRISPRESSO®2. n = 3 mice with the highest on-target editing efficiency were used. Editing efficiencies were measured by HTS and analyzed with CRISPRESSO®2. N = 3 mice were randomly selected from the injected cohort. FIG. 5C shows off-target RNA editing in liver transcriptomes at 6 and 16 weeks post-treatment in PEX7G844D / G844Dmice treated with AAV9-ABE8e-V106W at IxlO11vg (n = 4 per time point), 4xlO10vg (n = 4 per time point), or IxlO10vg (6 weeks n = 7; 16 weeks n = 4), and vehicle-treated controls (6 weeks n = 3; 16 weeks n = 4). A-to-G changes upon ABE deamination were analyzed in ABE8e-V106W-treated (IxlO11vg, 4xlO10vg, or IxlO10vg) or vehicle-treated PEX1G844D / G844Dmice liver samples. The percentage of total A-to-G change in the transcriptome was shown. N>3 mice were analyzed. FIG. 5D shows correction of pathogenic P 7PEX7-p. G843D variant in the patient-derived fibroblasts via lentivirus delivery of ABE8e-V106W. Editing efficiencies were measured by HTS and analyzed with CRISPRESSO®2. FIG. 5E shows amplicon sequencing analysis of CIRCLE-seq and CAS-OFFINDER™ nominated OT sites using lentiviral ABE8e-V106W transduced or untreated PEX7PEX7G843D / G843Dfibroblasts. The percentage of A*T-to-G*C change for all the adenines within the protospacer was plotted. Dots indicate values for individual mice in FIGs. 5B and11 / 149B1195.70208WO00#15198909v25C (N>3 mice). In FIGs. 5D and 5E, dots indicate values for individual replicates. Bars reflect the mean allele frequency with the specified change. Two replicates were performed in FIGs. 5D and 5E.

[0026] FIGs. 6A-6B show correction of PE T-p. GS SD allele in patient-derived fibroblasts restores peroxisome function and assessment of compact ABEs for single AAV vector delivery. FIG. 6A shows immunofluorescence analysis of peroxisomal biogenesis in ABE8e-V106W-treated patient derived fibroblasts. Primary anti-catalase and anti- ABCD3 antibodies probing endogenous proteins and secondary antibodies conjugated to fluorophores were used to assess the subcellular localization of peroxisomal proteins in the fibroblast samples treated by PEX7-P. G843D targeting guide or non-specific guide RNA (sgNT) along with editor mRNA. Signals indicate catalase and ABCD3. Nucleus was stained with DAPI. Colocalization of ABCD3 foci and catalase foci indicate the normal peroxisomal function and structure. FIG. 6B shows quantification of editing efficiencies using compact ABEs. Editing efficiencies were measured by HTS and analyzed with CRISPRESSO®2. The adenines within and near the protospacer were analyzed and plotted. The scale bar represents 20 pm. Dots indicate values for individual replicates (N>3) (Sp-ABE8e-V106W n = 3; Sauri-ABE8e-V106W n = 4; SAKKH-ABE8e-V106W n = 4; eNme2-ABE8e-V106W n = 4; Cj-ABE8e-V106W n = 4; Non-targeting control n = 3). in FIG. 6B. Bars reflect the mean of the treated samples in FIG. 6B. Authors who examined the cells using MICA® confocal microscope were blinded to the sample identities of sgNT and PEA7-p. G843D-targeting guide (FIG. 6A).N>50 cells were imaged and analyzed. More than 50 cells were imaged and analyzed from randomly sampled slide areas from three biological replicates. The areas of the glass slide were randomly sampled. Representative images of the examined cells were shown. The scale bar represents 20 pm.

[0027] FIGs. 7A-7F show a characterization of PEX7G844D / G844Dneonatal mice treated with 4 x 1011vg AAV9-ABE8e-V106W editor, related to FIGs. 2A-2F. FIG. 7A shows AAV9-ABE8e-V106W (4xl0nvg per mouse) was delivered via facial vein injection into Pl homozygous PEX7G844D / G844Dmice (n = 63). Vehicle-injected WT PEXl+l+)>mice (n = 40) and PEX7G844D / G844Dmice (n = 52) injected with vehicle (saline) were used as controls. All animals were randomized from multiple litters and N = 40-63 by sex and genotype was assigned to each group. FIG. 7B shows Kaplan-Meier survival curves for WT (n = 20), PexlG844D / G844Dvehicle-treated (n = 21), and PEX7G844D / G844Dmice treated with AAV9-GFP (4xl0nvg per mouse; n = 20) (n as in FIG. 7A). FIG. 7C shows quantification of editing12 / 149B1195.70208WO00#15198909v2efficiencies. Editing efficiencies were measured via HTS analysis for vehicle- (6 weeks n = 20; 16 weeks n = 19) or AAV9-ABE8e-V106W-treated (6 weeks n = 11; 16 weeks n = 8) mouse liver samples at 6 and 16 weeks post-treatment. The adenines within and near the protospacer were analyzed and plotted. Bars reflect the mean of the treated samples and error bars represent the standard deviation, dots represent individual mice. FIG. 7D shows growth curves for AAV9-ABE-treated and vehicle-treated mice. Growth is represented by mean+SEM of body weight for female and male mice (n as in FIG. 7A) in each experimental group. FIG. 7E shows a lipid profile of plasma and liver samples. Lipids were identified by GC / MS on plasma and liver samples collected at six and 16 weeks of age. The fold-change in observed signal for each lipid was calculated relative to the corresponding average for vehicle-treated PEX1+I+mice. The fold-change in abundance of each lipid is represented in volcano plots. The gray and dark gray dotted lines represent 2-fold lower and 2-fold higher change in lipid abundance, respectively. On the y-axis, the black dashed line represents a p-value of 0.05. P-values were calculated relative to vehicle-treated PEX1+I+samples by Dunn’s non-parametric many-to-one comparison test for Kruskal-type ranked data. FIG. 7F shows histological analysis of lipid content in liver sections. Lipid content in liver sections was assessed by Oil-Red O (ORO) staining. Representative images of ORO staining in liver at six and 16 weeks of age in vehicle-treated PEX1+I+mice (6 weeks n = 20; 16 weeks n = 15), PEX7G844D / G844Dmice (6 weeks n = 20; 16 weeks n = 18), or ABE8e-V106W-treated PEX7G844D / G844Dmice (6 weeks n = 11; 16 weeks n = 7) injected with 4xl0nvg per mouse. Representative images captured at 5x magnification, with insets at lOx magnification. The scale bar represents 100 pm. N = 9-10 mice by experimental group. Statistical analysis performed by two-way ANOVA and Sidack’s multiple comparison test. Values were considered statistically significant if p < 0.05 compared to vehicle-treated PEX7G844D / G844Dmice for each corresponding time point. Numbers above pairs of bars indicate p-values using the statistical methods specified above. Bars represent mean ± s.e.m; dots represent individual mice.

[0028] FIGs. 8A-8B show that AAV9-ABE8e-V106W treatment of PPX7G844D / G844Dneonatal mice rescues ZSD phenotypes, related to FIGs. 2A-2F. FIG. 8A shows a schematic of ABE-treatment of homozygous PEX7G844D / G844D. Homozygous PEX7G844D / G844Dmice wereinjected at Pl by facial vein injection with AAV9-ABE8e-V106W at total doses of IxlO11vg (n = 18; 9 females, 9 males), 4xl010vg (n = 13; 7 females, 6 males), or IxlO10vg (n = 18; 8 females, 10 males) per mouse. Wild-type PEX1+I+(n = 19; 9 females, 10 males), and13 / 149B1195.70208WO00#15198909v2PEX7G844D / G844D(n = 21; 12 females, 9 males) mice injected with vehicle were used as control. All animals were randomized from multiple litters, and each group was N = 9-11. FIG. 8B shows a lipid profile of plasma samples. Lipids were identified by GC / MS on plasma samples collected at six and 16 weeks of age. The fold-change in observed signal for each lipid was calculated relative to the corresponding average for vehicle-treated PEX1+I+mice. The fold-change in abundance of each lipid is represented in volcano plots. The gray and dark gray dotted lines represent 2-fold lower and 2-fold higher change in lipid abundance, respectively. On the y-axis, the black dashed line represents a p-value of 0.05. P-values were calculated relative to vehicle-treated PEX1+I+samples by Dunn’s non-parametric many-to-one comparison test for Kruskal-type ranked data.

[0029] FIGs. 9A-9C show an assessment of ABE8e-V106W editing in CNS tissues from the PEX7G844D / G844Dneonatal mice treated with three AAV9 doses at Pl, related to FIGs. 2A-2F. FIG. 9A shows base editing efficiencies quantified via HTS and analyzed with CRISPRESSO®2. Brain cortex tissues were collected from vehicle-treated PEX1+I+mice, vehicle-treated PEX7G844D / G844Dmice, or AAV9-ABE8e-V106W-treated (IxlO11vg, 4xlO10vg, or IxlO10vg dose) PEX7G844D / G844Dmice at 16 weeks. The adenines within and near the protospacer are shown. FIG. 9B shows quantification of base editing efficiencies in the cerebellum tissues as described in FIG. 9A. FIG. 9C shows quantification of base editing efficiencies in the whole eye tissues as described in FIG. 9A. N = 8 mice were assessed for the IxlO11vg AAV9-ABE-V106W dosing group, N = 9 mice were assessed for the 4xlO10vg dosing group, and N = 9 mice were assessed for the IxlO10vg AAV9 dosing group. N = 11 mice were assessed for vehicle (saline) treated PEX7G844D / G844D, and N = 10 mice were assessed for the vehicle-treated PEX1+I+WT mice.

[0030] FIGs. 10A-10B show an analysis of differentially expressed genes in vehicle- or AAV9-ABE8e-V106W-treated compared to vehicle-treated PEX7G844D / G844Dneonatal mice, related to FIGs. 3A-3D. FIG. 10A shows that RNA-seq was performed and analyzed. A false discovery rate (FDR < 1%) was applied to identify differentially expressed genes (DEGs) among vehicle-treated WT PEX1+I+mice, vehicle-treated PEX7G844D / G844Dmice, and AAV9-ABE8e-V106W-treated PEX7G844D / G844Dmice. Volcano plots showed DEGs by comparing different treatment conditions as specified in the plot (PEX7G844D / G844Dtreated with vehicle versus PEX1+I+treated with vehicle, PEX7G844D / G844Dtreated with IxlO11vg ABE AAV versus PEX1+I+treated with vehicle, PEX7G844D / G844Dtreated with 4xl010vg ABE AAV versus PEX1+I+treated with vehicle, and PEX7G844D / G844Dtreated with IxlO10vg versus WT14 / 149B1195.70208WO00#15198909v2from top to bottom). The cutoff was shown as black dashed lines on the plot. RNA-seq was performed using ground liver tissues (N>3 per condition): vehicle-treated WT mice (6 weeks n = 4; 16 weeks n = 3), vehicle-treated PEX1G844D / G844Dmice(g weeks n = 3; 16 weeks n = 4), and AAV9-ABE8e-V106W treated PE TG844D / G844Dmice(ixlO11vg: 6 weeks n = 4, 16 weeks n = 4; 4xlO10vg: 6 weeks n = 4, 16 weeks n = 4; IxlO10vg: 6 weeks n = 7, 16 weeks n = 4). Samples at six weeks post-injection are shown. FIG. 10B shows samples at 16 weeks post-injection were analyzed and plotted as described in FIG. 10A.

[0031] FIGs. 11A-11D show KEGG pathway and phenotype analyses of differentially expressed genes in treated neonatal mouse liver tissues. FIG. 11A shows differentially expressed genes between PEX1+I+treated with vehicle versus ppx / (iS44l) / (iS44l)treated with vehicle six weeks post injection were uploaded to WEBGESTALT™ for gene set analysis. All the categories from KEGG analysis that have FDR < 0.01 significance level (Benjamini-Hochberg method) are shown. Each category must be defined by 10-1000 genes, which eliminates hyper- specialized (<10 genes) or hyper-broad (>1000 genes) categories. FIGs. 11B, 11D show phenotype enrichment analyses. Enrichment ratio is indicated on the x-axis.FIG. 11C shows differentially expressed genes between PEX1+I+treated with vehicle versus PEX7G844D / G844Dtreated with vehicle at 16 weeks post injection were analyzed with the same analysis criteria as six weeks. KEGG pathway analysis is shown.

[0032] FIG. 12 -shows mature bile acids analysis for ABE-AAV9 treated 4-week-old mice.12 weeks after injection, bile acids were extracted from ABE- or vehicle-treated liver tissues from mice treated at 4 weeks of age. Mature C24 bile acids were analyzed by chromatographic separation and mass-spectrometry. Vehicle-treated WT PEX1+I+mice (N=5), vehicle-treated PPX / (|S44I) / (|S44I)mice (N = 5), and AAV9-ABE8e-V106W-treated AV / GS44D / GS44Dmice (N = 6) were analyzed. Numbers above pairs of bars indicate p-values using the statistical method specified above. Twelve weeks post-injection, liver bile acids were extracted from 4-week-old mice treated with ABE-AAV9 or vehicle control. Mature C24 bile acids were analyzed using chromatographic separation and mass spectrometry. Vehicle-treated WT PEX1+I+mice (n=5), vehicle-treated PEX7G844D / G844Dmice(n=5), and AAV9-ABE8e-V106W-treated PEX7G844D / G844D(n=6) were analyzed (shown in FIG. 12). Numbers above pairs of bars indicate p-values calculated using the statistical methods Brown-Forsythe and Welch ANOVA test corrected with the Dunnett comparison. Overall, mature bile acid levels in PEX7G844D / G844Dmjcetreated with the ABE8e-V106W differed from vehicle-treated controls and approached levels observed in wild-type PEX7+ / +mice.15 / 149B1195.70208WO00#15198909v2

[0033] FIGs. 13A-13B show an assessment of ABE8e-V106W editing of the patient-derived fibroblasts and live-cell imaging analysis of peroxisomal assembly, related to FIGs. 6A-6B. FIG. 13A shows two patient-derived fibroblast cell lines — homozygous PEXlG843D / G843Dand compound heterozygous PEXlG843D / 1700fs— were nucleofected with ABE8e-V106W mRNA and a synthetic guide RNA targeting PEX7-p. G843D (c.2528G> A) mutation or a nontargeting guide RNA (sgNT) that does not match any human genome sequence. Editing efficiencies were measured 72-hour post-nucleofection via HTS analysis. The indels and adenines modified near or within the protospacer were analyzed and plotted. N = 2 replicates were performed. FIG. 13B shows that nucleofected cells were confirmed by HTS and passaged. Cells were seeded onto a 24- well plate and then transduced by baculoviral vectors expressing a modified GFP fluorescent protein tethered with a C-terminal peroxisomal targeting signal (PTS1). Live-cell imaging analysis was performed using MICA® confocal microscope. Authors who examined the cells were blinded to the sample identities of sgNT and PEX7-p. G843D-targeting guide during imaging. N>3 replicates were performed and N>30 cells were imaged and analyzed. The scale bar represents 20 pm.

[0034] FIGs. 14A-14B show an assessment of AAV9 viral copies and cortex lipid profiles in AAV9-ABE-treated or vehicle-treated neonatal ZSD mouse liver tissues. FIG. 14A shows N-terminal and C-terminal components of dual AAV9 viral vectors expressing ABE8e-V106W editor were analyzed by droplet digital PCR (ddPCR) (N>4 mice per treatment condition) at 6 and 16 weeks using vector- specific fluorescent probes. All the treatment conditions including vehicle-treated WT PEX7+ / +mice, vehicle-treated PEX7G844D / G844Dmice, and AAV9-ABE8e-V106W-treated PEX7G844D / G844Dmice(with IxlO11vg, 4xl010vg, or IxlO10vg dose per mouse) were analyzed. Liver gDNA was extracted from vehicle-treated WT mice (6 weeks n = 9; 16 weeks n = 10), vehicle-treated PEX7G844D / G844Dmice(gand ig weeks n=10), and AAV9-ABE8e-V106W-treated PEX7G844D / G844Dmice adoses of IxlO11vg (6 weeks n = 9; 16 weeks n = 8), 4xl010vg (6 weeks n = 4; 16 weeks n = 9), or IxlO10vg (6 weeks n = 7; 16 weeks n = 9) per mouse. Bars represent mean ± s.e.m.; dots indicate individual mice.FIG. 14B shows a lipid profile of brain cortex samples. Lipids were identified by GC / MS on cortex samples collected at six and 16 weeks of age. The fold-change in observed signal for each lipid was calculated relative to the corresponding average for vehicle-treated PEX1+I+mice. The fold-change in abundance of each lipid is represented in volcano plots. The gray and dark gray dotted lines represent 2-fold lower and 2-fold higher change in lipid abundance, respectively. On the y-axis, the black dashed line represents a p-value of 0.05. P-16 / 149B1195.70208WO00#15198909v2values were calculated relative to vehicle-treated PEX1+I+samples by Dunn’s non-parametric many-to-one comparison test for Kruskal-type ranked data.

[0035] FIG. 15 shows reduced branched fatty acid content in PexlG844D / G844Dneonatal mice treated with AAV9-ABE8e-V106W editor and shows representative branched-chain fatty acids, very long-chain fatty acids, and plasmalogens in lipid analyses. Homozygous mice were injected at Pl by facial vein injection with AAV9-ABE8e-V106W at multiple doses: IxlO11vg (total dose), 4xlO10vg, or IxlO10vg. Wild-type Pexl+ / +, and PexlG844D / G844Dmice injected with saline vehicle were used as control. All animals were randomized from multiple litters and N = 5-6 (equal balanced sex) was assigned to each group. Lipid profile was analyzed by mass spectrometry (GC / MS) at six and 16 weeks post- injection in plasma and liver samples. Data for branched fatty acids is represented as bar graphs with the mean+SEM, and dots represent each individual mouse. Group comparisons were analyzed by Kruskal-Wallis test and Dunn’s multiple comparisons test. The adjusted p value is reported. Data pertaining to the levels of the branched-chain fatty acid species, phytanic and pristanic acid, were replotted from volcano plots to individual bar graphs for improved clarity. Following ABE-AAV9 treatment, the previously elevated phytanic and pristanic acid in the PPY / GS44I) / GS44I)mice were fully restored to wild- type levels in both plasma and liver at 16 weeks post-injection. Liver data were collected at 6 and 16 weeks. At 6 weeks, wild-type mice (n=6), P£X / G844D / G844Dmicetreated with vehicle (n=6), and P£X / G844D / G844Dmicetreated with ABE-MV9 at doses of IxlO11vg (n=5), 4xlO10vg (n=4), or IxlO10vg (n=4) were analyzed. At 16 weeks, wild- type mice (n=6), PEX7G844D / G844Dmicetreated with vehicle (n=6), and PEX7G844D / G844Dmicetreated with AAV at doses of 1 xlO11vg (n=7), 4xlO10vg (n=7), or IxlO10vg (n=9) were analyzed using Kruskal-Wallis test corrected with the Dunn’s multiple comparisons. Plasma data were also collected at 6 and 16 weeks. At 6 weeks, wildtype mice (n=5), PEX7G844D / G844Dmicetreated with vehicle (n=5), and PexPEX7G844D / G844Dmice treated with MV at doses of lxlOnvg (n=6), 4xlO10vg (n=4), or 1 xlO10vg (n=4) were analyzed. At 16 weeks, wild-type mice (n=5), P£X / G844D / G844Dmicetreated with vehicle (n=4), and PEX7G844D / G844Dmicetreated with AAV at doses of 1 xlO11vg (n=7), 4xlO10vg (n=8), or 1 xlO10vg (n=9) were analyzed using Kruskal-Wallis test corrected with the Dunn’s multiple comparisons.

[0036] FIG. 16 shows that hepatic VLCFA content is reduced in PEX1G844D / G844Dneonatal mice treated with AAV9-ABE8e-V106W editor. Homozygous mice were injected at Pl by facial vein injection with AAV9-ABE8e-V106W at multiples doses: IxlO11vg (total dose),17 / 149B1195.70208WO00#15198909v24xlO10vg, or IxlO10vg. Wild-type PEXl+,+and £xiG844D / G844Dmiceinjected with saline vehicle were used as control. All animals were randomized from multiple litters, and N = 5-6 (equal balanced sex) was assigned to each group. Lipid profile was analyzed by mass spectrometry (GC / MS) at six and 16 weeks post-injection in plasma and liver samples. Data for VLCFA C26:0 and C26:l is represented as the mean+SEM, and dots represent each individual mouse. Group comparisons were analyzed by Kruskal-Wallis test and Dunn’s multiple comparisons test. The adjusted p value is reported. Data pertaining to the levels of two very long-chain fatty acids (VLCFAs), C26:0 and C26:l, as well as C26:0-lysophosphatidylcholine (LPC) was plotted in bar graphs for improved clarity. Elevated C26:0 and C26:l VCLFA levels in the PEX1G844D / G844Dmice wererestored to at or near wildtype level in the liver 16 weeks after ABE-AAV9 treatment. In contrast, elevated plasma C26:0 levels in the ppxiG844D / G844Dmice were not substantially changed at 16 weeks after ABE-AAV9 treatment. However, elevated plasma C26:l levels in the ppxiG844D / G844Dmice were substantially reduced to near wild-type levels 16 weeks after ABE-AAV9 treatment. For C26:0 and C26:l analyses, liver and plasma samples were collected at 6 and 16 weeks. At 6 weeks, liver data included wild-type mice (n=6), P X\G844D / G844Dmice treated with vehicle (n=7 for C26:0; n=6 for C26:l ), and ppxiG844D / G844Dmice treated with AAV at doses of 1 xlO11vg (n=6 for both), 4xlO10vg (n=4 for both), or 1 xlO10vg (n=3 for C26:0; n=4 for C26:l ). At 16 weeks, liver data included wild-type mice (n=6), ppxiG844D / G844Dmicetreated with vehicle (n=6 for both), and PEX1G844D / G844Dmicetreated with AAV at doses of 1 xlO11vg (n=7 for both), 4xlO10vg (n=7 for both), or IxlO10vg (n=9 for both). Plasma data at 6 weeks included wild- type mice (n=5), P X \G844D / G844Dmicetreated with vehicle (n=5 for both), and ppxiG844D / G844Dmicetreated with AAV at doses of 1 xlO11vg (n=6 for both), 4xlO10vg (n=4 for both), or 1 xlO10vg (n=4 for both). At 16 weeks, plasma data included wild-type mice (n=5 for C26:0; n=6 for C26:l), ppxiG844D / G844Dmicetreated with vehicle (n=4 for C26:0; n=6 for C26:l), and ppxiG844D / G844Dmicetreated with AAV at doses of 1 xlO11vg (n=7 for both), 4xlO10vg (n=8 for C26:0; n=7 for C26:l), or IxlO10vg (n=9 for both). Data were analyzed using Kruskal-Wallis test corrected with the Dunn’s multiple comparisons.

[0037] FIG. 17 shows C26:0-LPC content is not corrected in p / / y|GS44I) / GS44I)neonatal mice treated with AAV9-ABE8e-V106W editor. Homozygous mice were injected at Pl by facial vein injection with AAV9-ABE8e-V106W at multiples doses: IxlO11vg (total dose), 4xlO10vg, or IxlO10vg. Wild-type PEX1+I+, and PEX7G844D / G844Dmice injected with saline vehicle18 / 149B1195.70208WO00#15198909v2were used as control. All animals were randomized from multiple litters, and N = 5-6 (equal balanced sex) was assigned to each group. C26:0-LPC content was analyzed by mass spectrometry (GC / MS) at six and 16 weeks post-injection in plasma and liver samples. Data is represented as the mean+SEM, and dots represent each individual mouse. Group comparisons were analyzed by Kruskal-Wallis test and Dunn’s multiple comparisons test. The adjusted p value is reported. ABE-AAV9 treatment did not rescue C26:0-LPC levels in plasma or liver which may reflect the turnover kinetics of VLCFAs in specific membrane lipids relative to those of total free and esterified VLCFAs present in all lipids, also including triglycerides. For C26 LPC analyses, liver and plasma samples were collected at 6 and 16 weeks. At 6 weeks, liver samples included wild-type mice (n=7), £X7G844D / G844Dmicetreated with vehicle (n=5), and PEX7G844D / G844Dmicetreated with AAV at doses of IxlO11vg (n=6), 4xlO10vg (n=4), or IxlO10vg (n=5). Plasma samples at 6 weeks included wild-type mice (n=5), PPX7G844D / G844Dmicetreated with vehicle (n=5), and PEX7G844D / G844Dmicetreated with AAV at doses of IxlO11vg (n=6), 4xlO10vg (n=4), or IxlO10vg (n=6). At 16 weeks, liver samples included wildtype mice (n=6), PPX7G844D / G844Dmicetreated with vehicle (n=6), and PEX7G844D / G844Dmicetreated with AAV at doses of IxlO11vg (n=7), 4xlO10vg (n=8), or IxlO10vg (n=9). Plasma samples at 16 weeks included wild-type mice (n=6), PEX7G844D / G844Dmice treated with vehicle (n=6), and PEX7G844D / G844Dmicetreated with AAV at doses of IxlO11vg (n=7), 4xlO10vg (n=9), or IxlO10vg (n=9). Data were analyzed using Kruskal-Wallis test corrected with the Dunn’s multiple comparisons.

[0038] FIG. 18 shows that plasmalogen content in RBC is not corrected in PEX7G844D / G844Dneonatal mice treated with AAV9-ABE8e-V106W editor. Homozygous mice were injected at Pl by facial vein injection with AAV9-ABE8e-V106W (4xl0nvg total dose). Wild-type PEX1+I+, and PEX7G844D / G844Dmiceinjected with saline vehicle were used as control. Red blood cells (RBC) were collected from N = 8-10 mice (equal balanced sex) at end point (16 weeks of age) and analyzed by GC / MS for C16:0 and C18:0 plasmalogens as dimethyl acetyl (DMA) and their cognate fatty acid as fatty acid methylester (FAME) derivatives. The C16:0 and Cl 8: plasmalogens content is reported as concentration ug / mL, and as the ratio DMA / FAME. Box plots represent the median, quartile 1, quartile 3, minimum and maximum. Group comparisons were analyzed by two-way ANOVA and Tukey’s multiple comparisons test. The adjusted p value is reported. In addition to the VLCFA and BFCA data, the levels of plasmalogens, ether-phospholipids reliant on peroxisome biosynthesis, in red blood cells (RBCs) were also examined. In the box plots shown in FIG. 18, the abundance of the C16:019 / 149B1195.70208WO00#15198909v2dimethylacetyl (dMA) and Cl 8:0 OMA derivatives of the chemical moieties present in the sn-1 position of plasmalogens relative to C16:0 fatty acid methyl esters (FAME) and C18:0 (FAME) were quantified. Results are reported as DMA / FAME ratios since the vinyl ether-linked groups and cognate fatty acids are converted to DMA and FAME derivatives, respectively, after RBC sample processing. In the left panel, C16:0 DMA and C18:0 DMA levels did not differ among RBCs from wild type and £X7G844D / G844Dmice. In the middle panel, RBC C16:0 FAME levels were slightly elevated in RBCs from PEX7G844D / G844Dmjcerelative to controls while Cl 8:0 levels were unchanged. In the right panel, a significant reduction in 16:0 DMA / FAME ratios in RBCS from ppx7G844D / G844Dmjce wasobserved. This effect was not rescued by ABE treatment. C18:0 DMA / FAME ratios in RBCS from PEX1G&44D / G&44Dmice did not differ from controls. For plasmalogen (C16:0 and C18) analyses, samples included wild- type mice (n=10), ppx7G844D / G844Dmicetreated with vehicle (n=10), and ppx7G844D / G844Dmicetreated with AAV at a dose of 1 xlO11vg (n=9). Data were analyzed using two-way ANOVA corrected with the Tukey multiple comparisons.

[0039] FIGs. 19A-19E show analysis of ABE-LNP treated 4- week-old mice. FIG. 19A is a schematic diagram of retro-orbital (RO) injection of ABE-LNP into 4-week-old mice. FIG.19B shows base editing efficiencies quantified via HTS and CRISPRESSO®278analysis of liver samples from vehicle (saline) (WT n = 7; PEX7G844D / G844Dn= 5).orLNP-ABE-treated PEX1- p. G844D homozygous (3 mg / kg n = 6; 1.5 mg / kg n = 5) and WT mice (non-targeting guide, 3 mg / kg n = 6). The adenines within and near the protospacer are shown. FIG. 19C shows base editing efficiencies in brain cortex tissue (n as in FIG. 19B). Bars represent the mean ± s.d.; dots indicate values for individual mice (>5 mice). FIG. 19D shows automated Western blot analysis of ABCD3 was performed using liver tissue homogenates treated with vehicle (saline) or ABE LNP (1.5 mg / kg or 3 mg / kg per mouse). The peak area measured for ABCD3 was normalized to total protein levels and the relative fold-change was calculated using wild-type (WT) PEX1+I+as reference. Statistical analysis was performed by two-way ANOVA and Sidack’s multiple comparison test. FIG. 19E shows a histological analysis of lipid content in liver sections. Lipid content in liver sections was assessed by ORO staining. Representative images of ORO staining in liver at 10 weeks of age in vehicle-treated PEX1+I+mice (n = 7), PEX7G844D / G844Dmice (n = 5),orABE8e-V106W-treated PEX7G844D / G844Dmiceinjected with 3 mg / kg (n = 5) or 1.5 mg / kg (n = 5) LNP per mouse. Representative images captured at 5x magnification, with insets at lOx magnification. The scale bar represents 100 pm. N 5 mice by experimental group. Statistical analysis performed by two-way ANOVA20 / 149B1195.70208WO00#15198909v2and Sidack’s multiple comparison test. Numbers above pairs of bars indicate p-values using the statistical method specified above.

[0040] FIGs. 20A-20C show off-target analyses for ABE8e-V106W treated mouse tissues and human cells, related to FIGs. 5A-5E. FIG. 20A shows jitter plots derived from RNA-seq experiments showing RNA adenines modified in the ABE8e-V106W-AAV9-treated or saline-treated PEX1 -p. G844D homozygous mouse liver tissues. Each dot represented an A-to-G change detected, n, average of total number of modified adenines identified in each mouse liver tissue at the same dose condition. FIG. 20B shows CIRCLE-seq analysis of ABE8e-V106W targeting human pathogenic variant was performed using patient-derived fibroblast (PEX7G843D / 1700fs) gDNA. Six potential off-target (OT) editing sites were nominated. FIG. 20C shows a schematic diagram of nominated OT editing sites from CIRCLE-seq and CAS-OFFINDER™. 20 potential OT sites nominated by CAS-OFFINDER™ are shown. Mismatched nucleotides in the OT sites are shown. No overlapping OT sites were observed between CIRCLE-seq and CAS-OFFINDER™ nominated sites in the Venn diagram. 26 potential off-target sites were further examined using amplicon sequencing of AAV9-ABE8e-V106W (1X1011vg) treated mouse liver gDNA.

[0041] FIG. 21 shows mouse brain cortex lipids in the treated Pl pexiG844D / G844Da6 weeks post injection. Branched FA (phytanic and pristanic) were reduced in PexlG844D / G844Dtreated at IxlO11vg AAV / ABE. Lipid profile of ABE-AAV9-treated Pl neonatal mice were based on GC-MS analysis of brain cortex samples collected at 6 and 16 weeks. Cortex of vehicle-treated WT mice (6 weeks n=9, 16 weeks n=10) Vehicle-treated PEX7G844D / G844Dmice(g weeks n=9, 16 weeks n=11), AAV9-ABE8e-V106W-treated PEX7G844D / G844Dmice at doses IxlO11vg (6 weeks n = 9, 16 weeks n=7).

[0042] FIG. 22 shows mouse brain cortex lipids in the treated Pl PEX7G844D / G844Dat 16 weeks post injection. Toxic branched fatty acids (FA) (phytanic and pristanic) were reduced in in PEX7G844D / G844Dtreated at IxlO11vg ABE-AAV9. Lipid profile of ABE-AAV9-treated Pl neonatal mice were based on GC-MS analysis of brain cortex samples collected at 6 and 16 weeks. Cortex of vehicle-treated WT mice (6 weeks n=9, 16 weeks n=10) Vehicle-treated PEX7G844D / G844Dmice (6 weeks n=9, 16 weeks n=11), AAV9-ABE8e-V106W-treated PEX7G844D / G844Dmice at doses IxlO11vg (6 weeks n = 9, 16 weeks n=7).

[0043] FIG. 23 shows editing in liver shows benefits in brain by preventing toxic accumulation of diet-derived Branched-Chain Fatty Acids (BCFA) in four- week-old mouse cortex. The level of VLCFAs (C22) stayed unchanged; but diet-derived BCFA reduced in21 / 149B1195.70208WO00#15198909v2brain after liver editing. Lipid profiles of ABE-AAV9-treated 4-week-old mice were based on GC-MS analysis of brain cortex samples collected at 16 weeks.

[0044] FIG. 24 shows LNP-treated Pexl-G844D mice show dose-dependent normalization of lipids (4-week-old mice were treated; measured at 6 weeks post injection). Lipid profiles of ABE-LNP-treated 4-week-old mice were based on GC-MS analysis of liver and brain cortex samples collected at 16 weeks. Vehicle-treated WT mice (n=6), vehicle-treated PEX7G844D / G844Dmice (n=6), AAV9-ABE8e-V106W-treated PEX7G844D / G844Dmice at 5x1011vg (n=7), c. Liver of vehicle-treated mice (WT n = 8; PEX7G844D / G844Dn= 5), sgPex1-ABE-LNP-treated PEX7G844D / G844Dmice(3 mg / kg n = 5; 1.5 mg / kg n = 4). Cortex of vehicle-treated mice (WT n=8, PEX7G844D / G844Dn =5, sgPEXl -ABE-LNP-treated PEX7G844D / G844Dmice (3 mg / kg n = 5; 1.5 mg / kg n = 5). For FIGs. 21-24, fold-change in signal for each lipid was calculated relative to the average for vehicle-treated WT mice. Volcano plots show foldchange in lipid abundance. Gray and dark gray dotted lines indicate twofold decrease and increase, respectively; black dashed line marks P = 0.05. P values were calculated relative to vehicle-treated WT samples using Dunn’s nonparametric many-to-one comparison test for Kruskal-type ranked data.DEFINITIONS

[0045] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them unless specified otherwise.Adenosine deaminase

[0046] As used herein, the term “adenosine deaminase” or “adenosine deaminase domain” refers to a protein or enzyme that catalyzes a deamination reaction of an adenosine (or adenine). The terms are used interchangeably. In certain embodiments, the disclosure provides nucleobase editor fusion proteins comprising one or more adenosine deaminase domains (e.g., fused to a napDNAbp such as a Cas9 protein). For instance, an adenosine deaminase domain may comprise a heterodimer of a first adenosine deaminase and a second22 / 149B1195.70208WO00#15198909v2deaminase domain, connected by a linker. Adenosine deaminases (e.g., engineered adenosine deaminases or evolved adenosine deaminases) provided herein may be enzymes that convert adenine (A) to inosine (I) in DNA or RNA. Such adenosine deaminases can lead to an A: T to G: C base pair conversion. In some embodiments, the deaminase is a variant of a naturally-occurring deaminase from an organism e.g., bacteria, such as E. coli). In some embodiments, the deaminase does not occur in nature. For example, in some embodiments, the deaminase is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a naturally-occurring deaminase.

[0047] In some embodiments, the adenosine deaminase is derived from a bacterium, such as, E. coli, S. aureus, S. typhi, S. putrefaciens, H. influenzae, C. jejuni, or C. crescentus. In some embodiments, the adenosine deaminase is a TadA deaminase. In some embodiments, the TadA deaminase is an E. coli TadA deaminase (ecTadA). In some embodiments, the TadA deaminase is a truncated E. coli TadA deaminase. For example, the truncated ecTadA may be missing one or more N-terminal amino acids relative to a full-length ecTadA. In some embodiments, the truncated ecTadA may be missing 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 N-terminal amino acid residues relative to the full length ecTadA. In some embodiments, the truncated ecTadA may be missing 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 C-terminal amino acid residues relative to the full length ecTadA. In some embodiments, the ecTadA deaminase does not comprise an N-terminal methionine. In some embodiments, the adenosine deaminase comprises ecTadA(8e) (i.e., as used in the base editor ABE8e) as described further herein. Adenosine deaminases are further described, for example, in International Patent Application Publication No. WO 2018 / 027078, which is incorporated herein by reference.ABE-targetable mutation

[0048] As used herein, the term “ABE-targetable” (or “ABE-correctable”) mutation (e.g., PEX1 mutation or PEX1 mutant allele) is a mutation which is capable of being targeted by an adenine base editor complexed with an appropriately designed guide RNA to result in a desired edit to correct a C> T or G> A mutation at a specified nucleotide residue position relative to a wildtype nucleotide sequence. Thus, an ABE-targetable mutation is either T: A base pair installed in place of a wildtype C: G base pair, or an A: T base pair installed in place of a wildtype G: C base pair. As a result of the edit by the ABE, the T: A pair is converted back to a C: G base pair, and the A: T pair is converted back to the G: C pair. The person having ordinary skill in the art will appreciate that an ABE-targetable mutation further23 / 149B1195.70208WO00#15198909v2requires that the target sequence comprising the mutation to be corrected comprises a suitable PAM (protospacer adjacent motif) sequence that is recognized and bound by the particular napDNAbp domain utilized as part of the ABE editor complex, and an editing window comprising the mutation to be corrected.Base editing

[0049] “Base editing” refers to a genome editing technology that involves the conversion of a specific nucleic acid base into another at a targeted genomic locus. In certain embodiments, this can be achieved without requiring double- stranded DNA breaks (DSB), or single stranded breaks (z.e., nicking). Many other genome editing techniques, including CRISPR-based systems, begin with the introduction of a DSB at a locus of interest. Subsequently, cellular DNA repair enzymes mend the break, commonly resulting in random insertions or deletions (indels) of bases at the site of the DSB. However, when the introduction or correction of a point mutation at a target locus is desired rather than stochastic disruption of the entire gene, these genome editing techniques are unsuitable, as correction rates are low (e.g., typically 0.1% to 5%), with the major genome editing products being indels. In order to increase the efficiency of gene correction without simultaneously introducing random indels, the CRISPR system is modified to directly convert one DNA base into another without DSB formation. See, Komor, A. C., et al., Programmable editing of a target base in genomic DNA without double- stranded DNA cleavage. Nature 533, 420-424 (2016), the entire contents of which is incorporated by reference herein. In some embodiments, base editing is accomplished using a fusion protein comprising a deaminase and napDNAbp (e.g., a Cas9 protein).

[0050] In principle, there are 12 possible base-to-base changes that may occur via individual or sequential use of transition (i.e., a purine-to-purine change or pyrimidine-to-pyrimidine change) or transversion (i.e., a purine-to-pyrimidine or pyrimidine-to-purine) editors. These include transition base editors such as the cytosine base editor (“CBE”), also known as a C-to-T base editor (or “CTBE”). This type of editor converts a C: G Watson-Crick nucleobase pair to a T: A Watson-Crick nucleobase pair. Because the corresponding Watson-Crick paired bases are also interchanged as a result of the conversion, this category of base editor may also be referred to as a guanine base editor (“GBE”) or G-to-A base editor (or “GABE”). Other transition base editors include the adenine base editor (or “ABE”), also known as an A-to-G base editor (“AGBE”). This type of editor converts an A: T Watson-Crick nucleobase pair to a G: C Watson-Crick nucleobase pair. Because the corresponding Watson-Crick paired bases24 / 149B1195.70208WO00#15198909v2are also interchanged as a result of the conversion, this category of base editor may also be referred to as a thymine base editor (or “TBE”) or T-to-G base editor (“TGBE”).Base editors

[0051] The terms “base editor (BE)” and “nucleobase editor,” which are used interchangeably herein, refer to an agent comprising a polypeptide that is capable of making a modification to a base (e.g., A, T, C, G, or U) within a nucleic acid sequence (e.g., DNA or RNA) that converts one base to another (e.g., A to G, A to C, A to T, C to T, C to G, C to A, G to A, G to C, G to T, T to A, T to C, or T to G). In some embodiments, the base editor is capable of deaminating a base within a nucleic acid, such as a base within a DNA molecule. In some embodiments, a base editor is an adenine base editor. In the case of an adenine base editor, the base editor is capable of deaminating an adenine (A) in DNA. Such base editors may include a nucleic acid programmable DNA binding protein (napDNAbp) fused to an adenosine deaminase. Some base editors include CRISPR-mediated fusion proteins that are utilized in the base editing methods described herein. In some embodiments, the base editor comprises a Cas9 protein fused to a deaminase that binds a nucleic acid in a guide RNA-programmed manner via the formation of an R-loop, but does not cleave the nucleic acid.

[0052] In some embodiments, a base editor is a macromolecule or macromolecular complex that results primarily (e.g., more than 80%, more than 85%, more than 90%, more than 95%, more than 99%, more than 99.9%, or 100%) in the conversion of a nucleobase in a polynucleotide sequence into another nucleobase (i.e., a transition or transversion) using a combination of 1) a nucleotide-, nucleoside-, or nucleobase-modifying enzyme, and 2) a nucleic acid binding protein that can be programmed to bind to a specific nucleic acid sequence.

[0053] In some embodiments, the base editor comprises a DNA binding domain (e.g., a programmable DNA binding domain, such as a Cas9 protein) that directs it to a target sequence. In some embodiments, the base editor comprises a nucleobase modification domain fused to a programmable DNA binding domain (e.g., a Cas9 protein). The terms “nucleobase modifying enzyme” and “nucleobase modification domain,” which are used interchangeably herein, refer to an enzyme that can modify a nucleobase and convert one nucleobase to another (e.g., a deaminase, such as a cytidine deaminase or an adenosine deaminase). In some embodiments, A to G editing is carried out by a deaminase, e.g., an adenosine deaminase.25 / 149B1195.70208WO00#15198909v2

[0054] In some embodiments, a base editor converts an A to a G. In some embodiments, the base editor comprises an adenosine deaminase. An “adenosine deaminase” is an enzyme involved in purine metabolism. It is needed for the breakdown of adenosine from food and for the turnover of nucleic acids in tissues. Its primary function in humans is the development and maintenance of the immune system. An adenosine deaminase catalyzes hydrolytic deamination of adenosine (forming inosine, which base pairs as G) in the context of DNA. There are no known natural adenosine deaminases that act on DNA. Instead, known adenosine deaminase enzymes only act on RNA (tRNA or mRNA). Evolved deoxy adenosine deaminase enzymes that accept DNA substrates and deaminate dA to deoxyinosine have been described, e.g., in International Patent Application No. PCT / US2017 / 045381, filed August 3, 2017, which published as WO 2018 / 027078, International Patent Application No.PCT / US2019 / 033848, which published as WO 2019 / 226953, International Patent Application No PCT / US2019 / 033848, filed May 23, 2019, which published as WO 2019226953, and International Patent Application No. PCT / US2020 / 028568, filed April 17, 2020, which published as WO 2020214842; each of which is incorporated herein by reference.

[0055] Exemplary adenine base editors are also described in Rees & Liu, “Base editing: precision chemistry on the genome and transcriptome of living cells,” Nat. Rev. Genet.2018;19(12):770-788; as well as U. S. Patent Application Publication No. 2018 / 0073012, published March 15, 2018, which issued as U. S. Patent No. 10,113,163 on October 30, 2018; U. S. Patent Application Publication No. 2017 / 0121693, published May 4, 2017, which issued as U. S. Patent No. 10,167,457 on January 1, 2019; PCT Application Publication No. WO 2017 / 070633, published April 27, 2017; U. S. Patent Application Publication No.2015 / 0166980, published June 18, 2015; U. S. Patent No. 9,840,699, issued December 12, 2017; and U. S. Patent No. 10,077,453, issued September 18, 2018, each of which is incorporated herein by reference.Cas9

[0056] The term “Cas9” or “Cas9 nuclease” refers to an RNA-guided nuclease comprising a Cas9 domain, or a fragment thereof e.g., a protein comprising an active or inactive DNA cleavage domain of Cas9, and / or the gRNA binding domain of Cas9). A “Cas9 domain,” as used herein, is a protein fragment comprising an active or fully or partly inactive cleavage domain of Cas9 and / or the gRNA binding domain of Cas9. A “Cas9 protein” is a full length Cas9 protein. A Cas9 nuclease is also referred to sometimes as a Cas9 nuclease or a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)-associated nuclease. CRISPR is26 / 149B1195.70208WO00#15198909v2an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements, and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc), and a Cas9 domain. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9 / crRNA / tracrRNA endonucleolytically cleaves a linear or circular dsDNA target complementary to the spacer. The strand in the target DNA not complementary to crRNA is first cut endonucleolytically, then trimmed 3 '-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs (“sgRNA”, or simply “gRNA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the contents of which are incorporated herein by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti et al., J. J., McShan W. M., Ajdic D. J., Savic D. J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A. N., Kenton S., Lai H. S., Lin S. P., Qian Y., Jia H. G., Najar F. Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S. W., Roe B. A., McLaughlin R. E., Proc. Natl. Acad. Sci. U. S. A.98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C. M., Gonzales K., Chao Y., Pirzada Z. A., Eckert M. R., Vogel J., Charpentier E., Nature 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by27 / 149B1195.70208WO00#15198909v2reference. In some embodiments, a Cas9 nuclease comprises one or more mutations that partially impair or inactivate the DNA cleavage domain.

[0057] A nuclease-inactivated Cas9 domain may interchangeably be referred to as a “dCas9” protein (for nuclease-“dead” Cas9). Methods for generating a Cas9 domain (or a fragment thereof) having an inactive DNA cleavage domain are known (see, e.g., Jinek et al., Science.337:816-821(2012); Qi et al., “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell. 28;152(5): 1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvCl subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC 1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al., Science. 337:816-821(2012); Qi etal., Cell. 28;152(5): 1173-83 (2013)). In some embodiments, a Cas9 protein comprises one or more mutations to inactivate the nuclease activity of only one of the HNH subdomain or the RuvC 1 subdomain.

[0058] In some embodiments, proteins comprising fragments of a Cas9 protein are provided. For example, in some embodiments, a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9, or fragments thereof, are referred to as “Cas9 variants.” A Cas9 variant shares homology to Cas9, or a fragment thereof. For example, a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, at least about 99.8% identical, or at least about 99.9% identical to wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 1). In some embodiments, the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more amino acid changes compared to wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 1). In some embodiments, the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99%28 / 149B1195.70208WO00#15198909v2identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 1). In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 1).Deaminase

[0059] The term “deaminase” or “deaminase domain” refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenosine. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenosine in deoxyribonucleic acid (DNA) to inosine.

[0060] The deaminases provided herein may be from any organism, such as a bacterium. In some embodiments, the deaminase or deaminase domain is a variant of a naturally occurring deaminase from an organism. In some embodiments, the deaminase or deaminase domain does not occur in nature. For example, in some embodiments, the deaminase or deaminase domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a naturally occurring deaminase.Fusion protein

[0061] The term “fusion protein” as used herein refers to a hybrid polypeptide that comprises protein domains from at least two different proteins. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C-terminal) protein, thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively. A protein may comprise different domains, for example, a Cas9 protein fused to a deaminase (i.e., a base editor). Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (2012)), the entire contents of which is incorporated herein by reference.29 / 149B1195.70208WO00#15198909v2Guide RNA (“gRNA”)

[0062] As used herein, the term “guide RNA” is a particular type of guide nucleic acid which is commonly associated with a Cas protein (e.g., a Cas9 protein), directing the Cas protein to a specific sequence in a DNA molecule that includes complementarity to the protospacer sequence of the guide RNA. For example, a gRNA may direct a Cas protein (e.g., as part of a base editor) to a target site in the PEX1 gene. However, this term also embraces the equivalent guide nucleic acid molecules that associate with Cas protein equivalents, homologs, orthologs, or paralogs, whether naturally occurring or non-naturally occurring (e.g., engineered or recombinant), and which otherwise program the Cas protein equivalent to localize to a specific target nucleotide sequence. The Cas protein equivalents may include other napDNAbps from any type of CRISPR system (e.g., type II, V, VI), including Cpfl (a type-V CRISPR-Cas system), C2cl (a type V CRISPR-Cas system), C2c2 (a type VI CRISPR-Cas system), and C2c3 (a type V CRISPR-Cas system). Further Cas-equivalents are described in Makarova et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” Science 2016; 353(6299), which is incorporated herein by reference. Exemplary sequences and structures of guide RNAs are provided herein.

[0063] Functionally, guide RNAs associate with a Cas protein, directing (or programming) the Cas protein to a specific sequence in a DNA molecule that includes a sequence complementary to the protospacer sequence for the guide RNA. A gRNA is a component of the CRISPR / Cas system. The sequence specificity of a Cas DNA-binding protein is determined by gRNAs, which have nucleotide base-pairing complementarity to target DNA sequences. The native gRNA comprises a 20 nucleotide (nt) spacer, which specifies the DNA sequence to be targeted, and is immediately followed by an 80 nt scaffold sequence, which associates the gRNA with the Cas protein. In some embodiments, an SDS of the present disclosure has a length of 15 to 100 nucleotides, or more. For example, an SDS may have a length of 15 to 90, 15 to 85, 15 to 80, 15 to 75, 15 to 70, 15 to 65, 15 to 60, 15 to 55, 15 to 50, 15 to 45, 15 to 40, 15 to 35, 15 to 30, or 15 to 20 nucleotides. In some embodiments, the SDS is 20 nucleotides long. For example, the SDS may be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides long. At least a portion of the target DNA sequence is complementary to the SDS of the gRNA. For a Cas protein to successfully bind to the DNA target sequence, a region of the target sequence is complementary to the SDS of the gRNA sequence and is immediately followed by the correct protospacer adjacent motif (PAM) sequence. In some embodiments, an SDS is 100% complementary to its target sequence. In some embodiments,30 / 149B1195.70208WO00#15198909v2the SDS sequence is less than 100% complementary to its target sequence and is, thus, considered to be partially complementary to its target sequence. For example, a targeting sequence may be 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% complementary to its target sequence. In some embodiments, the SDS of template DNA or target DNA may differ from a complementary region of a gRNA by 1, 2, 3, 4, or 5 nucleotides.

[0064] In some embodiments, the guide RNA is about 15-120 nucleotides long and comprises a sequence of at least 10 contiguous nucleotides that is complementary to a target sequence (e.g., a target sequence in PEX1). In some embodiments, the guide RNA is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 nucleotides long. In some embodiments, the guide RNA comprises a sequence of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more contiguous nucleotides that is complementary to a target sequence. Sequence complementarity refers to distinct interactions between adenine and thymine (DNA) or uracil (RNA), and between guanine and cytosine. In any of the guide RNA sequences provided herein, thymines and uracils may be used interchangeably, and a person of ordinary skill in the art will appreciate that the sequences comprise uracils because they are RNA.Linker

[0065] The term “linker,” as used herein, refers to a molecule linking two other molecules or moieties. The linker can be an amino acid sequence in the case of a linker joining two components of a fusion protein. For example, a napDNAbp (e.g., a Cas9 protein) can be fused to a deaminase (e.g., an adenosine deaminase) by an amino acid linker sequence. The linker can also be a nucleotide sequence in the case of joining two nucleotide sequences together (e.g., in a gRNA). In other embodiments, the linker is a non-peptide linker. In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-200 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.31 / 149B1195.70208WO00#15198909v2napDNAbp

[0066] As used herein, the term “nucleic acid programmable DNA binding protein” or “napDNAbp,” of which Cas proteins such as Cas9 and variants thereof are examples, refers to a protein that uses RNA: DNA hybridization to target and bind to specific sequences in a DNA molecule. Each napDNAbp is associated with at least one guide nucleic acid (e.g., guide RNA), which localizes the napDNAbp to a DNA sequence that comprises a DNA strand (i.e., a target strand) that is complementary to the guide nucleic acid, or a portion thereof (e.g., the protospacer of a guide RNA). In other words, the guide nucleic-acid “programs” the napDNAbp (e.g., Cas9, or a variant thereof) to localize and bind to a complementary sequence.

[0067] Without being bound by theory, the binding mechanism of a napDNAbp-guide RNA complex, in general, includes the step of forming an R-loop whereby the napDNAbp induces the unwinding of a double- strand DNA target, thereby separating the strands in the region bound by the napDNAbp. The guide RNA protospacer then hybridizes to the “target strand.” This displaces a “non-target strand” that is complementary to the target strand, which forms the single strand region of the R-loop. In some embodiments, the napDNAbp includes one or more nuclease activities, which then cut the DNA, leaving various types of lesions. For example, the napDNAbp may comprise a nuclease activity that cuts the non-target strand at a first location, and / or cuts the target strand at a second location. Depending on the nuclease activity, the target DNA can be cut to form a “double- stranded break” whereby both strands are cut. In other embodiments, the target DNA can be cut at only a single site, i.e., the DNA is “nicked” on one strand.Nickase

[0068] As used herein, a “nickase” refers to a napDNAbp (e.g., a Cas9 protein) that is capable of cleaving only one of the two complementary strands of a double- stranded target DNA sequence, thereby generating a nick in that strand. In some embodiments, the nickase cleaves a non-target strand of a double stranded target DNA sequence. In some embodiments, the nickase comprises an amino acid sequence with one or more mutations in a catalytic domain of a canonical napDNAbp (e.g., a Cas9 protein), wherein the one or more mutations reduces or abolishes nuclease activity of the catalytic domain. In some embodiments, the nickase is a Cas9 that comprises one or more mutations in a RuvC-like domain relative to a wild type Cas9 sequence or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the nickase is a Cas9 that comprises one or more32 / 149B1195.70208WO00#15198909v2mutations in an HNH-like domain relative to a wild type Cas9 sequence or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the nickase is a Cas9 that comprises an aspartate-to-alanine substitution (D10A) in the RuvCl catalytic domain of Cas9 relative to a canonical SpCas9 sequence or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the nickase is a Cas9 that comprises an H840A, N854A, and / or N863A mutation relative to a canonical SpCas9 sequence, or to an equivalent amino acid position in other Cas9 variants or Cas9 equivalents. In some embodiments, the term “Cas9 nickase” refers to a Cas9 with one of the two nuclease domains inactivated. This enzyme is capable of cleaving only one strand of a target DNA. In some embodiments, the nickase is a Cas protein that is not a Cas9 nickase.

[0069] In some embodiments, the napDNAbp of a base editor is a Cas9 nickase (nCas9) that nicks only a single strand. In other embodiments, the napDNAbp can be selected from the group consisting of: Cas9, Casl2e, Casl2d, Casl2a, Casl2bl, Casl2b2, Casl3a, Casl2c, Casl2d, Casl2e, Casl2h, Casl2i, Casl2g, Casl2f (Casl4), Casl2fl, Casl2j (Cas ), and Argonaute and optionally has a nickase activity such that only one strand is cut. In some embodiments, the napDNAbp is selected from Cas9, Casl2e, Cas 12d, Cas 12a, Casl2bl, Casl2b2, Casl3a, Casl2c, Casl2d, Casl2e, Casl2h, Casl2i, Casl2g, Casl2f (Casl4), Casl2fl, Casl2j (Cas ), and Argonaute, and optionally has a nickase activity such that one DNA strand is cut preferentially to the other DNA strand.Nuclear localization sequence (NLS)

[0070] The term “nuclear localization sequence” or “NLS” refers to an amino acid sequence that promotes import of a protein into the cell nucleus, for example, by nuclear transport. Nuclear localization sequences are known in the art and would be apparent to the skilled artisan. For example, NLS sequences are described in Plank et al., international PCT application, PCT / EP2000 / 011690, filed November 23, 2000, published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated herein by reference for its disclosure of exemplary nuclear localization sequences. In some embodiments, a base editor comprises one or more NLS as described herein.Nucleic acid molecule

[0071] The term “nucleic acid,” as used herein, (also referred to as a “polynucleotide”) refers to a polymer of nucleotides. The polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine,33 / 149B1195.70208WO00#15198909v2pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C5 bromouridine, C5 fluorouridine, C5 iodouridine, C5 propynyl uridine, C5 propynyl cytidine, C5 methylcytidine, 7 deazaadenosine, 7 deazaguanosine, 8 oxoadenosine, 8 oxoguanosine, 0(6) methylguanine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, dihydrouridine, methylpseudouridine, 1-methyl adenosine, 1-methyl guanosine, N6-methyl adenosine, and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g., methylated bases), intercalated bases, modified sugars (e.g., 2 '-fluororibose, ribose, 2 '-deoxyribose, 2'-0-methylcytidine, arabinose, and hexose), or modified phosphate groups (e.g., phosphorothioates and 5' N phosphoramidite linkages).Peroxisomes

[0072] Peroxisomes are metabolic membrane-bound organelles that serve as a central hub in eukaryotic cell signaling pathways and play an essential role in maintaining physiological homeostasis in mammalian cells. They are required for the biosynthesis of lipids, such as plasmalogens (a major constituent of myelin), platelet- activating factor (PAF), docosahexaenoic acid (DHA), and mature bile acids. They are also involved in the catabolism of branched-chain and very long chain (>22 carbons) fatty acids (BCFA and VLCFA), polyamines, D-amino acids, glyoxylate, and hydrogen peroxide byproducts of lipid oxidation. As highlighted by their involvement in the etiology of rare and common diseases, peroxisomes play essential roles in the development and function of mammalian tissues, such as hepatic, nervous, and sensory systems.Protein, peptide, and polypeptide

[0073] The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein, or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a famesyl group, an isofamesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination 34 / 149B1195.70208WO00#15198909v2thereof. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (2012)), the contents of which are incorporated herein by reference.Protospacer

[0074] As used herein, the term “protospacer” refers to the sequence (~20 bp) in DNA adjacent to the PAM (protospacer adjacent motif) sequence. The protospacer shares the same sequence as the spacer sequence of the guide RNA. The guide RNA anneals to the complement of the protospacer sequence on the target DNA (specifically, one strand thereof, i.e., the “target strand” versus the “non-target strand” of the target DNA sequence). The skilled person will appreciate that the literature in the state of the art sometimes refers to the “protospacer” as the ~20-nt target- specific guide sequence on the guide RNA itself, rather than referring to it as a “spacer.” Thus, in some cases, the term “protospacer” as used herein may be used interchangeably with the term “spacer.” The context of the description surrounding the appearance of either “protospacer” or “spacer” will help inform the reader as to whether the term is in reference to the gRNA or the DNA target.Spacer sequence

[0075] As used herein, the term “spacer sequence” in connection with a guide RNA refers to the portion of the guide RNA of about 20 nucleotides that contains a nucleotide sequence that shares the same sequence as the protospacer sequence in the target DNA sequence. The spacer sequence anneals to the complement of the protospacer sequence to form a ssRNA / ssDNA hybrid structure at the target site and a corresponding R loop ssDNA structure of the endogenous DNA strand.Subject

[0076] The term “subject,” as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode. In some embodiments, the subject is a 35 / 149B1195.70208WO00#15198909v2research animal. In some embodiments, the subject is genetically engineered, e.g., a genetically engineered non-human subject. The subject may be of either sex, and at any stage of development.Target site

[0077] The term “target site” refers to a sequence within a nucleic acid molecule that is modified e.g., edited) by a fusion protein disclosed herein (e.g., a base editor). The target site further refers to the sequence within a nucleic acid molecule (e.g., a nucleic acid molecule comprising PEX1) to which a complex of, for example, a base editor and a gRNA binds. Treatment

[0078] The terms “treatment,” “treat,” and “treating,” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder (e.g., Zellweger spectrum disorder), or one or more symptoms thereof, as described herein. As used herein, the terms “treatment,” “treat,” and “treating” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder (e.g., Zellweger spectrum disorder), or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and / or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease (e.g., Zellweger spectrum disorder). For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.Variant

[0079] As used herein, the term “variant” should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature, e.g., a variant Cas9 is a Cas9 comprising one or more changes in amino acid residues (i.e., “substitutions”) as compared to a wild type Cas9 amino acid sequence. The term “variant” encompasses homologous proteins having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with a reference sequence and having the same or substantially the same functional activity or activities as the reference sequence. The term36 / 149B1195.70208WO00#15198909v2also encompasses mutants, truncations, or domains of a reference sequence that display the same or substantially the same functional activity or activities as the reference sequence. Vector

[0080] The term “vector,” as used herein, refers to a nucleic acid that can be modified to encode a gene of interest and that is able to enter a host cell, mutate, and replicate within the host cell, and then transfer a replicated form of the vector into another host cell. Exemplary suitable vectors include viral vectors, such as retroviral vectors or bacteriophages and filamentous phage, and conjugative plasmids. Additional suitable vectors will be apparent to those of skill in the art based on the instant disclosure.Zellweger Spectrum Disorder (ZSD)

[0081] Zellweger spectrum disorder (ZSD) is a disease spectrum caused by biallelic loss-of-function mutations in any of one of the 13 PEX genes that encode peroxin proteins, which are required for normal peroxisome assembly, structure, abundance, and function. The PEX1 gene is a member of the AAA ATPase protein family and an essential component of the PEX1-PEX6-PEX26 exportomer complex, which is required for peroxisome assembly.Mutations in PEX1 (such as G843D), can cause ZSD. ZSD patients frequently display hepatomegaly, coagulation defects, and liver abnormalities that can lead to frequent hospitalizations and a shortened lifespan, and they can also show progressive vision and hearing loss, intellectual disabilities, osteopenia, kidney stones, adrenal insufficiency, and amelogenesis imperfecta (Al). Patients may also show a milder course of degenerative disease that typically results in progressive vision and hearing loss and Al with hepatomegaly, coagulation defects, and adrenal insufficiency in some individuals.

[0082] Zellweger spectrum disorder is further described, for example, in Steinberg, S. et al., GeneReviews, 2003, and Bose, M. et al., Cells 2022, 11(12), 1891, each of which is incorporated herein by reference. The amino acid and nucleotide sequences of the human and mouse PEX1 gene and Navl.l product are provided herein in the Sequences section. In addition, the amino acid and nucleotide sequences of the human PEX1 G843D and mouse PEX1 G844D mutant alleles and mutant Navl.lG843Dand Navl.lG844Dproducts are provided herein in the Sequences section.

[0083] As used herein, “a symptom or condition associated with a PEX1 mutant allele” refers to any ZSD-associated symptom or condition arising due to the underlying disease, and may include, but is not limited to, the following symptoms or conditions: liver abnormalities,37 / 149B1195.70208WO00#15198909v2intellectual disabilities, vision loss, hearing loss, peroxisome dysfunction, toxic bile acid intermediate accumulation, liver pathologies, and increased body weight.DETAILED DESCRIPTION

[0084] The present disclosure describes the discovery that adenine base editing (ABE) is an effective method for correcting mutations in the PEX1 gene that cause Zellweger spectrum disorder (ZSD). This disclosure includes various compositions such as adenine base editors (ABEs), guide RNAs designed to target and correct PEX1 mutations, and complexes that comprise ABEs and guide RNAs. It also encompasses nucleic acid molecules encoding these ABEs and guide RNAs, as well as vectors and delivery systems that facilitate their use.Additionally, the disclosure covers cells and tissues containing ABEs and guide RNAs aimed at PEX1 mutations, along with pharmaceutical compositions and kits containing these components for targeting PEX1 mutations. Methods for correcting one or more PEX1 mutations in mutant alleles, including the PEX1 (G843D) human mutant allele and the PEX1 (G844D) mouse mutant allele, are disclosed herein under in vivo, ex vivo, or in vitro conditions using the disclosed ABEs, guide RNAs, complexes, and associated compositions or vectors.

[0085] Adenine base editing (ABE) is a technique that converts A T base pairs to G C base pairs (or T A base pairs to C-G base pairs) at targeted locations in the genome without causing double- stranded DNA breaks. ABEs consist of a nucleic acid-programmable DNA-binding domain, such as a Cas9 nickase, fused to an adenosine deaminase, allowing for modularity that enhances the editor’s capabilities. Adenosine deaminases can be paired with various Cas domains to alter the editing window and PAM preference, which helps accurately position the target base for deamination while minimizing unwanted edits to adjacent bases. The deaminase domain can also be modified to adjust the editing window, improve enzyme efficiency, or reduce unintended deamination events. Since their development, ABEs have been utilized in both ex vivo and in vivo applications, including treatments for sickle cell disease, Hutchinson-Gilford progeria syndrome, acute lymphoblastic leukemia, spinal muscular atrophy, and other genetic disorders. The ABE-mediated correction of the PEX1 G844D mutation in mice has shown promise for alleviating ZSD-related pathology, suggesting that any ABE-targetable PEX1 mutant allele can be effectively corrected, positioning ABE editing as a potential treatment for ZSD and its symptoms.38 / 149B1195.70208WO00#15198909v2Nucleic Acid-Programmable DNA Binding Proteins (napDNAbp)

[0086] In various embodiments, the adenine base editors contemplated by the present disclosure for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene, comprise a napDNAbp. In some embodiments, the napDNAbp is a Cas protein (e.g., a Cas9 protein, including a Cas9 nickase or a nuclease-inactivated (dCas9) protein). Suitable napDNAbp sequences that can be used in base editors will be apparent to those of skill in the art based on this disclosure, and such proteins include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; which is incorporated herein by reference. Exemplary Cas variants and homologs include, but are not limited to, Cas9 (e.g., dCas9 and nCas9), Cpfl, CasX, CasY, C2cl, C2c2, C2c3, GeoCas9, CjCas9, Casl2a, Casl2b, Casl2g, Casl2h, Casl2i, Casl3b, Casl3c, Casl3d, Casl4, Csn2, xCas9, SpCas9-NG, Nme2Cas9, circularly permuted Cas9, Argonaute (Ago), Cas9-KKH, SmacCas9, Spy-macCas9, SpCas9-VRQR, SpCas9-NRRH, SpaCas9-NRTH, SpCas9-NRCH, LbCasl2a, AsCasl2a, CeCasl2a, MbCasl2a, Cas3, Cas, and circularly permuted Cas9 domains such as CP1012, CP1028, CP1041, CP1249, and CP1300, and variants and homologs thereof.

[0087] For example, a base editor may include a napDNAbp domain having a wild type Cas9 sequence, including, for example, the canonical Streptococcus pyogenes Cas9 sequence, shown as follows:39 / 149B1195.70208WO00#15198909v2

[0088] In some embodiments, a base editor for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene may include a napDNAbp domain having a modified Cas9 sequence, including, for example, nickase or nuclease-inactivated (dead) variants of Streptococcus pyogenes Cas9, shown as follows:40 / 149B1195.70208WO00#15198909v241 / 149B1195.70208WO00 #15198909v2Cas9 ortholog from another bacterial species different from the canonical Cas9 from. S'. pyogenes. For example, modified versions of the following Cas9 orthologs can be used in connection with the base editors described in this specification by making mutations at positions corresponding to D10A and / or H840A or any other amino acids of interest in wild type SpCas9. In addition, any variant Cas9 orthologs having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of the below orthologs may also be used with the base editors.42 / 149B1195.70208WO00#15198909v243 / 149B1195.70208WO00 #15198909v244 / 149B1195.70208WO00 #15198909v245 / 149B1195.70208WO00 #15198909v246 / 149B1195.70208WO00 #15198909v247 / 149B1195.70208WO00 #15198909v248 / 149B1195.70208WO00 #15198909v249 / 149B1195.70208WO00 #15198909v250 / 149B1195.70208WO00 #15198909v251 / 149B1195.70208WO00 #15198909v2

[0090] In some embodiments, a base editor may include a napDNAbp domain having a modified Cas9 sequence, including, for example, Cas9 proteins with alternative PAM specificities, such as the following:52 / 149B1195.70208WO00#15198909v253 / 149B1195.70208WO00 #15198909v254 / 149B1195.70208WO00 #15198909v255 / 149B1195.70208WO00 #15198909v256 / 149B1195.70208WO00 #15198909v2

[0091] Additional suitable napDNAbp sequences that can be used in base editors for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene will be apparent to those of skill in the art based on this disclosure. A person of ordinary skill in the art will also understand that a napDNAbp may be used in a base editor with or without an N-terminal methionine if one is shown in any of the sequences above (z.e., if the napDNAbp is not located at the N-terminus of the base editor, the N-terminal methionine normally present in the napDNAbp sequence (due to the start codon in the nucleotide sequence encoding the napDNAbp) does not need to be present in the base editor).Adenosine Deaminases

[0092] In various embodiments, the adenine base editors contemplated for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene comprise a deaminase domain. In some embodiments, a base editor converts an A to a G. In some embodiments, the base editor comprises an adenosine deaminase. In some embodiments, the deaminase is an E. coli TadA (ecTadA) deaminase, or a variant thereof. Adenosine deaminases are described, for example, in International PCT Application Publication No. WO 2018 / 027078, which is incorporated57 / 149B1195.70208WO00#15198909v2herein by reference. In some embodiments, an adenosine deaminase comprises any of the following amino acid sequences, or an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the following amino acid sequences:58 / 149B1195.70208WO00#15198909v259 / 149B1195.70208WO00 #15198909v260 / 149B1195.70208WO00 #15198909v261 / 149B1195.70208WO00 #15198909v262 / 149B1195.70208WO00 #15198909v263 / 149B1195.70208WO00 #15198909v2Adenine Base Editors

[0093] The present disclosure provides for the use of base editors in treating Zellweger spectrum disorder by editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene. In some embodiments, the base editor is an adenine base editor. In some embodiments, a base editor comprises at least two adenosine deaminase domains. Without wishing to be bound by any particular theory, dimerization of adenosine deaminases (e.g., in cis or in trans) may improve the ability (e.g., efficiency) of the base editor to modify a nucleic acid base (for example, to deaminate adenosine). In some embodiments, any of the base editors provided herein comprise 2, 3, 4, or 5 adenosine deaminase domains. In some embodiments, any of the base editors provided herein comprise two adenosine deaminases. In certain embodiments, the adenosine deaminases are the same. In some embodiments, the adenosine deaminases are any of the adenosine deaminases provided herein. In certain embodiments, the adenosine deaminases are different. Other adenosine deaminase domains besides those provided herein are known in the art, and a person of ordinary skill in the art would recognize which adenosine deaminase domains could be used in the fusion proteins of the present disclosure.

[0094] In some embodiments, the general architecture of the base editors contemplated by the present disclosure comprises any one of the following structures: NH2-[first adenosine deaminase] -[second adenosine deaminase]-[napDNAbp]-COOH; NH2-[first adenosine deaminase]-[napDNAbp]-[second adenosine deaminase]-COOH; NH2-[napDNAbp]- [first adenosine deaminase]-[second adenosine deaminase]-COOH; NH2-[second adenosine deaminase] -[first adenosine deaminase]-[napDNAbp]-COOH; NH2-[second adenosine deaminase] -[napDNAbp]- [first adenosine deaminase] -COOH; NH2-[napDNAbp]-[second adenosine deaminase] -[first adenosine deaminase] -COOH. In certain embodiments, the general architecture of the base editor comprises the structure NH2- [first adenosine deaminase] -[second adenosine deaminase] -[napDNAbp] -COOH.

[0095] In various embodiments, the base editors used in the present disclosure for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene may be fused to one or more nuclear localization sequences (NLS), which help promote translocation of the base editor into the cell nucleus. In some embodiments, the base editors described herein may comprise64 / 149B1195.70208WO00#15198909v2one or more NLS. Such sequences are well-known in the art and can include the following examples:

[0096] The NLS examples above are non-limiting. The fusion proteins provided herein may comprise any known NLS sequence, including any of those described in Cokol et al., “Finding nuclear localization signals,” EMBO Rep., 2000, 1(5): 411-415; and Freitas et al., “Mechanisms and Signals for the Nuclear Import of Proteins,” Current Genomics, 2009, 10(8): 550-7, each of which are incorporated herein by reference.

[0097] In various embodiments, the base editors and constructs encoding the base editors disclosed herein further comprise one or more, preferably at least two, nuclear localization sequences. In certain embodiments, the base editors comprise at least two NLSs. In embodiments with at least two NLSs, the NLSs can be the same NLSs, or they can be different NLSs. In some embodiments, one or more of the NLSs are bipartite NLSs (“bpNLS”). In certain embodiments, the disclosed base editors comprise two bipartite NLSs. In some embodiments, the disclosed base editors comprise more than two bipartite NLSs. The location of the NLS fusion can be at the N-terminus, the C-terminus, or within a sequence of a base editor

[0098] In certain embodiments, a base editor for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene comprises an NLS of the amino acid sequence PKKKRKV (SEQ ID NO: 73). In certain embodiments, a base editor comprises an NLS of the amino acid sequence MKRTADGSEFESPKKKRKV (SEQ ID NO: 74). In certain embodiments, a base editor comprises an NLS of the amino acid sequence KRTADGSEFEPKKKRKV (SEQ ID NO: 83).

[0099] Exemplary base editor fusion architectures comprising a first adenosine deaminase, a second adenosine deaminase, a napDNAbp, and an NLS are provided: NH2- [NLS] -[first65 / 149B1195.70208WO00#15198909v2adenosine deaminase]-[second adenosine deaminase]-[napDNAbp]-COOH; NH2-[first adenosine deaminase] -[NLS]- [second adenosine deaminase]-[napDNAbp]-COOH; NH2-[first adenosine deaminase]-[second adenosine deaminase]-[NLS]-[napDNAbp]-COOH; NH2-[first adenosine deaminase]-[second adenosine deaminase]-[napDNAbp]-[NLS]-COOH; NH2-[NLS]-[first adenosine deaminase]-[napDNAbp]-[second adenosine deaminase] -COOH; NH2-[first adenosine deaminase]-[NLS]-[napDNAbp]-[second adenosine deaminase] -COOH; NH2-[first adenosine deaminase]-[napDNAbp]-[NLS]-[second adenosine deaminase] -COOH; NH2-[first adenosine deaminase] -[napDNAbp]- [second adenosine deaminase]-[NLS]-COOH; NH2- [NLS] -[napDNAbp]- [first adenosine deaminase]-[second adenosine deaminase] -COOH; NH2- [napDNAbp] -[NLS] -[first adenosine deaminase]-[second adenosine deaminase] -COOH; NH2- [napDNAbp] -[first adenosine deaminase]-[NLS]-[second adenosine deaminase] -COOH; NH2- [napDNAbp] -[first adenosine deaminase] -[second adenosine deaminase]-[NLS]-COOH; NH2-[NLS]-[second adenosine deaminase] -[first adenosine deaminase] -[napDNAbp] -COOH; NH2-[second adenosine deaminase] -[NLS] -[first adenosine deaminase]-[napDNAbp]-COOH; NH2-[second adenosine deaminase] -[first adenosine deaminase]-[NLS]-[napDNAbp]-COOH; NH2-[second adenosine deaminase] -[first adenosine deaminase]-[napDNAbp]-[NLS]-COOH; NH2-[NLS]-[second adenosine deaminase] -[napDNAbp] -[first adenosine deaminase] -COOH; NH2-[second adenosine deaminase] -[NLS] -[napDNAbp] -[first adenosine deaminase] -COOH; NH2-[second adenosine deaminase] -[napDNAbp] -[NLS] -[first adenosine deaminase] -COOH; NH2-[second adenosine deaminase] -[napDNAbp] -[first adenosine deaminase]-[NLS]-COOH; NH2- [NLS] -[napDNAbp] -[second adenosine deaminase] -[first adenosine deaminase] -COOH; NH2- [napDNAbp] -[NLS] -[second adenosine deaminase] -[first adenosine deaminase] -COOH; NH2-[napDNAbp]-[second adenosine deaminase] -[NLS] -[first adenosine deaminase] -COOH; NH2-[napDNAbp]-[second adenosine deaminase] -[first adenosine deaminase] -[NLS] -COOH.

[0100] In some embodiments, each instance of “]-[” used in the general architecture above indicates the presence of an optional linker. In some embodiments, a base editor comprises one or more a peptide linkers. Exemplary peptide linkers for use in the base editors contemplated by the present disclosure include, but are not limited to, (GGGGS)n(SEQ ID NO: 85), (G)n (SEQ ID NO: 86), (EAAAK)n(SEQ ID NO: 87), (GGS)n(SEQ ID NO: 88), (SGGS)n (SEQ ID NO: 89), (XP)n(SEQ ID NO: 90), SGSETPGTSESATPES (SEQ ID NO: 91), SGSETPGTSESA (SEQ ID NO: 92), SGSETPGTSESATPEGGSGGS (SEQ ID NO: 93), SGGSSGGSSGSETPGTSESATPESSGGSSGGS (SEQ ID NO: 94), SGGSGGSGGS (SEQ ID NO: 95), SGGS (SEQ ID NO: 96),66 / 149B1195.70208WO00#15198909v2SGGSSGGSSGSETPGTSESATPESAGSYPYDVPDYAGSAAPAAKKKKLDGSGSGGSS GGS (SEQ ID NO: 97), GGSGGS (SEQ ID NO: 98), GGSGGSGGS (SEQ ID NO: 99), SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 100), or any combination thereof, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid.

[0101] In some embodiments, the base editor used in the methods, complexes, and compositions provided herein is ABE7.10, ABE8e, or ABE8e-V106W.

[0102] In some embodiments, base editors useful for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene include base editors comprising any of the following amino acid sequences, or comprising an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to any of the following amino acid sequences:67 / 149B1195.70208WO00#15198909v268 / 149B1195.70208WO00 #15198909v269 / 149B1195.70208WO00 #15198909v270 / 149B1195.70208WO00 #15198909v271 / 149B1195.70208WO00 #15198909v272 / 149B1195.70208WO00 #15198909v273 / 149B1195.70208WO00 #15198909v274 / 149B1195.70208WO00 #15198909v275 / 149B1195.70208WO00 #15198909v276 / 149B1195.70208WO00 #15198909v2Guide RNAs (gRNAs)

[0103] In general, a gRNA is any RNA sequence having sufficient complementarity with a target polynucleotide sequence (e.g., PEX1) to hybridize with the target sequence and direct sequence- specific binding of a napDNAbp (e.g., Cas9, which may be part of a base editor) to the target sequence. In some embodiments, the degree of complementarity between the spacer of a gRNA and its corresponding target sequence in PEX1, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more (or the spacer and the corresponding target sequence comprise one, two, three, four, five, six, seven, eight, nine, or ten amino acid differences). In certain embodiments, the spacer of a gRNA is 100% complementary to its corresponding target sequence in PEX1. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, NOVOALIGN™ (NOVOCRAFT® Technologies, ELAND® (ILLUMINA®, San Diego, Calif.), SOAP™ (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).

[0104] The ability of a gRNA to direct sequence- specific binding of a base editor to a target sequence may also be assessed by any suitable assay. For example, a base editor and gRNA may be provided to a host cell (e.g., a cell of the CNS, such as a neuron or a glial cell) having the corresponding target sequence (e.g., PEX1, or a portion thereof), such as by transfection with vectors encoding the base editor and gRNA or by transfection of a ribonucleoprotein (RNP) complex, followed by an assessment of preferential cleavage, nicking, or editing within the target sequence. Similarly, cleavage or editing of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, base editor, and gRNA to be tested and a control gRNA different from the test gRNA, and comparing binding or rate of77 / 149B1195.70208WO00#15198909v2cleavage or editing at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will be apparent to those skilled in the art.

[0105] In some embodiments, a gRNA is about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 75, about 100, or more nucleotides in length. In some embodiments, a gRNA is about 50-150, about 60-140, about 70-130, about 80-120, or about 90-110 nucleotides in length. In some embodiments, the spacer sequence of a gRNA is about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, or about 30 nucleotides in length.

[0106] In some embodiments, a gRNA comprises the structure 5 '-[spacer sequence] -[backbone sequence]-3'. In some embodiments, a gRNA comprises an optional linker sequence. For example, the gRNAs provided herein may comprise an optional linker sequence between the spacer and the backbone sequence of the gRNA. In certain embodiments, the optional linker sequence is at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, or at least 50 nucleotides in length.

[0107] Additional sequences of suitable gRNAs for targeting a base editor to PEX1 within the scope of the present disclosure will be apparent to those of skill in the art. Such suitable guide RNA sequences typically comprise a spacer sequence that is complementary to a nucleic sequence within 50 nucleotides (e.g., within 45, 40, 35, 30, 25, 20, 15, or 10 nucleotides) upstream or downstream of the target nucleotide to be edited (e.g., a target mutation in a PEX1 gene).

[0108] The present disclosure provides gRNAs for targeting a genome editing agent (e.g., a base editor) to a PEX1 gene or mutant allele (e.g., a human or mouse PEX1 gene or mutant allele). The gRNAs provided herein may be useful for treating Zellweger spectrum disorder by programming one or more base editors for editing mutations in a PEX gene, e.g., a mutation in a PEX1 gene, such as, a human PEX / -G843D (c.2528G> A) mutant allele or a mouse PEX / -G844D (c.2531G> A) mutant allele.78 / 149B1195.70208WO00#15198909v2

[0109] In some embodiments, the gRNA targets a human PEX1 gene, or mutant allele thereof. In other embodiments, the gRNA targets a mouse PEX1 gene, or mutant allele thereof.

[0110] In some embodiments, the gRNA targets a human PEX7-G843D (c.2528G> A) mutant allele. In other embodiments, the gRNA targets a mouse PEX7-G844D (c.2531G> A) mutant allele.

[0111] In some embodiments, the gRNA targets a human PEX7-G843D (c.2528G> A) mutant allele and comprises a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113) and has corresponding RNA spacer sequence of 5'-GUUGAUGGGUUACAUGAAGUU-3' (SEQ ID NO: 114).

[0112] In other embodiments, the gRNA targets a human PEX7-G843D (c.2528G> A) mutant allele and has a spacer that is encoded by a nucleotide sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113) or a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113). In still other embodiments, the gRNA comprises an RNA spacer of 5'-GUUGAUGGGUUACAUGAAGUU-3' (SEQ ID NO: 114) or an RNA sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with 5'-GUUGAUGGGUUACAUGAAGUU-3' (SEQ ID NO: 114), or a spacer sequence comprising one, two, three, four, five, six, seven, eight, nine, or ten or more nucleotide substitutions relative to the sequence 5'-GUUGAUGGGUUACAUGAAGUU-3' (SEQ ID NO: 114).

[0113] In other embodiments, the gRNA targets a mouse PEX7-G844D (c.2531G> A) mutant allele and comprises a spacer encoded by a nucleotide sequence of 5'-GTGATGGATTACATGAAGTT-3' (SEQ ID NO: 115) or a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with 5'-GTGATGGATTACATGAAGTT-3' (SEQ ID NO: 115). In still other embodiments, the gRNA has an RNA spacer of 5’-GUGAUGGAUUACAUGAAGUU-3’ (SEQ ID NO: 116) or an RNA spacer having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with 5'-GUGAUGGAUUACAUGAAGUU-3' (SEQ ID NO: 116), or a spacer sequence comprising one, two, three, four, five, six, seven, eight, nine, or79 / 149B1195.70208WO00#15198909v2ten or more nucleotide substitutions relative to the sequence 5'-GUGAUGGAUUACAUGAAGUU-3' (SEQ ID NO: 116).

[0114] In other embodiments, the gRNA is encoded by a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the nucleotide sequence of 5'- GTGATGGATTACATGAAGTT-3' (SEQ ID NO: 115) and / or as an RNA sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the 5'-GTGATGGATTACATGAAGTT-3' (SEQ ID NO: 115), or a spacer sequence comprising one, two, three, four, or five nucleotide substitutions relative to the sequence 5'-GTGATGGATTACATGAAGTT-3' (SEQ ID NO: 115).

[0115] In some embodiments, the gRNA comprises a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the RNA sequence of 5'-GTGAUGGAUUACAUGAAGUU-3' (SEQ ID NO: 117). In some embodiments, the gRNA comprises a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the RNA sequence of 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113) or a spacer sequence comprising one, two, three, four, or five nucleotide substitutions relative to the sequence 5'-GTTGATGGGTTACATGAAGTT-3' (SEQ ID NO: 113) (for targeting human PEX7-G843D (c.2528G> A) mutant allele in a human PEX1 gene).

[0116] In some embodiments, the gRNA targets the PEX1 (G843D) mutant allele. In some embodiments, the gRNA targets another PEX1 mutant allele. The person having ordinary skill in the art will also understand and know how to design an appropriate guide sequence to any PEX1 mutant allele. Some guiding principles that may be considered when designing a guide RNA to a target site, such as a PEX1 mutant allele, include but are not limited to:Target Specificity: Select a target sequence that is unique to the region of interest to minimize off-target effects. Ensure the target sequence is adjacent to a protospacer adjacent motif (PAM) sequence compatible with the Cas9 variant used in the ABE; Length and Structure: Typically, a gRNA spacer should be about 20 nucleotides long. Ensure the gRNA has a stable secondary structure, which can be predicted using RNA folding software to enhance binding efficiency; PAM Compatibility: Ensure that the sequence following the target site contains a PAM that the particular Cas9 variant used in the ABE can recognize. For example, the commonly used SpCas9 requires an NGG PAM; Optimization: Experiment80 / 149B1195.70208WO00#15198909v2with different gRNA sequences around the target site to identify the most effective one. Utilizing known computational tools and known databases can help predict the efficiency of each gRNA design; Consideration of Editing Window Understand the editing window of the ABE, as the ABE only modifies adenines within a specific range. This range typically extends from the 5 end of the gRNA target site. Experimental Validation After designing, validate the gRNA experimentally to confirm its efficiency and specificity in targeting the desired mutation, and evaluate effect on off-target or bystander editing.

[0117] In some embodiments, the guide RNA is designed against a mouse target sequence. In other embodiments, the guide RNA is designed against a human target sequence.

[0118] In some embodiments, the gRNAs target a base editor to a site in the human PEX1 gene of SEQ ID NO: 127. In some embodiments, the gRNAs target a base editor to a site in the human PEX1 gene such that the base editor corrects a mutation in the PEX1 gene, leading to correction of a mutation in the human PEX1 enzyme. In some embodiments, the gRNAs target a base editor to a site in the mouse PEX1 gene of SEQ ID NO: 129. In some embodiments, the gRNAs target a base editor to a site in the mouse PEX1 gene such that the base editor corrects a mutation in the PEX1 gene, leading to correction of a mutation in the mouse PEX1 enzyme.Methods of Use

[0119] In various embodiments, the disclosure relates to methods of using any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits or combinations thereof disclosed herein for correcting one or more ABE-targetable mutations in a PEX1 gene, including the PEX1 G843D human mutant allele (z.e., a c.2528G> A mutation in the human PEX1 gene sequence) and the PEX1 G844D mouse mutant allele (z.e., a c.2531G> A mutation in the mouse PEX1 gene sequence).

[0120] In other embodiments, the disclosure relates to methods of treating Zellweger spectrum disorder or one or more symptoms thereof by administering an effective amount of any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits, or combinations thereof disclosed herein for editing one or more ABE-targetable mutations in a PEX1 gene, including the PEX1 G843D human mutant allele (z.e., a c.2528G> A mutation in the human PEX1 gene sequence) and the PEX1 G844D mouse mutant allele (z.e., a c.2531G> A mutation in the mouse PEX1 gene sequence).81 / 149B1195.70208WO00#15198909v2

[0121] In yet other embodiments, the disclosure also relates to methods of using any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits or combinations thereof disclosed herein for correcting one or more ABE-targetable mutations in the PEX1 gene of any of the ABEs disclosed herein.

[0122] In still other embodiments, the disclosure relates to methods of treating Zellweger spectrum disorder or one or more symptoms thereof by administering an effective amount of any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits, or combinations thereof disclosed herein for editing one or more ABE-targetable mutations in the PEX1 gene of any of the ABEs disclosed herein.

[0123] In yet other embodiments, the disclosure relates to methods of using any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits or combinations thereof disclosed herein for correcting a PEX1 G843D human mutant allele. In yet other embodiments, the disclosure relates to methods of using any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits or combinations thereof disclosed herein for correcting a PEX1 G844D mouse mutant allele.

[0124] In still other embodiments, the disclosure relates to methods of treating Zellweger spectrum disorder or one or more symptoms thereof by administering an effective amount of any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits, or combinations thereof disclosed herein for a PEX1 G843D human mutant allele. In still other embodiments, the disclosure relates to methods of treating Zellweger spectrum disorder or one or more symptoms thereof by administering an effective amount of any one of the adenine base editors (ABEs), guide RNAs, complexes, compositions, vectors, cells, and / or kits, or combinations thereof disclosed herein for a PEX1 G844D mouse mutant allele.Delivery Methods and AAV Particles

[0125] The present disclosure provides, in some aspects, methods and uses comprising delivering any of the gRNAs, complexes, polynucleotides, vectors, and pharmaceutical compositions described herein. In some embodiments, a gRNA is delivered to a cell, e.g., in combination with a base editor. The base editor and / or gRNA can be delivered in any form, e.g., each may independently be delivered in DNA, RNA, or (for the base editor) protein form. Conventional viral and non-viral based gene transfer methods can be used to introduce82 / 149B1195.70208WO00#15198909v2nucleic acids in cells (e.g., mammalian cells) or target tissues. Such methods can be used to administer nucleic acids encoding components of a base editor and gRNA to cells in culture, or in a host organism. Non- viral vector delivery systems include ribonucleoprotein (RNP) complexes, DNA plasmids, RNA, naked nucleic acid, and nucleic acid complexed with, part of, or associated with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Feigner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10): 1149- 1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51 (1):31-44 (1995); Haddada et al., in Current Topics in Microbiology and Immunology Doerfler and Bihm (eds) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).

[0126] In some embodiments, the gRNA and base editor are delivered or administered as a protein:mRNA complex. In certain embodiments, the method of delivery comprises delivering an RNP complex. For example, RNP delivery of base editors markedly increases the DNA specificity of base editing. RNP delivery of base editors leads to fewer off-target effects. RNP delivery ablated off-target editing at non-repetitive sites while maintaining on-target editing comparable to plasmid delivery, and greatly reduced off-target editing even at the highly repetitive VEGFA site 2. See Rees, H. A. et al., Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery, Nat. Commun.8, 15790 (2017), which is incorporated herein by reference.

[0127] Methods of non- viral delivery of nucleic acids include RNP complexes, lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in, e.g., U. S. Pat. Nos. 5,049,386, 4,946,787, and 4,897,355, and lipofection reagents are sold commercially (e.g., Lipofectamine, Lipofectamine 2000, Lipofectamine 3000, Transfectam™ and Lipofectin™). In certain embodiments of the disclosed methods of editing, a cationic lipid comprising Lipofectamine 2000 is used for delivery of nucleic acids to cells. Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner (see WO 1991 / 17424 and WO 1991 / 16024). Delivery of, e.g., Cas9 proteins and gRNAs using cationic lipids and cationic polymers is also described in International Patent83 / 149B1195.70208WO00#15198909v2Application Publication Nos. WO 2015 / 035136 and WO 2016 / 070129, each of which is incorporate herein by reference. Delivery can be to cells (e.g., in vitro or ex vivo administration) or target tissues (e.g., in vivo administration).

[0128] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); GaoAhmad et al., Cancer Res. 52:4817-4820 (1992); U. S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, 4,946,787, 9,526,784, and 9,737,604).

[0129] The use of RNA or DNA viral based systems for the delivery of nucleic acids (e.g., nucleic acids encoding a base editor and gRNA as described herein) take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo), or they can be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo). Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associated, and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene.Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.

[0130] In some embodiments, an adeno-associated virus (AAV)-based system is used for delivery of nucleic acid molecule(s) encoding a gRNA and base editor. Particularly in applications where transient expression is preferred, adenoviral-based systems may be used. Adenoviral-based vectors are capable of very high transduction efficiency in many different cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. AAV vectors may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West etal., Virology 160:38-47 (1987); U. S. Pat. No.4,797,368; WO 93 / 24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994). Construction of recombinant AAV vectors is described in a number of publications, including U. S. Pat. No. 5,173,414; Tratschin etal., Mol. Cell. Biol.84 / 149B1195.70208WO00#15198909v25:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); Samulski et al., J. Virol. 63:03822-3828 (1989); and International Patent Application No. PCT / US2023 / 066389, filed April 28, 2023.

[0131] Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and q / 2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by producing a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polynucleotide(s) to be expressed. The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess ITR sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line may also be infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. In some embodiments, the AAV targets the central nervous system (CNS). In some embodiments, the AAV targets neurons. In certain embodiments, the AAV is AAV9.

[0132] In various embodiments, the constructs for expressing a gRNA and base editor described herein may be engineered for delivery in one or more AAV vectors. An AAV as related to any of the methods and compositions provided herein may be of any serotype including any derivative or pseudotype e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 2 / 1, 2 / 5, 2 / 8, 2 / 9, 3 / 1, 3 / 5, 3 / 8, or 3 / 9). An AAV may comprise a genetic load (i.e., a recombinant nucleic acid vector that expresses gene products of interest, such as a base editor and / or gRNA that is carried by the AAV into a cell) that is to be delivered to a cell.

[0133] In one aspect, the present disclosure provides one or more AAV particles comprising one or more polynucleotides encoding any of the gRNAs and base editors, or portion(s) thereof, provided herein. In some embodiments, the polynucleotide encoding the base editor is split between a first and a second AAV particle. In certain embodiments, the polynucleotides encoding the split base editor comprise an N-intein and a C-intein. In some85 / 149B1195.70208WO00#15198909v2embodiments, the first and / or the second AAV particle further comprises the polynucleotide encoding the gRNA.Pharmaceutical Compositions

[0134] Other aspects of the present disclosure relate to pharmaceutical compositions comprising any of the gRNAs, base editors, complexes, AAV particles, polynucleotides, vectors, and / or cells described herein. The term “pharmaceutical composition,” as used herein, refers to a composition formulated for pharmaceutical use. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises additional agents (e.g., for specific delivery, increasing half-life, or other therapeutic compounds).

[0135] As used here, the term “pharmaceutically-acceptable carrier” (or “pharmaceutically acceptable excipient”) means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the compound from one site (e.g., the delivery site) of the body, to another site (e.g., organ, tissue or portion of the body). A pharmaceutically acceptable carrier is “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the tissue of the subject (e.g., physiologically compatible, sterile, physiologic pH, etc.). Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids; (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols,86 / 149B1195.70208WO00#15198909v2such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservatives, and antioxidants can also be present in the formulation. Terms such as “excipient,” “carrier,” “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” or the like are used interchangeably herein.

[0136] In some embodiments, the pharmaceutical composition is formulated for delivery to a subject for gene editing (e.g., base editing). In some embodiments, the pharmaceutical composition comprises an AAV for delivery to a subject for gene editing (e.g., base editing).

[0137] The pharmaceutical compositions described herein may be administered or packaged as a unit dose, for example. The term “unit dose” when used in reference to a pharmaceutical composition of the present disclosure refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

[0138] In some embodiments, an article of manufacture containing materials useful for the treatment of the diseases described above is included. In some embodiments, the article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. In some embodiments, the container holds a composition that is effective for treating a disease and may have a sterile access port. For example, the container may be an intravenous solution bag or a vial having a stopper pierce-able by a hypodermic injection needle. The active agent in the composition is a compound of the invention. In some embodiments, the label on or associated with the container indicates that the composition is used for treating the disease of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically acceptable buffer, such as phosphate-buffered saline, Ringer’s solution, or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.Polynucleotides, Vectors, Cells, and Kits

[0139] The present disclosure provides, in some aspects, polynucleotides and vectors encoding any of the gRNAs, base editors, complexes, and / or AAV particles described herein.87 / 149B1195.70208WO00#15198909v2In some aspects, the present disclosure provides polynucleotides and vectors encoding a gRNA and a base editor as disclosed herein. In some embodiments, the polynucleotides and vectors provided herein comprise DNA (e.g., plasmid DNA or viral DNA). In some embodiments, the polynucleotides and vectors provided herein comprise RNA (e.g., mRNA or viral RNA).

[0140] Cells that may contain any of the gRNAs, base editors, complexes, AAV particles, polynucleotides, and / or vectors described herein are also provided by the present disclosure. The methods described herein may be used to deliver a gRNA and base editor into a eukaryotic cell (e.g., a mammalian cell, such as a human cell). In some embodiments, the cell is in vitro (e.g., a cultured cell). In some embodiments, the cell is in vivo e.g., in a subject, such as a human subject). In some embodiments, the cell is ex vivo (e.g., isolated from a subject and may be administered back to the same or a different subject).

[0141] In some embodiments, a host cell is transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject. In some embodiments, a cell that is transfected is taken from a subject. In some embodiments, the cell is derived from cells taken from a subject, such as a cell line. In some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences. In some embodiments, a cell transiently transfected with the components of a base editing system as described herein (such as by transient transfection of one or more vectors, or transfection with RNA), and modified through the activity of a base editing complex, is used to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence.

[0142] The gRNAs, base editors, complexes, AAV particles, polynucleotides, and / or vectors described herein may also be assembled into kits. In some embodiments, the kit comprises polynucleotides for expression of the gRNAs, base editors, complexes, and / or AAV particles described herein. In some embodiments, the kit comprises appropriate gRNAs or nucleic acid vectors for the expression of such gRNAs to target the Cas9 protein of a base editor to a desired target sequence, e.g., in PEX1. In some embodiments, the gRNAs in the kit are useful for correcting an G843D mutation in a PEX1 enzyme (i.e., a c.2528G> A mutation in the human PEX1 gene sequence).

[0143] The kits described herein may include one or more containers housing components for performing the methods described herein, and optionally instructions for use. Any of the kits88 / 149B1195.70208WO00#15198909v2described herein may further comprise components needed for performing the base editing methods described herein. Each component of the kits, where applicable, may be provided in liquid form (e.g., in solution) or in solid form, (e.g., a dry powder). In certain cases, some of the components may be reconstitutable or otherwise processible (e.g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water), which may or may not be provided with the kit.

[0144] In some embodiments, the kits may optionally include instructions and / or promotion for use of the components provided. As used herein, “instructions” can define a component of instruction and / or promotion, and typically involve written instructions on or associated with packaging of the disclosure. Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (e.g., videotape, DVD, etc.), Internet, and / or web-based communications, etc. The written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which can also reflect approval by the agency of manufacture, use, or sale for animal administration. As used herein, “promoted” includes all methods of doing business including methods of education, hospital and other clinical instruction, scientific inquiry, drug discovery or development, academic research, pharmaceutical industry activity including pharmaceutical sales, and any advertising or other promotional activity including written, oral, and electronic communication of any form, associated with the disclosure. Additionally, the kits may include other components depending on the specific application, as described herein.

[0145] The kits may contain any one or more of the components described herein in one or more containers. The components may be prepared sterilely, packaged in a syringe, and shipped refrigerated. Alternatively, they may be housed in a vial or other container for storage. A second container may have other components prepared sterilely. Alternatively, the kits may include the active agents premixed and shipped in a vial, tube, or other container.

[0146] The kits may have a variety of forms, such as a blister pouch, a shrink-wrapped pouch, a vacuum sealable pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the accessories loosely packed within the pouch, one or more tubes, containers, a box, or a bag. The kits may be sterilized after the accessories are added, thereby allowing the individual accessories in the container to be otherwise unwrapped. The kits can be sterilized using any appropriate sterilization techniques, such as radiation sterilization, heat89 / 149B1195.70208WO00#15198909v2sterilization, or other sterilization methods known in the art. The kits may also include other components, depending on the specific application, for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration, etc.EXAMPLESExample 1. In Vivo Base Editing Rescues Liver Pathologies and Peroxisome Dysfunction in a Mouse Model of Zellweger Spectrum Disorder

[0147] Peroxisomes are metabolic membrane-bound organelles that serve as a central hub in eukaryotic cell signaling1 3and play an essential role in maintaining physiological homeostasis in mammals1,4. They are required for the biosynthesis of mature bile acids, platelet-activating factor (PAF), docosahexaenoic acid (DHA), and ether lipids such as plasmalogens, a major constituent of myelin5.

[0148] They are also involved in the catabolism of branched-chain and very long-chain (>22 carbons) fatty acids (BCFAs and VLCFAs), polyamines, D-amino acids, glyoxylate, and hydrogen peroxide byproducts of lipid oxidation6 s. As highlighted by their involvement in the etiology of rare and common diseases9, peroxisomes play essential roles in the development and function of mammalian hepatic, nervous, and sensory systems3,10.

[0149] Zellweger spectrum disorder (ZSD) is a disease spectrum with an overall incidence of approximately 1 in 50,000-90,000 births in North America10,11. ZSD is caused by biallelic loss-of- function pathogenic variants in any of one of the 13 PEX genes that encode peroxin proteins, which are required for normal peroxisome assembly, structure, abundance, and functions10. PEX1 is a member of the AAA ATPase protein family and an essential component of the PEX1-PEX6-PEX26 exportomer complex required for peroxisome assembly12 l4. The partial loss-of-function PEX7-p. G843D (c.2528G> A) variant represents approximately 30% of all ZSD alleles10(FIG. 1A). Consistent with its residual activity, patients with at least one P 7-p. G843D allele typically show milder clinical phenotypes and a more degenerative course of disease compared to patients with two null PEX1 gene alleles, who commonly do not survive beyond the first year of life10,15. Patients who are compound heterozygous for the P Xl-p. GM D allele and a null PEX1 allele often show moderate forms of disease. Although precise genotype information is often limited, patients with moderate ZSD frequently display hepatomegaly, coagulation defects, and progressive liver cholestasis that can lead to cirrhosis, hepatocellular carcinoma, and shortened lifespan15 17. Additionally,90 / 149B1195.70208WO00#15198909v2they can show progressive vision and hearing loss, intellectual disabilities, osteopenia, kidney stones, adrenal insufficiency, and amelogenesis imperfecta15 17 l9. Patients who are homozygous for the PEX7-p. G843D allele commonly show a milder course of degenerative disease that typically results in progressive vision and hearing loss and amelogenesis imperfecta with hepatomegaly, coagulation defects, and adrenal insufficiency in some individuals15 18,20.

[0150] ZSD can be detected prior to substantial irreversible damage to the liver and other organs in patients with less severe disease, which provides therapeutic windows for potential treatment. Widely adopted newborn screening for adrenoleukodystrophy (ALD), which measures C26:0-lysophosphatidylcholine (LPC) levels in dried blood spots, can also identify ZSD since these metabolites are elevated in both conditions21,22. This opportunity for early diagnosis highlights the urgent unmet need for developing effective therapies for ZSD since current treatments are palliative and do not address the root cause of disease23. Cholic acid supplementation is used to suppress bile acid synthesis and reduce the accumulation of toxic C27-bile acid intermediates caused by impaired peroxisomal beta-oxidation; however, its effect on clinically relevant outcome measures is still under discussion24 26. While liver and hepatocyte transplantation has been used to address liver disease or improve clinical outcomes, these are invasive procedures that require long-term immunosuppression, and few ZSD patients receiving transplants have been reported thus far27 30.

[0151] Base editing is a precision genome editing tool that typically uses a DNA deaminase tethered to a Cas9 nickase to enable targeted, single nucleotide conversion. Adenine base editors (ABEs), as one class of base editors, can convert A»T-to-G»C and have demonstrated tremendous potential in the treatment of genetic diseases in ex vivo and in vivo, such as in recent examples of progeria31, sickle cell disease32, CD36 severe combined immunodeficiency33, and spinal muscular atrophy3435. Presented herein is an adenine base editing strategy to directly correct the PPX / -p. G844D (c.2531G> A) allele, the murine equivalent of the human PEX7-p. G843D allele, in a preclinical ZSD mouse model. This ZSD mouse model is homozygous for the PPX / -p. G844D allele (the murine equivalent of the human PEX / -p. G843D allele) and recapitulates key disease features including fatty liver with cholestasis and progressive vision loss36 40. Dual adeno-associated virus (AAV) vectors (encoding ABE8e-V106W and a guide RNA that targets the ABE to PEX7-p. G844D) were delivered to neonatal and 4- week-old mice and achieved robust correction of disease alleles in the bulk liver in a highly specific and dose- and time-dependent manner. Lipid91 / 149B1195.70208WO00#15198909v2nanoparticle (LNP) delivery of the ABE8e-V106W mRNA and PEX1 guide RNA also yielded substantial bulk liver correction of the pathogenic mutation, demonstrating the possibility of a non-viral in vivo base editing approach to address the root cause of ZSD.

[0152] AAV9-ABE-mediated correction of the murine PEX1 pathogenic allele, restored normal hepatic metabolic functions, reduced circulating and / or tissue levels of toxic peroxisome metabolites, rescued liver pathologies, and improved growth. In cultured patient- derived skin fibroblasts, ABE editing resulted in the robust correction of PEX7-p. G843D alleles and rescued impaired peroxisome biogenesis. These results establish for the first time that a precision gene editing strategy can correct the root cause of ZSD liver disease and rescue its phenotypic consequences in both animal models and in patient-derived cells.ResultsThe PEXl-p. G843D allele is associated with liver disease in patients with ZSD

[0153] To better understand the natural course of ZSD liver disease caused by PEX1- p. G843D allele(s), clinical data from 52 individuals (age of assessment: 0.04 to 49.9 years) enrolled in an ongoing longitudinal natural history study of ZSD (ClinicalTrials.gov ID NCT01668186) and being either homozygous or compound heterozygous for this allele, were analyzed. Evidence of liver disease was subclassified into liver dysfunction (including elevated liver transaminases and hepatomegaly) and severe liver disease (including any of cirrhosis, portal hypertension, esophageal varices, gastrointestinal bleeding, ascites, or hepatic cancer). There was frequent evidence of liver dysfunction or severe liver disease in patients homozygous for the PEX7-p. G843D allele (67%: liver dysfunction; 9%: severe disease) or compound heterozygous (64%: liver dysfunction; 26%: severe disease) for the PEX1- p. G843D allele (FIG. 1G). On average, PEX7-p. G843D homozygotes, which have two PEX1 alleles with residual activity, showed less severe liver disease than compound heterozygous patients, who could also carry a PEX1 null allele (indeed, frameshift or nonsense variants were found in 24 such patients). Overall, the clinical phenotypes observed in this cohort further support the unmet need for therapies for ZSD liver disease caused by PPX / -p. G843D allele(s).Development of a base editing strategy to correct the PEXl-p. G843D allele in patient-derived fibroblasts

[0154] To correct the deleterious PEX7-p. G843D (c.2528 G> A) variant, a Streptococcus pyogenes Cas9 (SpCas9) guide RNA was designed that places the pathogenic c.2528 G> A92 / 149B1195.70208WO00#15198909v2adenine variant at the fourth position (A4) of the protospacer 5 TTGATGGGTTACATGAAGTT-3 ' (SEQ ID NO: 118), a position located within the 5-nt base editing window (5 -N4NNNNs-3 ') for most base editors that use SpCas941(FIG. IB). Next, three different adenine base editors (ABEs) were tested that use SpCas9 domains to recognize NGG protospacer-adjacent motif (PAM) sequences: ABE7.1042, ABE8e43, and ABE8e-V106W43. Laboratory-evolved deoxyadenosine deaminases ABE8e and ABE8e-V106W offer higher editing efficiencies than ABE7.10. ABE8e-V106W is a high-fidelity version of ABE8e that results in efficient on-target editing but reduced RNA editing and Cas-independent off-target DNA editing due to a V106W substitution in the deaminase43. After nucleofecting patient-derived homozygous PEX1- p. G843D skin fibroblasts with in vitro transcribed ABE7.10 mRNA and synthetic guide RNA, 20% of total sequencing reads contained the corrected base edit (from the pathogenic A4 to wild-type G4) and 7.6% of sequencing reads showed bystander editing (synonymous mutation) at protospacer position All (FIG. 1C). Using ABE8e and ABE-V106W to target this protospacer yielded a 4-fold improvement in editing efficiency in patient-derived fibroblasts compared to ABE7.10, achieving 80% correction with ABE8e and ABE8e-V106W. This large improvement in editing efficiency was accompanied by increased bystander editing at positions Al 1 and A13, consistent with previous observations. Given the enhanced adenosine deaminase activity, some bystander editing at these neighboring bases was expected43. Bystander A*T-to-G*C editing at All results in a synonymous mutation (p. L845L, TTA> TTG) that is predicted not to impact PEX1 RNA splicing44(FIG. 1C). Bystander editing at position A13 introduces a missense mutation (p. H846R) that is predicted to be benign by the variant classification algorithms tested44,45and gnomAD46databases, and has not been reported in the ClinVar database47. Bystander editing (A 13) was observed at a frequency of 19% with ABE8e and 9.3% with ABE8e-V106W, respectively, and low levels of indels (<2%) within 20 bp of the protospacer in all ABE-treated fibroblasts. Further assessment of recently reported compact ABE editors in the homozygous PEX7-p. G843D skin fibroblasts showed largely reduced editing efficiency for this pathogenic allele compared to the ABE8e (FIG. 6B).

[0155] These results demonstrate that adenine base editing can efficiently correct the PEX1-p. G843D pathogenic variant in patient-derived cells while minimizing the production of uncontrolled indels that could alter protein function. These ABE8e and ABE8e-V106W PEX7-p. G843D correction strategies were therefore applied in vivo using mouse models of ZSD.93 / 149B1195.70208WO00#15198909v2In vivo adenine base editing efficiently corrects the mouse PEXl-p. G844D allele

[0156] To investigate the potential of an ABE-mediated therapeutic strategy for ZSD, an SpCas9 guide RNA was designed to target the PPX / -p. G844D murine equivalent of the PEXl-p. G843D deleterious allele PEX1. The mouse allele differs from the corresponding PEX7-p. G843D human allele at the target protospacer by a single nucleotide at the eighth position (5 -TTGATGGATTACATGAAGTT-3' (SEQ ID NO: 119). A dual-AAV9 vector system was designed that encodes the ABE as two halves, each linked to a fast-splicing intein48(FIG. ID). Following the co-transduction of AAV encoding both ABE halves, the complete base editor can form upon association of the two halves, which can be made permanent by intein-catalyzed protein splicing48.

[0157] To determine the ability of ABE8 variants to correct the PEX7-p. G844D allele in the liver of mice, Pl PEX7G844D / +heterozygous mice were treated with one of three doses of AAV9 (4xl0n, 4xlO10, or 4xl09vg per mouse) encoding ABE8e or ABE8e-V106W and the above guide RNA by facial vein injection (FIG. IE). Heterozygous mice did not tolerate the highest dose of ABE8e (4xl0nvg / mouse, equivalent to 2.8xl014vg / kg); all mice in this cohort died by day 15 post-injection. In contrast, all five mice successfully injected with the ABE8e-V106W base editor at the same dose of 4xl0nvg per mouse survived. Six weeks after injection, the mice were sacrificed, and liver tissues were harvested, revealing 52% bulk liver correction of P£X / -p. G844D pathogenic alleles, the highest editing efficiency among all surviving cohorts (FIG. IF). At 4xlO10and 4xl09vg doses, ABE8e did not lead to any lethality and yielded 47% and 13% correction of the PEX7-p. G844D alleles. 44% and 10% correction of the pathogenic alleles were observed in ABE8e-V106W injected Pl mice dosed with 4xlO10and 4xl09vg, respectively. Very low levels of undesired bystander editing (<0.1% for A at the minus one position relative to the protospacer, p. I843V) and indels (<0.55%) were also observed across all mice treated with either ABE variant.

[0158] Collectively, these results in heterozygous mice establish that AAV-mediated in vivo delivery of ABE can correct the PPX / -p. G844D allele in animals. Moreover, it suggested an AAV9-ABE8e-V106W dose range to evaluate potential phenotypic rescue in the homozygous PPX / -p. G844D mouse model. As high editing efficiency and no evident toxicity was observed when using AAV9 as a delivery vehicle, the ABE8e-V106W base editor was advanced to in vivo phenotypic rescue studies with homozygous PPX / -p. G844D mice.94 / 149B1195.70208WO00#15198909v2In vivo base editing in homozygous PEXl-p. G844D mice

[0159] Homozygous PEX7-p. G844D mice have a severe neonatal mortality when bred in the B6 / J (B6. Cg-PEXltml lSjms / Mmiax, catalog 25065)39or B6 / N37genetic background strains. In contrast, homozygous PPX / -p. G844D mice have been previously characterized on mixed genetic backgrounds to support more prolonged survival and facilitate studies36,39. A more defined breeding strategy was used herein by crossing B6. Cg-PEX / "" / / S / "'' / Mmjax with 129S6. Cg-PEX77m7,7S7ms / Mmjax, thus the use of Fl hybrid mice provides advantages on reproducibility and less phenotypic variation due to segregating genetic modifiers. The resulting homozygous mice for the PPX / -p. G844D allele have a normal survival, but still show growth deficits, retinal degeneration38,49, and liver pathologies resulting from impaired peroxisomal metabolic activities.

[0160] To test the potential of base editing to restore peroxisome and liver function, dual-AAV9 ABE8e-V106W was delivered to Pl PEX7G844D / G844DpUpSsystemically, via facial vein injection (FIG. 7A). All vehicle (saline)-treated homozygous mice survived until 16 weeks post-injection, the endpoint of the study, confirming that the B6;129S6 Fl hybrid background addressed the neonatal lethality observed in pure B6 or pure 129S6 mouse strains (FIG. 7B). While the 4xl0nvg AAV9-ABE8e-V106W dose did not affect the viability of healthy heterozygous ppxiG&44D / +mice, PEX7G844D / G844Dmice wereless tolerant of this dose, most likely due to their reduced weight at Pl (1.4 g homozygous vs 1.6 g heterozygous on average) and pronounced liver disease. A total of 44 out of 63 injected Pl homozygous PPX / -p. G844D mice died during the first three weeks after injection with the 4xl0nvg dose AAV9-ABE8e-V106W (FIG. 7B). Among the 19 surviving mice, an average of 59% bulk liver correction of the G844D deleterious allele was observed. Since hepatocytes account for the majority (-60%) of mouse liver cells50this degree of bulk liver editing is consistent with robust editing of hepatocytes (FIG. 7C). The body weight of PEX7G844D / G844Dmicetreated with ABE8e-V106W improved compared to untreated controls (FIG. 7D). All 19 mice showed a normalization of hepatic lipid profiles with decreased levels of free and esterified VLCFAs and BCFAs by gas chromatography-mass spectrometry (GC-MS) (FIG. 7E).Further histopathology analysis showed a reduction of lipid accumulation in the liver by Oil Red-0 (ORO) staining (FIG. 7F), suggesting restored peroxisome function and rescued liver steatosis.95 / 149B1195.70208WO00#15198909v2

[0161] In light of the above data suggesting saturating levels of hepatocyte editing from the 4xlOnvg dose of AAV9-ABE8e-V106W, the amount of AAV9 ABE8e-V106W administered to PEX7G844D / G844Dmicewas next lowered to identify a safe yet effective viral dose. Facial vein injection was performed at Pl of IxlO11, 4xlO10, or IxlO10vg (FIG. 8A).These doses were chosen based on the dose-dependent editing observed in the heterozygous cohort. After injection, all three dosing conditions were well tolerated (more than 90% of treated mice survived) (FIG. 2A). The growth deficit in the PexlG844D / G844Dmice waseffectively rescued at all doses of ABE8e-V106W in both males and females (FIG. 2B). Additionally, high-throughput sequencing (HTS) analysis at six weeks of age showed 56% and 57% average correction in the bulk liver of the PEX7-p. G844D allele at the IxlO11vg and 4xlO10vg doses, respectively, with average indel frequencies below 0.12%. Although the IxlO10vg dose yielded 29% editing of pathogenic alleles at week six, the frequency of corrected alleles increased 1.8-fold by week 16, resulting in an average of 53% editing efficiency, similar to what was observed in mice treated with the IxlO11vg and 4xlO10vg doses (FIG. 2C). Higher doses led to faster correction, consistent with the durable expression of ABE from AAV among transduced cells (FIG. 14A). Base editing of the PEX7-p. G844D mutation was also assessed in central nervous system tissues such as cortex, cerebellum, and eye 16 weeks post-injection. Efficiencies of 0.35%, 0.14%, and 0.51%, respectively, were observed, likely due to the inefficiency of AAV9 transduction of mouse CNS following systemic administration51(FIGs. 9A-9C).ABE rescues liver pathologies and peroxisome metabolites in homozygous PEXl-p. G844D mice

[0162] To assess the impact of gene editing on peroxisome biogenesis, ABCD3 (also called PMP70) peroxisomal membrane protein levels were measured in vehicle-treated and ABE8e-V106W-treated PEX7G844D / G844Dmice. Consistent with the known peroxisome deficit in this mouse model, Western blot analysis revealed little-to-no detected ABCD3 protein in PEX7G844D / G844Dvehicle-treated mice liver tissues (FIG. 2D). In contrast, liver tissue from ABE8e-V106W-treated PEX7G844D / G844Dmice revealed a dramatic increase in ABCD3 protein levels at all tested doses (FIG. 2D). Indeed, the increased protein levels at all three doses were similar to those in wild-type mice (FIG. 2D), suggesting that even the lowest tested dose of IxlO10vg of AAV encoding ABE8e-V106W could begin to impact peroxisome biogenesis.96 / 149B1195.70208WO00#15198909v2

[0163] Next, the levels of free and esterified fatty acids were analyzed in plasma and liver, and a dose-dependent rescue of hepatic peroxisomal metabolic activities in PEX7G844D / G844Dmice was observed at early time points (six weeks post-injection). The IxlO11vg and 4xlO10vg ABE doses normalized elevated phytanic and pristanic acid (BCFA), consistent with a rescue of the peroxisomal alpha- and beta- oxidation activity, while the lowest dose tested (IxlO10vg) resulted in a partial reduction (FIG. 2E, FIG. 8B). Likewise, at six weeks, the IxlO11vg and 4xlO10vg doses resulted in near complete normalization of elevated hepatic VLCFA (including C26:0 and C26:l n-9) levels in PEX7G844D / G844Dmice, consistent with rescue of the hepatic peroxisomal beta- oxidation pathway, while the lowest dose tested (IxlO10vg) resulted in partial reduction (FIG. 2E). Elevated hepatic levels of the membrane lipid C26:0-lysophosphatidylcholine (LPC) in PEX1G844D / G844Dmice were unchanged after ABE-AAV9 treatment, suggesting heterogeneity in the rates of metabolism of specific C26:0-containing lipids (FIG. 15). At 6 weeks, elevated plasma C26:l n-9 levels were partially reduced at the IxlO11vg and 4xlO10vg doses, but elevated plasma C26:0 levels were unchanged. Elevated plasma C26:0-LPC levels were not reduced in treated PEX7G844D / G844Dmice (FIG. 8B and FIG. 15).

[0164] At 16 weeks post-injection, more robust rescue of hepatic peroxisome lipid metabolism in PAA / GS44D / GS44Dmice was observed. Phytanic and pristanic (BCFA) levels in plasma (FIG. 2E) and liver (FIG. 8B) were significantly lowered to levels wild-type mice leveled for all doses tested (see also FIGs. 15-18 with bar graphs for representative lipids phytanic, pristanic, C26:0, C26:l, C26:0-LPC, and plasmalogen). Hepatic VLCFA levels in PEX7G844D / G844Dmice were near wild-type for all doses. Plasma C26:l n-9 levels in PEX7G844D / G844Dmice were substantially reduced for all doses tested, but plasma C26:0 levels were mildly reduced. No reduction in liver or plasma C26:0-LPC levels were observed for any dose tested in these mice (FIG. 8B and FIG. 15). Overall, these results support the conclusion that although varying the ABE- AAV dose changes the kinetics of gene correction, the major outcome — after 16 weeks — robust correction of free and esterified BCFA and VLCFA levels in liver — were observed across all doses tested.

[0165] Histological analysis of lipid content in liver sections by ORO staining also revealed a dose- dependent efficacy at an early age. The liver tissue in the low-dose treated neonatal mice was characterized by irregular hepatic ORO staining (FIG. 2F, upper-left panel). In contrast, by 16 weeks post-injection, hepatic lipid content was reduced to near wild-type levels (FIG. 2F, lower panel). These results demonstrate that ABE8e-V106W-mediated97 / 149B1195.70208WO00#15198909v2correction of pathogenic PEX7-G844D alleles rescues clinically relevant peroxisomal of liver disease phenotypes when delivered to neonatal mice at all tested doses.Transcriptome analysis on ABE8e-V106W-treated ppxiG844D / G844Dneonatal mice

[0166] To further understand the mechanisms underlying the phenotypic correction in mice treated with AAV9-ABE8e-V106W, RNA-seq analysis of liver tissues from mice injected with IxlO11vg, 4xlO10vg, or IxlO10vg was performed at six weeks and 16 weeks postinjection. A stringent false discovery rate (FDR<1%) was applied to identify differentially expressed genes (DEGs) among vehicle-treated wild-type (WT) mice, vehicle-treated PEX7G844D / G844Dmice, and AAV9-ABE8e-V106W treated PEX7G844D / G844Dmice_At sixweeks, 691 DEGs were identified in livers from the homozygous PEX7G844D / G844Dand WT mice. Even at this early time point, there were dramatic decreases in the numbers of DEGS in the base-edited PEX7G844D / G844Dcompared to saline-treated WT mice (105 DEGs at the IxlO10vg dose, 13 at the 4xlO10vg dose, and 38 at the IxlO11vg dose) (FIG. 10A). By the 16-week time point, a total of 352 DEGs were identified in livers from the PEX7G844D / G844Dand WT mice. Remarkably, there were no DEGs detected between livers of PEX7G844D / G844Dmice treated with the ABE8e-V106W at the 4xlO10vg and IxlO11vg doses and WT mice at 16 weeks. Only one DEG was detected in the liver of the PEX7G844D / G844Dmicetreated with the ABE8e-V106W at the lower IxlO10dose (FIG. 10B). These data indicate that in vivo base editing mediated correction of PPX / -p. G844D normalizes the liver transcriptomic profile 16 weeks post-treatment.

[0167] To explore this rescue further, hierarchical clustering analysis was performed on all DEGs from ABE-treated vs. vehicle-treated PEX7G844D / G844Dmouse livers at six weeks (363 genes) and 16 weeks (250 genes) post-injection (FIG. 3A). Interestingly, the lowest AAV9-ABE dose, IxlO10vg (equivalent to 7xl012vg / kg), resulted in a partially rescued transcriptome state between WT and homozygous disease mice at six weeks post-injection. In comparison, by 16 weeks, the mice showed near-complete reversal of transcriptome changes, suggesting that increased correction of PEX7-G844D pathogenic variants from 29% to 53% during this time contributed to transcriptome normalization.

[0168] Gene-set-based KEGG and phenotype pathway analysis of DEGs between livers of saline- treated PEX7G844D / G844Danc| WT mice at six and 16- weeks revealed DEGs related to physiological responses to liver injury, fibrosis, and hepatocellular carcinoma. These severe liver disease-associated DEGs (Abcc4, Acot2, Apes, Areg, Arhgef2, Cd63, Cyp4al0,98 / 149B1195.70208WO00#15198909v2Cyp4al4, Cyp4a31, Ehhadh, Gpat3, Gstal, Gstm3, Lonpl, Mtl, Mt2, Npdcl, Nuprl, Rtn4, Sox4, and Trib3) were more highly expressed in PEX7G844D / G844Dmice compared to WT controls (FIG. 3B). Consistent with a rescue of liver health, these genes were down-regulated to at or near WT levels in the ABE-treated ppx / G844D / G844Dmice(FIG. 3B). Additionally, alterations in hepatic carbohydrate metabolism have been reported in mouse models with ZSD and Drosophila models with other peroxisomal biogenesis disorders39,53. Many DEGs found between the mutant and WT mice are associated with peroxisomal and mitochondrial lipid metabolic dysfunctions and carbohydrate metabolism and were rescued upon ABE treatment (FIG. 3A, FIGs. 11A-11D). Furthermore, histologic analysis of liver tissues via periodic acid-Schiff (PAS) staining revealed restoration of normal glycogen stores upon ABE treatment (FIG. 3C and 3D), supporting the conclusion that phenotypic rescue is the result of ABE-mediated correction.

[0169] It was identified that Cyp4al0, Cyp4al4, and Cyp4a31 — genes associated with liver co-oxidation52-54— were more highly expressed in ppx / GS44l) / GS44l)compared to WT mice, potentially reflecting PPAR-mediated activation of a compensatory mechanism to catabolize BCFAs. These same genes were downregulated upon ABE treatment at 16 weeks postinjection compared to the vehicle-treated ppx / GS44l) / GS44l)mice, suggesting that ABE-enabled rescue minimized dependence on the compensatory co-oxidation pathway due to the restoration of peroxisomal oc-oxidation activity.

[0170] Taken together, the transcriptome analysis above strongly supports the therapeutic benefit of AAV9-ABE-V 106W treatment for rescuing liver pathogenicity in £x / G844D / G844Dneonatal mice.Therapeutic base editing in four-week-old ppxiG844D / G844Dmice

[0171] While neonatal treatment with ABE8e-V106W resulted in an almost complete rescue of the ZSD hepatic phenotypes, testing the effect of in vivo base editing in animals at a more advanced disease stage would inform the potential of treatment of patients of different ages. Therefore, AAV encoding ABE8e-V106W was injected at a dose of 5xlOnvg / mouse (equivalent to the neonatal dose of IxlO11vg / mouse or 7xl013vg / kg) via retro-orbital (RO) injection into four-week-old PEX7G844D / G844Dmice(FIG. 4A). The lipid profile was tested in plasma at six- and 12-weeks post-injection and in the liver at 12 weeks post-injection (FIG.4A). The treatment was well tolerated, and all animals survived until the 16-week endpoint (FIG. 4B). The body weight of PEX7G844D / G844Dmicetreated with ABE8e-V106W improved99 / 149B1195.70208WO00#15198909v2compared to vehicle-treated controls from eight weeks of age onward (FIG. 4C). Base editing efficiency was assessed at 16 weeks of age, revealing 50% bulk liver correction of the PEX / -p. G844D allele with no detected non-synonymous bystander editing (FIG. 4D).ABCD3 protein levels was restored in base-edited mice to levels similar to wild-type controls, consistent with improved peroxisome biogenesis (FIG. 4E). The levels of phytanic and pristanic BCFAs and most VLCFAs in plasma and liver, were also restored to those comparable to wild-type controls (FIG. 4F).

[0172] Consistent with the cholestatic liver disease present in people with moderate and severe ZSD, by 16 weeks £x / G844D / G844Dmiceshowed an accumulation of C27-bile acid intermediates [3a,7a-dihydroxycholestanoic acid (DHCA) and 3a, 7a, 12a-trihydroxycholestanoic acid (THCA)] thought to be involved in its etiology16(FIG. 4G). To determine if restoration of PEX1 activity could address the accumulation of these C27-bile acid intermediates, young PEX7G844D / G844Dmjce weretreated at four weeks with ABE8e-V106W. Analysis at 12 weeks post-injection revealed that C27-bile acid intermediates DHCA, THCA, and 7a-hydroxy-3-oxo-4-cholestenoic acid (7-HOCA) in the liver were restored to wild-type levels, reflecting the rescue of a biosynthetic pathway requiring peroxisomal beta- oxidation (FIG. 4G). Mature bile acid levels did not differ significantly in wild-type and mutant mice or mice treated with the ABE (FIG. 12). Histologic analysis of the liver suggested rescue of hepatic lipids and carbohydrate metabolism (FIG. 4H). These findings indicate that base editing resulted in physiologically relevant rescue of liver function when administered to 4- week-old PEX1G844D / G844Dmice.

[0173] LNP delivery systems offer a more transient, non-viral delivery modality for gene editing agents. LNP-mediated base editor delivery has been used effectively in non-human primates and in human patients to introduce a splice site point mutation in PCSK9, resulting in durably lowered serum LDL cholesterol55,56. In addition to being amenable to well-established, clinically accepted manufacturing methods, the transience of LNP-mediated base editor mRNA delivery minimizes the potential for off-target editing after the targeted edits are made57,58. To test the feasibility of LNP-mediated ABE mRNA delivery in PPX / GS44I) / GS44I)mice, liver-tropic OF-02 LNPs59were formulated and delivered ABE8e-V106W mRNAs and modified sgRNA into 4- week-old mice (FIG. 19A). Encouragingly, up to 27% pathogenic allele correction in a dose- dependent manner was observed, with minimal unwanted bystander editing or indels (FIG. 19B-19C). Average ABCD3 protein levels were increased 7.6-fold in ppx / GS44l) / GS44l)mjcetreated with the highest dose of ABE-LNP (3100 / 149B1195.70208WO00#15198909v2mg / kg) compared to saline-treated mice, indicating an improvement in peroxisome function (FIG. 19D). Histological analysis of lipid content in liver sections via ORO staining also showed elevated hepatic lipids in the £x / G844D / G844Dmicewere reduced by 33% 6 weeks after treatment with 3 mg / kg ABE-LNP, approaching lipid levels in wild-type mice (FIG. 19E). Furthermore, PAS staining revealed restoration of normal hepatic glycogen levels upon 3 mg / kg ABE-LNP treatment. These findings demonstrate the compatibility of the base editing strategy developed in this work with clinically validated non-viral in vivo base editor delivery methods. Although systemic delivery of ABE8e-V106W resulted in low genome editing in the CNS of treated mice as expected, a significant reduction in BCFAs (phytanic and pristanic acids) was observed, but not VLCFAs, in the cortex of AAV- and LNP-treated mice post-injection (FIGs. 21-24). This observation suggests that restoring hepatic alphaoxidation reduced the pool of circulating phytanic acid that would otherwise accumulate in the cortex.

[0174] Collectively, these results establish that AAV9-ABE8E-V106W-mediated correction of the pathogenic P 7-p. G844D allele in four- week-old mice results in near-complete rescue at genomic, lipidomic, and phenotypic levels. Importantly, these findings indicate that the therapeutic benefits of ABE-V106W observed in neonates can be extended to young mice with a more advanced stage of liver disease.In vivo and in vitro off-target analysis ofABE8e-V106W targeting PEX1 and PEX1 pathogenic variants

[0175] To fully characterize Cas-dependent DNA and Cas-independent RNA off-target editing in the liver samples of ABE-V106W-treated mice, CIRCLE-seq60, an unbiased and sensitive experimental genome-wide off-target detection method that nominates genomic DNA sites engaged by SpCas9 nuclease complexed with the PEX1 -p. G844D targeting guide RNA in vitro, was performed. When applied to mouse genomic DNA, CIRCLE-seq nominated 631 ranked candidate off-target sites. The top 30 sites were picked, and each of these sites was amplified using the liver genomic DNA samples collected from the homozygous mice treated with IxlO11vg of ABE-AAV at six weeks and 16 weeks postinjection (three mice per condition) (FIG. 5A). Despite treatment with a high dose of AAV9-ABE8e-V106W, minimal off-target editing was observed, with only two off-target (OT) sites showing signal exceeding background levels from vehicle-treated controls: OT1 (<0.35%) and OT15 (<0.29%). Increased off-target editing was not observed in samples at 16 weeks101 / 149B1195.70208WO00#15198909v2compared with 6 weeks. These two OT sites are in intergenic regions and are not annotated as regulatory elements in the mouse genome. These data suggest minimal alteration in proteincoding genes or regulatory functions from off-target base editing in the treated mice (FIG. 5B). To identify Cas-independent RNA off-target editing in the ABE-treated PEX7G844D / G844Dmice, RNA-seq datasets generated from liver tissue from mice treated with IxlO11, 4xlO10, or IxlO10vg of AAV-ABE were analyzed. At six weeks post-injection, but not at 16 weeks postinjection, we observed a slight potential increase averaging 1.2-fold in transcriptome- wide A-to-G RNA changes in ABE-AAV-treated mice compared to vehicle-treated control mice (FIG. 5C and FIG. 20A). This potential elevation is likely due to the higher expression level of AAV9-ABE8e-V106W six weeks post-injection compared to 16 weeks, together with the transient nature of cellular RNA. These findings further support that ABE8e-V106W base editing of the PPX / -p. G844D allele is highly site- specific, with minimal detected genetic or transcriptomic changes in treated ZSD mice. In juvenile mice treated with ABE-AAV9 or ABE-LNPs, no significant increases in OT1 and OT15 editing relative to saline-treated controls were detected. Differences in viral vector transduction efficiency between the neonatal and juvenile cohort may influence ABE expression levels, and / or target site accessibility could vary with age (FIG. 5B).

[0176] To identify potential off-target editing associated with the ABE8e-V106W base editor and a guide RNA targeting human PEX7-p. G843D, CIRCLE-seq analysis was performed using patient-derived compound heterozygous PEX7G843D / I700fscultured skin fibroblasts, resulting in the nomination of six candidate off-target sites in total. Additionally, in silico analysis, CAS-OFFINDER™61, was also performed, and 20 potential off-target sites with three or fewer mismatched nucleotides compared to the targeted protospacer were predicted (FIG. 20B). To assess off-target editing associated with high and prolonged expression of ABE8e-V106W, two sets of patient-derived cultured fibroblasts (homozygous PEX1G&43D / G&43Dand compound heterozygous ppx / (ls43l) / l700lrespectively), with lentivirus to deliver ABE-V106W and guide RNA were incubated. Efficient on-target editing was confirmed with up to 73% correction of target PEX7-p. G843D alleles two weeks after transduction (FIG. 5D). Next, the lentivirus-treated gDNAs were amplified from PEX7G843D / G843Dcells at 26 nominated OT sites (the six from CIRCLE-seq and 20 from CAS-OFFINDER™), and all possible A»T-to-G»C changes within the protospacers were examined. Sequence modifications above the 0.1% detection threshold for HTS or above levels of genetic variation present in vehicle-treated samples were not detected for 25 of the 26 tested102 / 149B1195.70208WO00#15198909v2sites. One OT site in an intron of FBXO38 showed 0.88% A»T-to-G»C substitution, which could potentially affect a splicing acceptor sequence (FIG. 5E).

[0177] Overall, these off-target analyses suggest that the ABE8E-V106W editing strategies both in vivo in mice and in vitro in patient-derived cells result in high- specificity editing, with minimal observed DNA or RNA off-target editing, even following a high-dose AAV treatment that leads to prolonged expression of ABE.Correction of PEXl-p. G843D variant in patient-derived fibroblasts restores peroxisome assembly

[0178] Next, immunofluorescence was performed to assess if the correction of PEX1-p. G843D in patient-derived fibroblasts can rescue peroxisome assembly. Two patient-derived fibroblasts, homozygous PEX1G843D / G843Dand compound heterozygous PEXlG843D / I700fs, were nucleofected with ABE8e-V106W mRNA and a guide RNA targeting the P 7-p. G843D (c.2528G> A) allele or a non-targeting guide RNA (sgNT) that does not match any human genome sequence62. Robust disease mutation correction efficiency exceeding 80% was observed in PEX1G843D / G843Dand PEXlG843D / I700fscells upon treatment with ABE and the PE’X7-p. G843D-targeting guide RNA (FIG. 13A).

[0179] In patient cells, a peroxisome biogenesis defect caused by PEX1 -p. G843D and other pathogenic variants in the PEX1 gene leads to mislocalized peroxisome matrix proteins such as catalase62. Anti-catalase and anti-ABCD3 antibodies and corresponding secondary antibodies conjugated to fluorophores were used to directly probe endogenous proteins in the nucleofected fibroblasts. Confocal microscopy revealed that cells treated with sgNT and ABE8e-V106W show cytosolic catalase signals and foci of the peroxisome membrane protein ABCD3, consistent with observations from previous reports in the cells from donors with ZSD63,64(FIG. 6A, row 2 and 4). In contrast, following treatment with the PEX1-p. G843D targeting guide and ABE8e-V106W, catalase was now observed in red foci, colocalizing with PMP70 green foci, recapitulating peroxisome structure in healthy donor fibroblasts (FIG. 6A, row 1, 3, and 5). These results suggest the restoration of peroxisomal biogenesis following direct correction of the PEXl-.pG843D pathogenic variant.

[0180] Finally, to evaluate peroxisomal assembly via live cell imaging, the nucleofected PEX1G&43D / G&43Dfibroblasts were transduced with a baculovirus vector expressing a GFP fluorescent reported protein tethered with an N-terminal peroxisome targeting signal 1 (GFP-PTS1) (Thermo)65,66. The sgNT-treated cells, upon GFP-PTS1 viral transduction, showed103 / 149B1195.70208WO00#15198909v2diffuse, cytosolic distribution of GFP signals. In contrast, PEX7-p. G843D corrected fibroblasts showed green punctate structure similar to fibroblasts from healthy donors, indicating import of GFP-PTS1 into the peroxisomes and restoration of peroxisome biogenesis (FIG. 13B). Altogether, these results indicate that treating cells with ABE8e-V106W and a guide RNA targeting PEX7-p. G843D can rescue peroxisomal assembly defects in patient cells.Discussion

[0181] Current treatments for ZSD focus on managing symptoms and improving the quality of life for patients, but do not address the root cause of the disease, namely pathogenic variants that impair the function of PEX genes required for normal peroxisome assembly, proliferation, and metabolic activities17,23. Patients who are homozygous or compound heterozygous for the PPX / -p. G843D founder allele are at risk for developing progressive liver disease that can lead to frequent hospitalizations and a shortened lifespan. Here, a PEX1 base editing strategy was used to rescue liver functions in a dose- and time- dependent manner in a ZSD mouse model. The successful translation of these results to patients with liver disease could have a profound impact on their quality of life and longevity16. Newborn screening for ZSD21,22on an international scale provides an unprecedented opportunity for implementing targeted genetic therapies prior to irreversible liver damage that will affect the CNS and other systems.

[0182] The testing of various base editing strategies (FIGs. 1C and 6B)67,68resulted in the identification of ABE8e-V106W to correct the common PEX7-p. G843D pathogenic variant both in patient-derived fibroblasts, and in the homozygous PPX / -p. G844D ZSD mouse model. Editing was very efficient, correcting >80% PPX / -p. G843D deleterious alleles in patient fibroblasts via mRNA delivery and up to 60% of the bulk liver of ZSD mice following a one-time AAV9-ABE treatment, enabling permanent and precise correction of the root cause of peroxisomal dysfunction. Since hepatocytes, the primary liver cell type transduced by AAV9, make up -60% of the mouse liver50, these results suggest efficient base editing of the majority of hepatocytes69.

[0183] Three AAV9 doses were tested in the neonatal (Pl) ZSD mouse model, and it was observed that after 16 weeks post-injection, even the lowest dose tested (IxlO10vg / mouse or 7xl012vg / kg) achieved near maximal observed levels of in vivo PEX7-p. G843D correction.104 / 149B1195.70208WO00#15198909v2Editing efficiency nearly doubled (1.8-fold increase) between weeks six and 16 following Pl injection.

[0184] Consistent with the increased efficiency in DNA correction that was observed over time, transcriptomic, lipidomic, and histological analysis showed a robust rescue of hepatic gene expression and most fatty acid profiles normalizing to wild-type or near- wild-type levels by week 16. Despite normalization of majority of hepatic free and esterified VLCFA levels on the list, hepatic C26:0-LPC levels did not change in response to ABE treatment in the homozygous A7< X -p. G844D mice. This observation highlights heterogeneity in the metabolism of specific VCLFA-containing lipid species, such as those present in membranes, which should be considered when selecting biomarkers for future studies. Regardless, this heterogeneity did not prevent base editor-mediated rescue of growth phenotypes, liver histology, or liver transcriptome abnormalities in homozygous A7< X7-p. G844D mice. Indeed, base editing in homozygous P£’X7-p. G844D mice resulted in rescue of hepatic transcriptomic signatures relevant to hepatic lipid metabolism and peroxisome functions, as well as physiological responses to liver injury, fibrosis, and fatty liver disease (FIG. 3B). The increased base editing and achievement of near-complete phenotypic rescue between week 6 and week 16 in the neonatal mouse liver is likely the result of durable ABE expression from AAV9 (FIG. 14A), the proliferation rate of hepatocytes, and / or improved fitness among edited cells. These findings collectively suggest the potential for an ABE- mediated therapeutic strategy for rescuing hepatic pathogenicity in ZSD using a relatively low AAV9 dose.

[0185] Although systemic delivery of ABE8e-V106W resulted in low to minimal gene editing in the CNS of neonatal treated mice, a significant reduction in the content of the BCFA phytanic acid, but not VLCFAs, was also observed in the brain cortex at six- and 16-weeks post-injection (FIGs. 14B, 21-23). Unlike VLCFAs that are primarily made endogenously by the elongation of long-chain fatty acids (LCFAs)70'71, phytanic acid is obtained strictly from the diet in mammals72. Phytanic acid over- accumulation in the PEX1G&44D, G&44Dmouse cortex most likely results from circulating phytanic acid70,71that crosses the blood-brain-barrier, but is poorly metabolized by peroxisomal alpha-oxidation in the brain. Hence, restoring hepatic alpha- oxidation in this model reduces the pool of circulating phytanic acid that would otherwise accumulate in the cortex. Further, LNP-treated kw / GS44l)mice (4- week-old mice were treated; measured at 6 weeks post injection) showed dose-dependent normalization of lipids in both liver and brain tissues (FIG. 24.) This finding105 / 149B1195.70208WO00#15198909v2has translational implications, since it suggests that an effective gene editing correction of the peroxisomal alpha- oxidation pathway in liver could help prevent toxic accumulation of diet-derived BCFAs in the CNS, and possibly other tissues. This finding also has implication for the treatment of adult Refsum disease, which is primarily caused by the impaired activity of the PHYH gene critical for peroxisomal alpha- oxidation that can lead to the toxic accumulation of diet-derived phytanic acid in sensitive tissues, resulting in polyneuropathy, ataxia, retinitis pigmentosa, anosmia, deafness, and ichthyosis73.

[0186] ZSD can serve as an archetype of complex groups of multisystemic Mendelian disorders whose clinical heterogeneity is influenced by residual levels of gene activity. The present Example focused on using a gene editing strategy to restore liver physiology, which could have a profound effect on the lifespan and quality of life for ZSD patients with liver disease14. Given the progressive and degenerative nature of ZSD, early intervention strategies are likely to be particularly successful. Newborn screening measuring elevated levels of C26:0-LPC in blood spots can identify babies affected by ZSD, thereby increasing the opportunity for early intervention prior to irreversible organ damage. Such screening could interface with early intervention strategies such as the base editing treatment herein19.

[0187] Importantly, ABE8e-V106W treatment of a four-week-old cohort of ZSD mice with a more advanced liver disease phenotype also demonstrated near-complete rescue at genomic, lipidomic, and histological levels in the liver compared to wild-type mice. Given the progressive nature of liver disease in both the PEX / -p. G844D preclinical mouse model and the patient population, this result suggests that the therapeutic window for treating ZSD liver disease by gene correction strategies may be long enough to benefit a significant proportion of patients. Collectively, these results suggest the potential of using a base editing therapeutic strategy to address the chronic liver disease found in many patients with ZSD.

[0188] Non-viral LNP delivery of base editor mRNA in our study demonstrated the potential to correct pathogenic PEX1 alleles and rescue ABCD3 peroxisomal transporter proteins and liver steatosis. While redosing with AAV delivery systems is currently a challenge due to the stimulation of neutralizing antibodies following AAV treatment74, transient delivery systems such as LNPs57,75or engineered virus- like particles76,77in conjunction with adeno-associated vehicles that have brain and retina tropism could open new therapeutic opportunities for ameliorating multisystemic genetic disorders such as ZSD in a variety of other tissues and organs including the retina, brain, and cochlea.106 / 149B1195.70208WO00#15198909v2MethodsMaterials Availability

[0189] Plasmids generated herein are available from ADDGENE®. Additional details are provided in the Key Resources Table, below.Clinical analysis of liver disease in patients with Zellweger spectrum disorder (ZSD)

[0190] Patients with a diagnosis of a peroxisome biogenesis disorder (PBD) were enrolled in a longitudinal, retrospective natural history study at the Research Institute of the McGill University Health Center with informed consent. Patients were recruited internationally, including 87% from North America, 2.7% Australia, 1.3% Europe, and 0.7% South America. Medical records were requested from birth to study entry, and annually thereafter from each participant’ s healthcare institutions following authorization from the patient or parent / legal representative. De-identified longitudinal clinical data were collected from participants with at least one P 7-c.2528G> A (p. G843D) allele. Patients without any liver-related abnormalities were classified as no liver disease (normal); patients reported with any of the following — hepatomegaly, jaundice, elevated liver enzymes in blood, or coagulopathy — were considered to have some hepatic dysfunction; patients diagnosed with cirrhosis, portal hypertension, esophageal varices, gastrointestinal bleeding, ascites, or hepatic cancer were classified as severe liver disease. The study was registered on ClinicalTrials.gov(NCT01668186) where the study protocol and analysis plan are provided.Mammalian cell culture conditions

[0191] Zellweger spectrum disorder (ZSD) patient-derived ppx / GS43l) / l700ls(Cat. IDGM 16510) and healthy donor derived fibroblast cells (Cat. ID GM03348) were purchased from Coriell Institute. ZSD patient-derived homozygous ppx / GS43D / GS43l)primary skin fibroblasts were obtained from the Peroxisomal Diseases Laboratory at the Kennedy Krieger Institute. Fibroblasts were cultured in Dulbecco’s Modified Eagle Medium (DMEM) plus GLUTAMAX® (THERMO FISHER SCIENTIFIC®) supplemented with 15% (v / v) fetal bovine serum (FBS) (THERMO FISHER SCIENTIFIC®). HEK293T was purchased from American Type Culture Collection (ATCC®, Cat# CRL-3216). All cell lines were incubated, maintained, and cultured at 37°C with 5% CO2. Cell lines were authenticated by their respective suppliers and tested negative for mycoplasma.107 / 149B1195.70208WO00#15198909v2Zellweger spectrum disorder (ZSD) mouse models

[0192] All animals were Mus musculus. Mixed genetic background mice B6129F1-Pexl<tml-lsjms> / Lutzy / Mrnjax, were obtained by crossing heterozygous B6. Cg- Pexltml ls ms / Mrnjax (Jax stock # 25065) with heterozygous 129S6. Cg-Pexltml ls ms / Mrnjax (Jax stock # 30931). All mice (3-5 per cage) were housed in individually high efficiency particulate air (HEPA)-filtered polysulfonate cages, under controlled conditions of 12-hour light / dark cycles (6 am to 6 pm), room temperature of 22 ± 4°C and 50 ± 15% humidity, with 15 air exchanges per hour. Animals had access to acidified tap water (pH 2.5-3.0) and normal rodent chow ad libitum. Animal welfare and survival were monitored twice a day. All experiments followed National Institute of Health (NIH) guidelines and the Jackson Laboratory and IACUC committee (protocol 20029-1).General methods and molecular cloning

[0193] All plasmids used in this Example were cloned using Gibson assembly or Restriction Enzyme Cloning. DNA was PCR-amplified using PHUSION®U Green Multiplex PCR Master Mix (THERMO FISHER SCIENTIFIC®). Gene fragments and plasmid backbones were generated through PCR, restriction digestion, or purchased from INTEGRATED DNA TECHNOLOGIES® (IDT). The recombinant plasmids were assembled using NEBUILDER® HiFi DNA assembly master mix or T4 ligation (NEB®). Maehl™ (THERMO FISHER SCIENTIFIC®) and NEB® Stable (High Efficiency) chemically competent E. coli cells were used for plasmid propagation.Electroporation of patient-derived fibroblast cells

[0194] An -80-90% confluent T-75 flask of patient-derived fibroblasts (CORIELL™) were washed with phosphate-buffered saline (PBS) (THERMO FISHER SCIENTIFIC®), trypsinized using TRYPLE® Express enzyme (THERMO FISHER SCIENTIFIC®), and resuspended in 10 mL of media. Cells were transferred to falcon tubes and centrifuged for 5 minutes at 110 g. During centrifugation, RNA reagents were prepared. For each sample, 1 pg base editor mRNA and 50 pmol of synthetic guide RNA were mixed together (2 pL in volume) and then added to 20 pL of P2 Primary Cell NUCLEOFECTOR® Solution and Supplement Solution mixture following manufacturer’s recommended protocol (LONZA®, P2 Primary Cell 96-well NUCLEOFECTOR® Kit). Pelleted cells were washed with PBS and resuspended in the reconstituted LONZA® buffer. 20 pL of resuspended cells was added to108 / 149B1195.70208WO00#15198909v2each editor / guide RNA mixture, transferred to NUCLEOCUVETTE® plates (LONZA®), and electroporated using program DS 150 on a LONZA® 4D NUCLEOFECTOR® with X unit (200,000 cells per electroporation condition). Immediately after electroporation, 80 pL of media was added to each well and incubated at room temperature for 10 minutes. 1 mL of media was aliquoted into each well of a 24- well plate and pre-equilibrated in the incubator, and all cells were seeded onto this plate. Cells were cultured for 3 days before lysis and sequencing.High-throughput sequencing of genomic DNA

[0195] Seventy-two hours after nucleofection, cells were washed with PBS (THERMO FISHER SCIENTIFIC®) and lysed for 1 hour at 37 °C in lysis buffer (10 mM Tris-HCl pH 8, 0.05% SDS and 25 pg / mL proteinase K (THERMO FISHER SCIENTIFIC®)). Lysate was then heat inactivated at 80 °C for 30 minutes. 1 pL of lysate was used as an input for PCR1. PCR1 reactions were 25 pL total, using the PHUSION® Hot Start II kit or PHUSIONU® Green Multiplex PCR Master Mix (THERMO FISHER SCIENTIFIC®), and 0.125 pL of each lOOpM primer. PCR1 was performed under the following cycle conditions: 98°C for 2 minutes, [98 °C for 10 seconds, 61 °C for 20 seconds, 72 °C for 30 seconds] x 28 cycles, 72 °C 2 minutes.

[0196] Samples were barcoded in a second PCR reaction (PCR 2). PCR2 reactions were 25 pL total, using the PHUSIONU® Green Multiplex PCR Master Mix, 1.25 pL each of 10 pM ILLUMINA® barcoding primers, and 1 pL of PCR 1. All PCR2 reactions were performed using the following cycling conditions: 98 °C for 2 minutes, [98 °C 10 seconds, 61 °C 20 seconds, 72 °C 30 seconds] x 10 cycles, 72 °C 2 minutes. After PCR2, samples of similar lengths were pooled and gel extracted in a 1.5% agarose gel using a QIAQUICK® gel extraction kit (QIAGEN®). Concentrations of purified libraries were determined using a Qubit double- stranded DNA high sensitivity kit (THERMO FISHER SCIENTIFIC®) according to the manufacturer’s instructions. Libraries were diluted to 4 nM and sequenced using an ILLUMINA® MISEQ® v2 Reagent kit or an ILLUMINA® MISEQ® v2 Micro Reagent kit using single read cycles.High-throughput sequencing data analysis

[0197] Samples were demultiplexed with MISEQ® Reporter (ILLUMINA®).CRISPRESSO®2 was used to analyze demultiplexed reads. Samples were aligned to the wild109 / 149B1195.70208WO00#15198909v2type amplicon in batch mode, using the following parameters: “-q 30” and “-qwc”. The value of the qwc parameter, which defined the portion of the sequence to be analyzed for indels. The qwc interval covered the entire protospacer and the nucleotides adjacent (26-30 bp quantification window). To calculate percent indels, the reads containing insertions and deletions were summed and then divided by “Reads_aligned” in the “CRISPResso_quantification_of_editing_frequency.txt” CRISPRESSO®2 output file. Percent editing was calculated from the specified base conversion in the genomic sequence using “Nucleotide_percentage_summary.txt” CRISPRESSO®2 output file.In vitro transcription (IVT) of editor mRNA

[0198] IVT of editor mRNA was performed as described previously75with minor modifications. Editor sequences were cloned into pT7 expression plasmids (example ADDGENE® #178113). To generate linear DNA templates for IVT, the pT7-editor plasmids were amplified by PCR using the PHUSION® U green multiplex master mix (NEB®) using IVT forward and IVT reverse primers. PCRs were purified using the QIAQUICK® PCR purification kit (QIAGEN®) and eluted in water. IVT reactions were performed using a T7 high yield RNA synthesis kit (NEB®), following the manufacturer’s directions with two exceptions: TRILINK® ’s CLEANCAP® reagent AG was added, and the uridine 5' triphosphate in the kit was replaced with N1-methylpseudouridine 5 ' triphosphate (TRILINK®). Each 160 pL reaction used 8 pL lOx reaction buffer, 8 pL 100 mM ATP, 8 pL 100 mM CTP, 8 pL 100 mM GTP, 8 pL 100 mM -methylpseudouridine 5' triphosphate, 6.4 pL 100 mM CLEANCAP® AG, 16 pL T7 RNAP mix, and 1 microgram of purified linear template DNA. After assembly, reactions were incubated at 37 °C for 2 hours. Samples were then purified using a lithium chloride precipitation, followed by 70% ethanol wash. RNA was resuspended in nuclease-free water, and purity and quality were verified using a 2% agarose gel electrophoresis stained with SYBR Gold (THERMO FISHER SCIENTIFIC®). RNA was diluted to 2 pg / pL and was stored in aliquots in -80 °C freezer until use.Lentivirus production and transduction of patient-derived fibroblasts

[0199] To produce ABE8e-V106W and guide RNA lentivirus to infect ZSD patient-derived fibroblast cells, HEK293T cells were seeded in 6-well plates (CORNING®) at 7.5 x 105cells per well in DMEM supplemented with 10% FBS. At 60-80% confluency 16 hours after seeding, cells were transfected with 12 pL Lipofectamine 2000 (THERMO FISHER110 / 149B1195.70208WO00#15198909v2SCIENTIFIC®) following the manufacturer’s recommended protocol and 1.33 pg lentiviral transfer plasmid, 0.67 pg pMD2. G (ADDGENE®#12259), and 1 pg psPAX2 (ADDGENE® #12260). Six hours after transfection, media was exchanged with DMEM supplemented with 10% FBS. Forty-eight hours after transfection, viral supernatant was centrifuged at 3000 g for 15 minutes to remove cellular debris, filtered through a 0.45 pm PVDF filter (CORNING®), and stored at -80 °C. Lentiviral transduction of fibroblasts was performed as reported previously76. ZSD patient-derived fibroblasts were plated in six well culture plates at a density IxlO5cells per well and incubated for 18 hours before infection. The filtered, lentiviral supernatant was added with a high MOI. Polybrene was added at a final concentration of 6 pg / mL. After 8 hours, the lentiviral supernatant was replaced with normal culture media containing 2 pg / mL puromycin for selection. Fibroblasts were passaged and expanded with puromycin selection media for two weeks and then lysed for assessing pathogenic variant correction and off-target analysis.AAV production

[0200] High-titer qualified AAV9 was produced as previously described46by triple transfection or obtained through the Viral Vector Core at UMass Medical School. Briefly, HEK293T / 17 cells were plated in 15 cm dishes to about 80-85% confluency 24 hours before transfection. Cells were then transfected with PEI containing 5.7 pg AAV genome, 11.4 pg pHelper (ClontechCLONTECH®), and 22.8 pg of AAV9 rep-cap plasmid per 15 cm dish. Media was exchanged for DMEM with 5% fetal bovine serum the following day. Three days after the media change, cells were harvested using a rubber cell scraper (CORNING®), pelleted via centrifugation (10 minutes, 2,000 g), resuspended in 500 pL hypertonic lysis buffer (40 mM Tris base, 2 mM MgCh, 500 mM NaCl, and 100 U mL’1salt active nuclease (ARCTICZYMES TECHNOLOGIES™)) per plate, and incubated at 37 °C for 1 hour. The media was decanted and combined with 5x solution of polyethylene glycol (PEG) 8000 (SIGM A- ALDRICH®) and NaCl to achieve a final concentration of 8% PEG and 500 mM NaCl. This solution was incubated on ice for 2 hours or overnight to facilitate PEG precipitation and then centrifuged (3,200 g, 30 minutes). The supernatant was discarded, and the pellet was resuspended in 500 pL hypertonic lysis buffer per plate. This was added to the cell lysate, which was either immediately ultracentrifuged or stored at 4 °C overnight.

[0201] Cell lysates were first clarified by centrifugation at 3,400 g for 10 minutes and added to BECKMAN COULTER® QUICK-SEAL® tubes using a 16-gauge, 5-inch needle (AIR-111 / 149B1195.70208WO00#15198909v2TITE® N 165) in a discontinuous gradient of iodixanol. All the viruses were purified with an iodixanol step gradient using a Ti 70 fixed angle rotor at 58,600 rpm for 2 hours 15 minutes at 4 °C. Ultracentrifugation was followed with buffer exchange and a concentration step using 100-kD MWCO columns (EMD MILLIPORE®). The concentrated viral solution was sterile-filtered using a 0.22 pm filter and stored at 4 °C until use. All viruses were titered via quantitative PCR using the AAVpro Titration Kit v.2 (CLONTECH®), following the manufacturer’s protocol (TAKARA BIO®).Lipid nanoparticle (LNP) formulation and characterization

[0202] LNPs were prepared in a microfluidic chip device by mixing an aqueous phase containing the mRNA with an ethanol phase containing the lipids90. The aqueous phase was prepared in a 10 mM citrate buffer with either ABE8e mRNA or sgRNA targeting PEX1 or a non-targeting sgRNA control (5'-GAUCUCGCUUAUAUAACGAG-3') (SEQ ID NO: 137). The ethanol phase was prepared by solubilizing a mixture of OF-02 (CAYMAN CHEMICAL®), l,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE; AV ANTI POLAR LIPIDS®), cholesterol (SIGMA- ALDRICH®) and l,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (C14-PEG2000; AV ANTI POLAR LIPIDS®) at a molar ratio of 35:16:46.5:2.5 (OF-02: DOPE:cholesterol: C14-PEG2ooo) with an ionizable lipid:mRNA weight ratio of 10:1. The aqueous and ethanol phases were mixed in a microfluidic device at a 3:1 ratio by syringe pumps to a final mRNA concentration of 0.15 mg / ml. The resultant formulation was dialyzed overnight against PBS in a 20 kDa molecular weight cut-off dialysis cassette (THERMO FISHER SCIENTIFIC®) at 4 °C.Following dialysis, LNPs were concentrated using Amicon 100 kDa molecular weight cut-off centrifugation filters (SIGMA- ALDRICH®) at 4 °C. Total RNA concentration in the LNP solution was measured with a Stunner spectrophotometer (UNCHAINED LABS®). LNPs were stored in a PBS solution with 10% (w / v) sucrose at -80 °C until further use.Animal treatments

[0203] For neonatal treatments, Pl mice were cryo-anesthetized and injected intravenously (IV) through the facial vein with 5 pl of gene editors or vehicle (PBS). After recovery from anesthesia, all pups were returned to their corresponding parent. For young adult treatments, P28 mice were anesthetized with isoflurane and injected via retro-orbital with a maximum volume of 200 pl of gene editors or vehicle (PBS). The mice were recovered from anesthesia112 / 149B1195.70208WO00#15198909v2and returned to their home cage. All animals were monitored daily post-injection; those with >20% loss of maximum body weight or body conditioning score <2 were humanely euthanized. For lipid nanoparticle (LNP) IV injections, a 1:1 RNA weight ratio of mRNA-LNP:sgRNA-LNP was administered via RO. Experimental groups were sex-balanced and randomly assigned at dosing. Investigators were blinded to treatment groups during outcome assessment.Mouse tissue sample preparation

[0204] All mice were euthanized at 6 weeks and 16 weeks of age by CO2 asphyxiation and perfused with a 10 mL syringe mounted on a 25G needle at a speed of 5 mL / min with Phosphate-buffered saline (PBS). The perfusion quality was checked by observing liver discoloration. The entire liver was harvested and cut into 3 sections. A fifth of the top of the liver was cut and fixed in 10% NBF and then placed in PBS for 24 hours before being paraffin embedded and cut at 5 pm on a microtome for histological staining. The largest lobe was fixed 24 hours in 4% paraformaldehyde (PFA) before being rinsed 15 minutes in PBS on a shaker and put in 30% sucrose solution for 24 hours. Then it was embedded in optimal cutting temperature (OCT) solution and cut at 10 pm with a cryostat for further histological staining. The remaining liver was placed into a cryobag and dropped into liquid nitrogen to snap freeze it before being stored at -80°C until use.Blood collection

[0205] Mice were anesthetized under isoflurane inhalation to effect ~2% diluted in oxygen at 6 weeks and 16 weeks of age, and blood was collected via retro-orbital bleed into a K2EDTA tube (THERMO FISHER® cat# 365974). Total blood was next centrifuge at 4°C, 12,700 rpm for 5 minutes to separate plasma from blood cells. Plasma and the remaining cells fractions of blood cells were stored at -80°C until use.Histology analysis

[0206] Oil Red O (ORO) staining was utilized to identify the presence of lipids in cells or tissues. Liver cryo-sections were exposed with Oil Red Stock solution saturated with isopropanol (ROWLEY BIOCHEMICAL INSTITUTE™, cat# SO-385). Slides were placed in 10% neutral buffered formalin and in Mayers Hematoxylin solution (SIGMA- ALDRICH®, cat.# MHS32-1), and finally placed in lithium carbonate to blue the hematoxylin before113 / 149B1195.70208WO00#15198909v2coverslip them (CORNING® cat.# 2980-225). To eliminate inter-batch differences, the slides for each time-point were dyed at the same time. The slides were digitalized with a slide scanner (NANOZOOMER® S210, HAMAMATSU®) at 40x magnification. Three regions of interest (ROI) were selected at lOx magnification. Periodic acid Schiff (PAS) was used to detect polysaccharides such as glycogen in the liver. Paraffin sections of liver were treated with 0.5% periodic acid for 5 minutes, followed by Schiff’s reagent (POLY SCIENTIFIC® cat.# S-272-32oz) for 30 minutes, and counterstained with Mayer’s hematoxylin (THERMO FISHER® cat.# 72804). To eliminate inter-batch differences, the slides for each time-point were dyed at the same time. The slides were digitalized using a slides scanner (NANOZOOMER® S210, HAMAMATSU®) at 40x magnification. Three regions of interest (ROI) were selected at lOx magnification. The measurement of the average stained area for ORO and PAS over the whole tissue area was done using CELLPROFILER™ (version 4.2.4), a free open-source software (supplemental CELLPROFILER™ Pipeline).Mouse tissue genomic DNA (gDNA) purification

[0207] Mouse brain, eye, and liver tissues were processed and bead-purified using the DNAdvance kit following manufacturer’s instructions (BECKMAN COULTER®, cat.A48705). Approximately 50 mg ground frozen tissue was placed in the 1.5-mL Eppendorf tube was lysed in the lysis buffer (-500 pL-1 mL) supplemented with proteinase K overnight in the 55°C benchtop shaker (800 rpm). On the second day, the lysed tissues were purified by bead clean-up and 70% ethanol wash. The concentration of purified gDNA was measured by nanodrop spectrophotometry and used for subsequent high-throughput sequencing or droplet digital PCR analysis.RNA sequencing (RNA-seq) and data analysis

[0208] Total RNA from ground liver samples was extracted using the RNeasy kit (QIAGEN®) and the RNA concentration was quantified using Qubit HS kit (THERMO FISHER SCIENTIFIC®). 20ng purified total RNA was used for 3' RT primer (5 -AAGCAGTGGTATCAACGCAGAGTAC(T30)VN-3' (SEQ ID NO: 120)) annealing with 0.1 pL 100 pM 3' RT primer, 1 pL dNTP mix (10 mM each dNTP), 0.1 pL RNase inhibitor (40 U / uL) and water in the 4 pL reaction at 72 °C for 3 minutes. To perform the first-strand synthesis, 0.1 pL template switching oligo (100 pM, 5'-AGCAGTGGTATCAACGCAGAGTACrGrG+G-3' (SEQ ID NO: 121)), 2.46 pL water, 2114 / 149B1195.70208WO00#15198909v2pL of 5X MAXIMA™ RT buffer, 2 pL Betaine (5M), 0.09 pL MgCl2, 0.25 pL Rnase inhibitor (40 U / |aL), and 0.1 |aL MAXIMA™ Rnase H-minus RT were added to the annealed reaction, and the reaction was incubated in the thermal cycler following: 42°C for 90 minutes, [50°C 2 min, 42°C 2 minutes] x 10 cycles, 72°C 15 minutes. Next, 1.2 |jL water, 0.05 |aL ISPCR primer (100 pM, 5 -AAGCAGTGGTATCAACGCAGAGT-3 ' (SEQ ID NO: 122)), 0.25 pL 100X SYBR green, and 12.5 pL 2X KAPA® HiFi HotStart Ready Mix were added to the first-strand synthesis tube (25 pL final volume). The reaction was run on qPCR thermal cycler using the program 98 °C for 3 minutes, [98 °C 15 seconds, 67 °C 20 seconds, 72 °C 6 minutes] x 14 cycles, 72 °C 5 minutes and stopped before the qPCR signal plateaued. The transcriptome product was then washed with fresh 70% ethanol, cleaned up with 0.8X SPRI beads, and washed with 70% ethanol another two times on the magnetic rack. The whole transcriptome product was assayed with TAPESTATION® D5000. For the tagmentation step, 0.2 ng whole transcriptome product, 2.5 pL tagment DNA buffer, and 1.25 pL Tn5 enzyme were prepared and incubated in the thermal cycler at 55 °C for 10 minutes. Afterwards, 1.25 pL NT buffer was immediately added and then incubated for 5 minutes at room temperature. To index and prepare the DNA library, 1.25 pL NEXTERA® i7 (5 pM), 1.25 pL NEXTERA® i5 barcode (5 pM), and 3.75 pL NEXTERA® PCR master mix were added to the tagmented DNA (12.5 pL total volume for each sample). The samples were run on thermal cycler using the program at 95 °C for 30 seconds, [95 °C 10 seconds, 55 °C 30 seconds, 72 °C 1 minute] x 12 cycles, 72 °C 5 minutes. Libraries were then pooled and cleaned up with 0.9 SPRI beads and 80% fresh ethanol wash. The pooled library was run on an ILLUMINA® sequencer using NOVASEQ® 6000 S2 kit. 93% of the samples have more than 25 million reads. Three samples that had fewer reads were dropped for the downstream analysis.

[0209] FASTQ files were generated using bcl2fastq v2.20. Raw sequencing data were first processed with Trim Galore vO.6.7 in paired-end mode with default parameters to remove low-quality bases, adapter sequences, and unpaired sequences. Trimmed reads were aligned to the GENCODE mouse reference genome M31 (GRCm39) using STAR (v2.7.10a), quantified using kallisto, and refined to canonical coding sequences using CCDS release 21.

[0210] All differential expression analyses were performed with PyDESeq2. The effects on transcript abundance were modeled according to the following general formula:log q ~ / ?0+ / ?i ‘ (treatment) + f>2’ (sex)115 / 149B1195.70208WO00#15198909v2

[0211] Either vehicle-treated P£X / WI7WTorP£X / G844D / G844Dwere use as t|ie reference|eve| for the treatment variable (depending on the analysis performed) and male mice as the reference level for the sex variable. Inferred log2 fold-change values were shrunk with a heavy-tailed Cauchy prior, and p-values were calculated according to Wald’s test. Reported effect sizes correspond to post-shrinkage log2 fold-change values.

[0212] Volcano plots are shown in FIGs. 10A-10B and differentially expressed genes were further analyzed via WEBGESTALT™91. KEGG, Phenotype, and other related pathway analyses were conducted and reported in FIGs. 11A-11D, focusing on the PPX1G844D / G844D-vehicle versus WT-vehicle at six weeks and 16 weeks post injection. Enrichment analyses focused on categories meeting a 1% FDR and defined by 10-1000 genes thereby avoiding overly specialized or broad categories.

[0213] Analysis of the transcriptome-wide editing RNA-seq data was performed as follows. Prior to the analysis described below, FASTQ files were generated using Bcl2fastq2, then trimmed using CUT AD APT™76v.1.18 to remove adapter sequences, unpaired sequences, and low-quality bases. Sorted bam alignments were created using STAR v.2.7.11a to align paired reads from each of three biological replicates to the mm 10 mouse reference genome (ENSEMBL®). To calculate the average percentage of A-to-I editing among adenosines sequenced in transcriptome-wide sequencing analysis, REDItools2 was used to quantify the percentage of A-to-I editing in each sample. All nucleotides except adenosines were removed from the analysis, and then all adenosines with a read coverage less than 10 were removed to avoid errors due to low sampling; additionally, positions with a mapping or read quality score below 25 were removed. Next, the number of adenosines that were converted to an inosine in each sample were calculated, and this was divided by the total number of adenosines in the data set after filtering to obtain a percentage of adenosines that were edited to inosine in the transcriptome.

[0214] To investigate how transcriptome-wide A-to-I editing levels vary with AAV dose and time, the investigation focused on a set of high-confidence A-to-I off-targets. This set of sites was determined by identifying adenosines with non-zero (>0.1%) A-to-I editing in either both male high-dose mice at 6 weeks or both female high-dose mice at 6 weeks (22,131 A’s), then removing all overlap with sites that also exhibit non-zero (>0.1%) A-to-I editing in at least two saline-treated control samples (96,097 A’s). This filtering procedure left4,161 adenosines that were investigated as candidate off-target A-to-I editing sites. Jitter plots116 / 149B1195.70208WO00#15198909v2were generated for each sample by plotting each of the 4,161 off-target sites that showed nonzero editing.Lipid analysis

[0215] Fatty acids in plasma were hydrolyzed from triglycerides and phospholipids in a two-step process of acidification with 90:10 v:v acetonitrile: 6 N HC1 and neutralization with 90:10 v:v methanol: 10 N NaOH, with incubations at 104 °C for 45 minutes, then reacidified in 6N HC1. Total fatty acids were extracted in hexane then derivatized77,78with triethylamine and pentafluorobenzyl bromide (in acetonitrile) at room temperature 15 minutes. The resulting fatty acid pentafluorobenzyl (PFB) esters were separated and quantified by GC / MS operating in negative ion chemical ionization (NCI) mode using ammonia as reagent gas (source pressure, 1.6 Torr) on a SP2560 capillary column (50 m x 0.25 mm x 0.2 pm) with helium as carrier gas and column pressure of 20 psi following the Lagerstedt et al. method79. After a 1 pl 1:35 split injection, a slower and lower ramping of oven temperature at lower temperatures over two steps and increased run time of 55 minutes on an Agilent 6890 / 5973 GC / MS were used. An initial oven temperature of 60 °C was held for 2 minutes, then ramped at 10 °C / min to 180 °C, followed by a second ramping at 2.5 °C / min to a final temperature of 250 °C, then held for 14 minutes. The MSD transfer line had an initial temperature of 240 °C for 33 minutes and then was increased at a rate of 2.5°C / min to a final temperature of 250 °C and a final time of 32 minutes. The acquisition was in select ion monitoring (SIM) mode and dwell times ranging from 50 milliseconds to 100 milliseconds for each ion species. Each analyte was matched to one of 13 stable-isotope labeled internal standards that was of closest chain length and retention time and calculated from a calibration curve created from 50 different analyte standards; when pure standards were not available, the calibration curve of the closest available analytes was used. Individual fatty acids were expressed as pg / mL in plasma and as pg / mg of total lipid fatty acid content. The lipid foldchange relative to WT controls for each lipid moiety was calculated using RSTUDIO® (version 2024.12.1_563) and P values calculated using Dunn’s nonparametric many-to-one comparison test for Kruskal-type ranked data.Bile acid analysis

[0216] Methanol, acetonitrile, water, and formic acid (all Optima grade) were purchased from Fisher Scientific. d4-t-CA, d4-g-CA, d4-g-CDCA, d4-CA, d4-CDCA, t-CA, g-CA, CA117 / 149B1195.70208WO00#15198909v2were purchased from CAYMAN CHEMICAL®, 7-HOCA from AVANTI POLAR LIPIDS®, and ds-THCA, ds-DHCA, THCA, and DHCA from VUMC, Herman ten Brink. Briefly, 25 mg of homogenized liver tissue in 50 pL PBS were transferred to a clean 13x100mm glass tube, to which 0.5 ml methanol was added and then incubated for 30 minutes at room temperature in a sonicator bath (Branson 3510). The extracted liver tissue was centrifuged at 2500 rpm for 10 minutes, and the supernatant was transferred to a clean glass tube. The supernatant was dried under nitrogen and then reconstituted in 240 pL of methanol / H20 (3:1 vol / vol) containing 100 ng internal standards (d3-THCA, d3-DHCA, d4-t-CA, d4-t-CDCA, d4-g-CA, d4-g-CDCA, d4-CA, and d4-CDCA). The samples were filtered through Costar Spin-X 0.22 pm nylon centrifuge. Reconstituted samples were transferred to verex injection vials (PHENOMENEX®) for analysis.

[0217] Chromatographic separation was achieved on a Waters TQD interfaced with an Acquity UPLC system comprising a sample manager (samples kept at T=10 °C), binary solvent manager, and a column manager with an Acquity HSST3 column 1.8 pm (particle size), 50x2.1 mm (T=50 °C) (Waters) operated in the negative ion electrospray ionization (ESI) mode. Samples were eluted at a flow rate of 0.5 mL / min with a linear gradient between mobile phase A [Water / 0.1% formic acid] and mobile phase B [Acetonitrile / 0.1% formic acid]. The elution gradient was as follows: initial solvent conditions: 75% A, 25% B; to 10% A, 90% B to for 1 minute, maintained at 10% A / 90% B from 1-2.25 minutes, and equilibration back to 75%. A / 25% from 2.25-3 minutes. MRM transitions for each analyte were monitored as follows: d4-t-CA, m / z 518.16 -^79.94; d4-t-CDCA, m / z 502.17^79.94; d4-g-CA, m / z 468.12— >73.95; d4-g-CDCA, m / z 452.19^73.95 d4-CA, m / z 411.10^411.10; d4-CDCA, m / z 395.04^395.23; CA, m / z 407.00^407.05; CDCA m / z 391.07^391.07; 7-HOCA m / z 429.08^411.17; d3-THCA m / z 452.20^452.33; d3-DHCA, m / z 436.14^436.32 THCA, m / z 449.11^-449.08; and DHCA, m / z 433.12^-433.12. Quantification was performed using MASSLYNX® 4.1 where MRM peaks were integrated with the TARGETLYNX™ program, and areas were exported for further calculations in MS Excel. Graphs were generated with GRAPHPAD PRISM® 10.Western blotting

[0218] Liver lysates from Pexl+ / +and PexlG844Dmale and female mice were prepared in the radioimmunoprecipitation assay (RIPA) buffer (THERMO FISHER®, cat. 89901) containing HALT™ Protease Inhibitor Cocktail (THERMO FISHER SCIENTIFIC®, cat. 1861284).118 / 149B1195.70208WO00#15198909v2Total protein content was quantified by detergent compatible (DC) assay (BIORAD®, cat. 5000113, 5000114, 5000115) and adjusted to 4 mg / ml in RIPA buffer. Protein lysates were prepared for automated western blot using the Simple Wes system (ProteinSimple, cat. 004-600). Briefly, samples were mixed at a 4: 1 ratio with 5x fluorescent master mix, producing a final protein concentration of 0.75 mg / ml, and heated at 95 °C for 5 minutes. ABCD3 protein levels were quantified using automated capillary Western blotting (SIMPLE WES™, PROTEINSIMPLE®), with an anti-PMP70 / ABCD3 antibody (ABCAM®, ab85550) at a 1:50 dilution. Samples plus biotinylated molecular weight standards (PROTEINSIMPLE®, cat. PS-ST01EZ-8) were loaded along with blocking solution, biotin labeling reagent, wash buffers, primary antibodies, horseradish-peroxidase conjugated secondary antibodies and chemiluminescent substrate into a plate prefilled with stacking and separation matrices (PROTEINSIMPLE®, SM-W001). For immunodetection anti-PMP-70 antibody was used at a dilution of 1:50 (ABCAM®, cat. ab85550) with a 30-minute incubation time. ABCD3 protein levels were quantified using automated capillary Western blotting (SIMPLE WES™, PROTEINSIMPLE®), with an anti-PMP70 / ABCD3 antibody (ABCAM®, ab85550) at a 1:50 dilution. Chemiluminescent signal was captured, and the resulting image was analyzed using the Compass for Simple Western software package (Compass for SW, version 6.2.0). Total protein staining was performed following PROTEINSIMPLE® instructions. The PMP-70 peak area was normalized to total protein area following PROTEINS IMPLE® recommendations and standard guidelines80,81. Relative fold change was calculated as the ratio of experimental samples corrected area to the reference group corrected area (PEX1+ / )).Droplet digital PCR ( ddPCR ) analysis

[0219] DNAdvance kit (BECKMAN COULTER®, cat. A48705) purified 100 ng liver gDNA was used for droplet digital PCR (ddPCR) analysis, using the BIO-RAD® QX ONE platform. In the reaction, lOOng gDNA, 900nM each primer (forward and reverse), 250nM probe, 2X ddPCR Supermix for Probes without dUTP (BIO-RAD®, #1863024), and nuclease-free water were added at a final volume of 25 pL, and processed according to manufacturer guidelines, and then transferred to the QX ONE® GCR96 cartridge (BIO-RAD®, cat. 12006859). Droplet generation, PCR, and droplet reading steps were all performed using the BIO-RAD® QX ONE® platform with QX ONE® oils. PCR was performed with the following conditions: 95 °C for 10 minutes, 50 cycles of 94 °C for 30 seconds and 58 °C for 2 minutes, and finally119 / 149B1195.70208WO00#15198909v298 °C for 10 minutes. Data from ddPCR were analyzed using the QX ONE® software 1.3 Standard Edition.Off-target editing analysis

[0220] CIRCLE- seq off-target analysis was performed as described previously52,82. Briefly, genomic DNA from N2A mouse cells or ZSD patient-derived £x / G843D / I700fsfibroblasts was isolated using Centra PUREGENE® Kit (QIAGEN®) according to manufacturer’ s instructions. Purified genomic DNA was sheared with a Covaris S2 instrument to an average length of 300 bp. The fragmented DNA was end repaired, poly-A tailed, and ligated to a uracil-containing stem-loop adaptor using the KAPA® HTP Library Preparation Kit, PCR Free (KAPA BIOSYSTEMS®). Adaptor ligated DNA was treated with Lambda Exonuclease (NEB®) and E. coli Exonuclease I (NEB®), then with USER enzyme (NEB®) and T4 polynucleotide kinase (NEB®). Intramolecular circularization of the DNA was performed with T4 DNA ligase (NEB®), and residual linear DNA was degraded by Plasmid-Safe ATP-dependent DNase (LUCIGEN®). In vitro cleavage reactions were performed with 250 ng of Plasmid-Safe ATP-dependent DNase-treated circularized DNA, 90 nM of SpCas9 nuclease protein, Cas9 nuclease buffer (NEB®), and 90 nM of synthetic chemically modified guide RNA (SYNTHEGO®), in 100 pl. Cleaved products were poly-A tailed, ligated with a hairpin adaptor (NEB®), treated with USER enzyme (NEB®), and amplified by PCR with barcoded universal primers. NEB NEXT® Multiplex Oligos for ILLUMINA® (NEB®), using Kapa HiFi Polymerase (KAPA BIOSYSTEMS®). Libraries were sequenced with 150-bp paired-end reads on an ILLUMINA® MISEQ® instrument. CIRCLE-seq data analyses were performed using open-source CIRCLE-seq analysis software and default recommended parameters.

[0221] CAS-OFFINDER™ analysis was performed online. Filtering criteria for potential off-target editing based on DNA sequence similarity was set as sequence mismatch number equal or less than three for SpCas9. Twenty predicted off-target sites were nominated.

[0222] Top 30 CIRCLE-seq nominated off-target sites for mouse genome and all the CIRCLE-seq and CAS-OFFINDER™ nominated sites were examined via amplicon sequencing using the gDNA from editor-treated liver tissues or patient-derived fibroblasts specified in the texts and figures.120 / 149B1195.70208WO00#15198909v2Baculoviral Peroxisome-GFP transduction of patient derived fibroblasts

[0223] CELLLIGHT™ Peroxisome-GFP, BacMam 2.0 kit was ordered from THERMO FISHER SCIENTIFIC® (cat. C 10604). Healthy donor derived fibroblasts, base editor-treated, and non-target guide treated control fibroblasts were plated onto 24- well plates with glass bottom (GREINER®, cat. 662892). On the second day, fibroblasts grew to 70% confluency and were transduced with baculoviral peroxisome-GFP vectors following the manufacturer’s recommended steps. Cells were incubated for 16 hours and then treated with far red nuclear staining dye (MILLIPORE SIGMA®, cat. SCT117) before imaging. Live cell imaging was performed using MICA® confocal microscope. Incubation temperature was set at 37 °C and CO2 was set at 5%. 24-well plate and imaging characteristics (“dynamics and living”) were set for live cell imaging. The absorbance and emission were set for the fluorophores specified in the product’s manual. A 63x water-immersion objective lens was used to capture images. Treated samples for comparison were taken using the same imaging settings. Further imaging processing was done with ImageJ™2 (version: 2.14.0 / 1.54f).Immunofluorescence microscopy of ABE-treated patient-derived fibroblast cells

[0224] Cells for immunofluorescence microscopy were grown on sterile glass coverslips. Nucleofected patient-derived and healthy donor fibroblasts were washed with PBS and fixed using 3% formaldehyde in PBS at room temperature for 20 minutes. Cells were then subjected to a 5-minute extraction with 1% Triton X in PBS and PBS wash before incubation with primary antibodies (anti-catalase (THERMO FISHER SCIENTIFIC®) and anti-PMP70 (ABCD3) (ABCAM®) overnight in a 4 °C cold room. On the second day, cells were washed with PBS and incubated with fluorescent labeled secondary antibodies (ALEXA FLUOR® 594 goat anti-rabbit IgG (THERMO FISHER SCIENTIFIC®) and Alexa Fluor 488 goat antimouse IgG) for 20 minutes at room temperature. Cells on coverslip were washed with PBS before being mounted onto a glass slide with a dot of Prolong Diamond Antifade Mountant (THERMO FISHER SCIENTIFIC®, cat. P36965). Image processing was done as described above using Leica MICA® recommended settings for fixed cells. Further imaging processing was done with ImageJ2.Quantification and Statistical Analysis

[0225] The number of independent biological replicates and technical replicates for each experiment are described in the figure legends or the Methods section. Statistical tests were121 / 149B1195.70208WO00#15198909v2performed using GRAPHPAD PRISM® version 10.1.1 for Windows and 10.3.0 for Mac (GRAPHPAD® Software, San Diego, CA).

[0226] Guide RNA sequences used in this Example:

[0227] Summary of materials used to generate sequencing data and other analyses in the figures:122 / 149B1195.70208WO00#15198909v2123 / 149B1195.70208WO00 #15198909v2REFERENCES1. Wanders, R. J. A. Peroxisomes and their Key Role in Cellular Signaling and Metabolism. Subcell. Biochem. 69, 23-44 (2013).2. Fransen, M. & Lismont, C. Redox Signaling from and to Peroxisomes: Progress, Challenges, and Prospects. Antioxid. Redox Signal. 30, 95-112 (2019).3. Tripathi, D. N. & Walker, C. L. The peroxisome as a cell signaling organelle. Curr. Opin. Cell Biol. 39, 109-112 (2016).4. He, A., Dean, J. M. & Lodhi, I. J. Peroxisomes as cellular adaptors to metabolic and environmental stress. Trends Cell Biol. 31, 656-670 (2021).5. Okumoto, K., Tamura, S., Honsho, M. & Fujiki, Y. Peroxisome Biology:Experimental Models, Peroxisomal Disorders and Neurological Diseases. Adv. Exp. Med. Biol. 1299, 3-17 (2021).6. Wanders, R. J. A., Baes, M., Ribeiro, D., Ferdinandusse, S. & Waterham, H. R. The physiological functions of human peroxisomes. Physiol. Rev. 103, 957-1024 (2023).7. Fujiki, Y., Okumoto, K., Honsho, M. & Abe, Y. Molecular insights into peroxisome homeostasis and peroxisome biogenesis disorders. Biochim. Biophys. Acta (BBA) - Mol. Cell Res. 1869, 119330 (2022).8. Wanders, R. J. A., Waterham, H. R. & Ferdinandusse, S. Metabolic Interplay between Peroxisomes and Other Subcellular Organelles Including Mitochondria and the Endoplasmic Reticulum. Front. Cell Dev. Biol. 3, 83 (2016).9. Zalckvar, E. & Schuldiner, M. Beyond rare disorders: A new era for peroxisomal pathophysiology. Mol. Cell 82, 2228-2235 (2022).10. Steinberg, S. J. Zellweger Spectrum Disorder. GeneReviews (2003).11. Vasiljevic, E. et al. Carrier frequency estimation of Zellweger spectrum disorder using ExAC database and bioinformatics tools. Genet. Med. 21, 1969-1976 (2019).12. Judy, R. M., Sheedy, C. J. & Gardner, B. M. Insights into the Structure and Function of the Pexl / Pex6 AAA-ATPase in Peroxisome Homeostasis. Cells 11, 2067 (2022).13. Riittermann, M. et al. Structure of the peroxisomal Pexl / Pex6 ATPase complex bound to a substrate. Nat. Commun. 14, 5942 (2023).14. Pedrosa, A. G. et al. The Extraction Mechanism of Monoubiquitinated PEX5 from the Peroxisomal Membrane. J. Mol. Biol. 435, 167896 (2023).124 / 149B1195.70208WO00#15198909v215. Karuntu, J. S., Klouwer, F. C. C., Engelen, M. & Boon, C. J. F. Systematic study of ophthalmological findings in 10 patients with PEX1 -mediated Zellweger spectrum disorder. Ophthalmic Genet. 1-12 (2024).16. Berendse, K. et al. Hepatic symptoms and histology in 13 patients with a Zellweger spectrum disorder. J. Inherit. Metab. Dis. 42, 955-965 (2019).17. Bose, M. et al. Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings: A Scoping Review, Meta- Analysis and Medical Chart Review. Cells 11, 1891 (2022).18. Yergeau, C. et al. Zellweger Spectrum Disorder Ophthalmic Findings from a New Natural History Study Cohort and Scoping Literature Review. Ophthalmology 130, 1313— 1326 (2023).19. Braverman, N. E., D’Agostino, M. D. & MacLean, G. E. Peroxisome biogenesis disorders: Biological, clinical and pathophysiological perspectives. Dev Disabil Res Rev 17, 187-196 (2013).20. Rosewich, H., Ohlenbusch, A. & Gartner, J. Genetic and clinical aspects of Zellweger spectrum patients with PEX1 mutations. J. Med. Genet. 42, e58-e58 (2005).21. Morales-Romero, B. et al. Plasma C24:0- and C26:0-lysophosphatidylcholines are reliable biomarkers for the diagnosis of peroxisomal P-oxidation disorders. J. Lipid Res. 65, 100516 (2024).22. Jaspers, Y. R. J. et al. Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcholine and Very Long-Chain Fatty Acids Analysis for Peroxisomal Disorders. Front. Cell Dev. Biol. 8, 690 (2020).23. Braverman, N. E. et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab 117, 313-321 (2016).24. Klouwer, F. C. C. et al. The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy. J. Inherit. Metab. Dis. 42, 303-312 (2019).25. Klouwer, F. C. C. et al. Oral Cholic Acid in Zellweger Spectrum Disorders. J.Pediatr. Gastroenterol. Nutr. 66, e57-e57 (2018).26. Berendse, K. et al. Cholic acid therapy in Zellweger spectrum disorders. J. Inherit. Metab. Dis. 39, 859-868 (2016).27. Menon, J., Shanmugam, N., Vij, M., Rammohan, A. & Rela, M. Liver Transplantation for Zellweger Syndrome. Indian J. Pediatr. 91, 507-509 (2024).125 / 149B1195.70208WO00#15198909v228. Demaret, T. et al. Living-donor liver transplantation for mild Zellweger spectrum disorder: Up to 17 years follow-up. Pediatr. Transplant. 22, el3112 (2018).29. Sokal, E. M. et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up 1. Transplantation 76, 735-738 (2003).30. Gonzalez, C. et al. Subacute Neuropathy Post-Liver Transplantation in Zellweger Spectrum Disorder: A Case Report. Am. J. Med. Genet. Part A e63941 (2024) doi:10.1002 / ajmg.a.6394L31. Koblan, L. W. et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature 589, 608-614 (2021).32. Newby, G. A. et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature 595, 295-302 (2021).33. McAuley, G. E. et al. Human T cell generation is restored in CD36 severe combined immunodeficiency through adenine base editing. Cell 186, 1398-1416.e23 (2023).34. Arbab, M. et al. Base editing rescue of spinal muscular atrophy in cells and in mice. Science eadg6518 (2023) doi:10.1126 / science.adg6518.35. Alves, C. R. R. et al. Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy. Nat. Biomed. Eng. 8, 118-131 (2024). 36. Hiebler, S. et al. The Pexl-G844D mouse: A model for mild human Zellweger spectrum disorder. Mol Genet Metab 111, 522-532 (2014).37. Berendse, K. et al. Liver disease predominates in a mouse model for mild human Zellweger spectrum disorder. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1865, 2774-2787 (2019).38. Argyriou, C. et al. A longitudinal study of retinopathy in the PEXl-Gly844Asp mouse model for mild Zellweger Spectrum Disorder. Exp. Eye Res. 186, 107713 (2019). 39. Demaret, T. et al. Longitudinal study of Pexl-G844D NMRI mouse model: A robust pre-clinical model for mild Zellweger spectrum disorder. Biochim. Biophys. Acta (BBA) -Mol. Basis Dis. 1866, 165900 (2020).40. Demaret, T. et al. High Dose Versus Low Dose Syngeneic Hepatocyte Transplantation in Pexl- G844D NMRI Mouse Model is Safe but Does Not Achieve Long Term Engraftment. Cells 10, 40 (2020).126 / 149B1195.70208WO00#15198909v241. Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 1-21 (2020) doi:10.1038 / s41587-020-0561-9.42. Gaudelli, N. M. et al. Programmable base editing of A»T to G*C in genomic DNA without DNA cleavage. Nature 551, 464 (2017).43. Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol 38, 1-9 (2020).44. Jaganathan, K. et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell 176, 535- 548.e24 (2019).45. Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).46. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434-443 (2020).47. Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, gkxll53- (2017).48. Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng 4, 97-110 (2020).49. Argyriou, C. et al. AAV-mediated PEX1 gene augmentation improves visual function in the PEX1- Gly844Asp mouse model for mild Zellweger spectrum disorder. Mol Ther -Methods Clin Dev 23, 225- 240 (2021).50. Braet, F., Taatjes, D. J. & Wisse, E. Probing the unseen structure and function of liver cells through atomic force microscopy. Semin. Cell Dev. Biol. 73, 13-30 (2018).51. Mathiesen, S. N., Lock, J. L., Schoderboeck, L., Abraham, W. C. & Hughes, S. M. CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain. Mol Ther - Methods Clin Dev 19, 447-458 (2020).52. MIURA, Y. The biological significance of co-oxidation of fatty acids. Proc. Jpn. Acad., Ser. B 89, 370 (2013).53. Ding, J. et al. The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids. Cell Rep. 5, 248-258 (2013).54. Khalil, Y. et al. Tissue Proteome of 2-Hydroxyacyl-CoA Lyase Deficient Mice Reveals Peroxisome Proliferation and Activation of co-Oxidation. Int. J. Mol. Sci. 23, 987 (2022).127 / 149B1195.70208WO00#15198909v255. Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429-434 (2021).56. Horie, T. & Ono, K. VERVE- 101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients. Eur. Hear. J. - Cardiovasc.Pharmacother. 10, 89-90 (2023).57. Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806-2827 (2022).58. Newby, G. A. & Liu, D. R. In vivo somatic cell base editing and prime editing. Mol Ther 29, 3107- 3124 (2021).59. Chen, D. et al. Rapid Discovery of Potent siRNA-Containing Lipid Nanoparticles Enabled by Controlled Microfluidic Formulation. J. Am. Chem. Soc. 134, 6948-6951 (2012).60. Tsai, S. Q. et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nature Methods 14, nmeth.4278 (2017).61. Bae, S., Park, J. & Kim, J.-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473-1475 (2014).62. Gao, X. D. et al. C-BERST: defining subnuclear proteomic landscapes at genomic elements with dCas9-APEX2. Nature Methods 15, 1-4 (2018).63. Honsho, M., Okumoto, K., Tamura, S. & Fujiki, Y. Peroxisome Biology:Experimental Models, Peroxisomal Disorders and Neurological Diseases. Adv. Exp. Med. Biol. 1299, 45-54 (2021).64. Demaret, T. et al. Accurate and live peroxisome biogenesis evaluation achieved by lentiviral expression of a green fluorescent protein fused to a peroxisome targeting signal 1. Histochem. Cell Biol. 153, 295-306 (2020).65. Wiemer, E. A. C., Wenzel, T., Deerinck, T. J., Ellisman, M. H. & Subramani, S. Visualization of the Peroxisomal Compartment in Living Mammalian Cells: Dynamic Behavior and Association with Microtubules. J. Cell Biol. 136, 71-80 (1997).66. Kost, T. A., Condreay, J. P. & Jarvis, D. L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 23, 567-575 (2005). 67. Davis, J. R. et al. Efficient in vivo base editing via single adeno-associated viruses with size- optimized genomes encoding compact adenine base editors. Nat Biomed Eng 1-12 (2022) doi: 10.1038 / s41551-022-00911-4.128 / 149B1195.70208WO00#15198909v268. Zhang, H. et al. Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector. Gen Biotechnology 1, 285-299 (2022).69. Sands, M. S. Adeno-Associated Virus, Methods and Protocols. Methods Mol. Biol. 807, 141-157 (2011).70. Schackmann, M. J. A., Ofman, R., Dijkstra, I. M. E., Wanders, R. J. A. & Kemp, S. Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis. Biochim. Biophys. Acta (BBA) - Mol. Cell Biol. Lipids 1851, 231-237 (2015). 71. Wang, X., Yu, H., Gao, R., Liu, M. & Xie, W. A comprehensive review of the family of very-long- chain fatty acid elongases: structure, function, and implications in physiology and pathology. Eur. J. Med. Res. 28, 532 (2023).72. Watkins, P. A. et al. Identification of differences in human and great ape phytanic acid metabolism that could influence gene expression profiles and physiological functions. BMC Physiol. 10, 19 (2010).73. Waterham, H. R., Wanders, R. J. & Leroy, B. P. Adult Refsum Disease Summary. GeneReviews (2006).74. Gross, D.-A., Tedesco, N., Leborgne, C. & Ronzitti, G. Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients. Front. Immunol. 13, 857276 (2022).75. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078-1094 (2021).76. Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250-265.el6 (2022).77. An, M. et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat. Biotechnol. 1-12 (2024) doi:10.1038 / s41587-023-02078-y.78. Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol 37, 224-226 (2019).79. Doman, J. L., Sousa, A. A., Randolph, P. B., Chen, P. J. & Liu, D. R. Designing and executing prime editing experiments in mammalian cells. NatProtoc 1-38 (2022) doi:10.1038 / s41596-022-00724- 4.80. He, X. et al. Optimized protocol for high-titer lentivirus production and transduction of primary fibroblasts. J. Basic Microbiol. 61, 430-442 (2021).129 / 149B1195.70208WO00#15198909v281. Elizarraras, J. M. et al. WebGestalt 2024: faster gene set analysis and new support for metabolomics and multi-omics. Nucleic Acids Res. 52, W415-W421 (2024).82. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetJ. 17, 10-12 (2011).83. Stellaard, F., Brink, H. J. ten, Kok, R. M., Heuvel, L. V. D. & Jakobs, C. Stable isotope dilution analysis of very long chain fatty acids in plasma, urine and amniotic fluid by electron capture negative ion mass fragmentography. Clin. Chim. Acta 192, 133-144 (1990).84. Brink, H. J. ten et al. Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography. J. lipid Res. 33, 41-7 (1992).85. Lagerstedt, S. A. et al. Quantitative Determination of Plasma C8-C26 Total Fatty Acids for the Biochemical Diagnosis of Nutritional and Metabolic Disorders. Mol. Genet. Metab. 73, 38-45 (2001).86. Taylor, S. C. & Posch, A. The Design of a Quantitative Western Blot Experiment. BioMed Res. Int. 2014, 361590 (2014).87. Fosang, A. J. & Colbran, R. J. Transparency Is the Key to Quality. J. Biol. Chem. 290, 29692- 29694 (2015).88. Eazzarotto, C. R. et al. Defining CRISPR-Cas9 genome-wide nuclease activities with CIRCEE-seq. Nat. Protoc. 13, 2615-2642 (2018).SEQUENCESHuman PEX1 wildtype amino acid sequenceNCBI Ref. No.: NP_000457. 11283 amino acids MWGSDRLAGAGGGGAAVTVAFTNARDCFLHLPRRLVAQLHLLQNQAIEWWSHQPAFLSWVEGRHFSDQGENVAE INRQVGQKLGLSNGGQVFLKPCSHWSCQQVEVEPLSADDWEILELHAVSLEQHLLDQIRIVFPKAIFPVWVDQQ TYIFIQIVALIPAAS YGRLETDTKLLIQPKTRRAKENTFSKADAEYKKLHS YGRDQKGMMKELQTKQLQSNTVGI TESNENESEIPVDSSSVASLWTMIGSIFSFQSEKKQETSWGLTEINAFKNMQSKWPLDNIFRVCKSQPPSI YNA SATSVFHKHCAIHVFPWDQEYFDVEPSFTVTYGKLVKLLSPKQQQSKTKQNVLSPEKEKQMSEPLDQKKIRSDHN EEDEKACVLQWWNGLEELNNAIKYTKNVEVLHLGKVWIPDDLRKRLNIEMHAWRITPVEVTPKIPRSLKLQPR ENLPKDISEEDIKTVFYSWLQQSTTTMLPLVISEEEFIKLETKDGLKEFSLSIVHSWEKEKDKNIFLLSPNLLQK TTIQVLLDPMVKEENSEEIDFILPFLKLSSLGGVNSLGVSSLEHITHSLLGRPLSRQLMSLVAGLRNGALLLTGG KGSGKSTLAKAICKEAFDKLDAHVERVDCKALRGKRLENIQKTLEVAFSEAVWMQPSWLLDDLDLIAGLPAVPE HEHSPDAVQSQRLAHALNDMIKEFISMGSLVALIATSQSQQSLHPLLVSAQGVHIFQCVQHIQPPNQEQRCEILC NVIKNKLDCDINKFTDLDLQHVAKETGGFVARDFTVLVDRAIHSRLSRQSISTREKLVLTTLDFQKALRGFLPAS LRSVNLHKPRDLGWDKIGGLHEVRQILMDTIQLPAKYPELFANLPIRQRTGILLYGPPGTGKTLLAGVIARESRM NFISVKGPELLSKYIGASEQAVRDIFIRAQAAKPCILFFDEFESIAPRRGHDNTGVTDRWNQLLTQLDGVEGLQ GVYVLAATSRPDLIDPALLRPGRLDKCVYCPPPDQVSRLEILNVLSDSLPLADDVDLQHVASVTDSFTGADLKAL LYNAQLEALHGMLLSSGLQDGSSSSDSDLSLSSMVFLNHSSGSDDSAGDGECGLDQSLVSLEMSEILPDESKFNM YRLYFGSSYESELGNGTSSDLSSQCLSAPSSMTQDLPGVPGKDQLFSQPPVLRTASQEGCQELTQEQRDQLRADI SIIKGRYRSQSGEDESMNQPGPIKTRLAISQSHLMTALGHTRPSISEDDWKNFAELYESFQNPKRRKNQSGTMFR PGQKVTLA ( SEQ ID NO: 123 )130 / 149B1195.70208WO00#15198909v2Human PEX1 wildtype nucleotide sequenceNCBI Ref. No.: NM_000466.34369 nucleotides atgtggggcagcgatcgcctggcgggtgctgggggaggcggggcggcagtgactgtggccttcaccaacgctcgc gactgcttcctccacctgccgcggcgtctcgtggcccagctgcatctgctgcagaatcaagctatagaagtggtc tggagtcaccagcctgcattcttgagctgggtggaaggcaggcattttagtgatcaaggtgaaaatgtggctgaa attaacagacaagttggtcaaaaacttggactctcaaatgggggacaggtatttctcaagccatgttcccatgtg gtatcttgtcaacaagttgaggtggaacccctctcagcagatgattgggagatactggagctgcatgctgtttcc cttgaacaacatcttctagatcaaattcgaatagtttttccaaaagccatttttcctgtttgggttgatcaacaa acgtacatatttatccaaattgttgcactaataccagctgcctcttatggaaggctggaaactgacaccaaactc cttattcagccaaagacacgccgagccaaagagaatacattttcaaaagctgatgctgaatataaaaaacttcat agttatggaagagaccagaaaggaatgatgaaagaacttcaaaccaagcaacttcagtcaaatactgtgggaatc actgaatctaatgaaaacgagtcagagattccagttgactcatcatcagtagcaagtttatggactatgatagga agcattttttcctttcaatctgagaagaaacaagagacatcttggggtttaactgaaatcaatgcattcaaaaat atgcagtcaaaggttgttcctctagacaatattttcagagtatgcaaatctcaacctcctagtatatataacgcg tcagcaacctctgtttttcataaacactgtgccattcatgtatttccatgggaccaggaatattttgatgtagag cccagctttactgtgacatatggaaagctagttaagctactttctccaaagcaacagcaaagtaaaacaaaacaa aatgtgttatcacctgaaaaagagaagcagatgtcagagccactagatcaaaaaaaaattaggtcagatcataat gaagaagatgagaaggcctgtgtgctacaagtagtctggaatggacttgaagaattgaacaatgccatcaaatat accaaaaatgtagaagttctccatcttgggaaagtctggattccagatgacctgaggaagagactaaatatagaa atgcatgccgtagtcaggataactccagtggaagttacccctaaaattccaagatctctaaagttacaacctaga gagaatttacctaaagacataagtgaagaagacataaaaactgtattttattcatggctacagcagtctactacc accatgcttcctttggtaatatcagaggaagaatttattaagctggaaactaaagatggactgaaggaattttct ctgagtatagttcattcttgggaaaaagaaaaagataaaaatatttttctgttgagtcccaatttgctgcagaag actacaatacaagtccttctagatcctatggtaaaagaagaaaacagtgaggaaattgactttattcttcctttt ttaaagctgagctctttgggaggagtgaattccttaggcgtatcctccttggagcacatcactcacagcctcctg ggacgccctttgtctcggcagctgatgtctcttgttgcaggacttaggaatggagctcttttactcacaggagga aagggaagtggaaaatcaactttagccaaagcaatctgtaaagaagcatttgacaaactggatgcccatgtggag agagttgactgtaaagctttacgaggaaaaaggcttgaaaacatacaaaaaaccctagaggtggctttctcagag gcagtgtggatgcagccatctgttgtcctgctggatgaccttgacctcattgctggactgcctgctgtcccggaa catgagcacagtcctgatgcggtgcagagccagcggcttgctcatgctttgaatgatatgataaaagagtttatc tccatgggaagtttggttgcactgattgccacaagtcagtctcagcaatctctacatcctttacttgtttctgct caaggagttcacatatttcagtgcgtccaacacattcagcctcctaatcaggaacaaagatgtgaaattctgtgt aatgtaataaaaaataaattggactgtgatataaacaagttcaccgatcttgacctgcagcatgtagctaaagaa actggcgggtttgtggctagagattttacagtacttgtggatcgagccatacattctcgactctctcgtcagagt atatccaccagagaaaaattagttttaacaacattggacttccaaaaggctctccgcggatttcttcctgcgtct ttgcgaagtgtcaacctgcataaacctagagacctgggttgggacaagattggtgggttacatgaagttaggcag atactcatggatactatccagttacctgccaagtatccagaattatttgcaaacttgcccatacgacaaagaaca ggaatactgttgtatggtccgcctggaacaggaaaaaccttactagctggggtaattgcacgagagagtagaatg aattttataagtgtcaaggggccagagttactcagcaaatacattggagcaagtgaacaagctgttcgggatatt tttattagagcacaggctgcaaagccctgcattcttttctttgatgaatttgaatccattgctcctcggcggggt catgataatacaggagttacagaccgagtagttaaccagttgctgactcagttggatggagtagaaggcttacag ggtgtttatgtattggctgctactagtcgccctgacttgattgaccctgccctgcttaggcctggtcgactagat aaatgtgtatactgtcctcctcctgatcaggtgtcacgtcttgaaattttaaatgtcctcagtgactctctacct ctggcagatgatgttgaccttcagcatgtagcatcagtaactgactcctttactggagctgatctgaaagcttta ctttacaatgcccaattggaggccttacatggaatgctgctctcgagtggactccaggatggaagttccagctct gatagtgacctaagtctgtcttcaatggtctttcttaaccatagcagtggctctgacgattcagctggagatgga gaatgtggcttagatcagtcccttgtttctttagagatgtccgagatccttccagatgaatcaaaattcaatatg taccggctctactttggaagctcttatgaatcagaacttggaaatggaacctcttctgatttgagctcacaatgt ctctctgcaccaagctccatgactcaggatttgcctggagttcctgggaaagaccagttgttttcacagcctcca gtgttaaggacagcttcacaagagggttgccaagaacttacacaagaacaaagagatcaactgagggcagatatc agtattatcaaaggcagataccggagccaaagtggagaggacgaatccatgaaccaaccaggaccaatcaaaacc agactggctattagtcagtcacatttaatgactgcacttggtcacacaagaccatccattagtgaagatgactgg aagaattttgctgagctatatgaaagctttcaaaatccaaagaggagaaaaaatcaaagtggaacaatgtttcga cctggacagaaagtaactttagcataa (SEQ ID NO: 127 )Human PEX1-P. G843D (c.2528G> A) variant amino acid sequenceNCBI Ref. No.: NP_000457. 1: p. Gly 843Asp131 / 149B1195.70208WO00#15198909v21283 amino acids MWGSDRLAGAGGGGAAVTVAFTNARDCFLHLPRRLVAQLHLLQNQAIEWWSHQPAFLSWVEGRHFSDQGENVAE INRQVGQKLGLSNGGQVFLKPCSHWSCQQVEVEPLSADDWEILELHAVSLEQHLLDQIRIVFPKAIFPVWVDQQ TYIFIQIVALIPAAS YGRLETDTKLLIQPKTRRAKENTFSKADAEYKKLHS YGRDQKGMMKELQTKQLQSNTVGI TESNENESEIPVDSSSVASLWTMIGSIFSFQSEKKQETSWGLTEINAFKNMQSKWPLDNIFRVCKSQPPSI YNA SATSVFHKHCAIHVFPWDQEYFDVEPSFTVTYGKLVKLLSPKQQQSKTKQNVLSPEKEKQMSEPLDQKKIRSDHN EEDEKACVLQWWNGLEELNNAIKYTKNVEVLHLGKVWIPDDLRKRLNIEMHAWRITPVEVTPKIPRSLKLQPR ENLPKDISEEDIKTVFYSWLQQSTTTMLPLVISEEEFIKLETKDGLKEFSLSIVHSWEKEKDKNIFLLSPNLLQK TTIQVLLDPMVKEENSEEIDFILPFLKLSSLGGVNSLGVSSLEHITHSLLGRPLSRQLMSLVAGLRNGALLLTGG KGSGKSTLAKAICKEAFDKLDAHVERVDCKALRGKRLENIQKTLEVAFSEAVWMQPSWLLDDLDLIAGLPAVPE HEHSPDAVQSQRLAHALNDMIKEFISMGSLVALIATSQSQQSLHPLLVSAQGVHIFQCVQHIQPPNQEQRCEILC NVIKNKLDCDINKFTDLDLQHVAKETGGFVARDFTVLVDRAIHSRLSRQSISTREKLVLTTLDFQKALRGFLPAS LRSVNLHKPRDLGWDKIDGLHEVRQILMDTIQLPAKYPELFANLPIRQRTGILLYGPPGTGKTLLAGVIARESRM NFISVKGPELLSKYIGASEQAVRDIFIRAQAAKPCILFFDEFESIAPRRGHDNTGVTDRWNQLLTQLDGVEGLQ GVYVLAATSRPDLIDPALLRPGRLDKCVYCPPPDQVSRLEILNVLSDSLPLADDVDLQHVASVTDSFTGADLKAL LYNAQLEALHGMLLSSGLQDGSSSSDSDLSLSSMVFLNHSSGSDDSAGDGECGLDQSLVSLEMSEILPDESKFNM YRLYFGSSYESELGNGTSSDLSSQCLSAPSSMTQDLPGVPGKDQLFSQPPVLRTASQEGCQELTQEQRDQLRADI SIIKGRYRSQSGEDESMNQPGPIKTRLAISQSHLMTALGHTRPSISEDDWKNFAELYESFQNPKRRKNQSGTMFR PGQKVTLA (SEQ ID NO: 124 )Human PEX1-P. G843D (c.2528G> A) variant nucleotide sequenceNCBI Ref. No.: NM_000466. 3 (PEX1 ): c. 2528G> A (p. Gly843Asp)4369 nucleotides atgtggggcagcgatcgcctggcgggtgctgggggaggcggggcggcagtgactgtggccttcaccaacgctcgc gactgcttcctccacctgccgcggcgtctcgtggcccagctgcatctgctgcagaatcaagctatagaagtggtc tggagtcaccagcctgcattcttgagctgggtggaaggcaggcattttagtgatcaaggtgaaaatgtggctgaa attaacagacaagttggtcaaaaacttggactctcaaatgggggacaggtatttctcaagccatgttcccatgtg gtatcttgtcaacaagttgaggtggaacccctctcagcagatgattgggagatactggagctgcatgctgtttcc cttgaacaacatcttctagatcaaattcgaatagtttttccaaaagccatttttcctgtttgggttgatcaacaa acgtacatatttatccaaattgttgcactaataccagctgcctcttatggaaggctggaaactgacaccaaactc cttattcagccaaagacacgccgagccaaagagaatacattttcaaaagctgatgctgaatataaaaaacttcat agttatggaagagaccagaaaggaatgatgaaagaacttcaaaccaagcaacttcagtcaaatactgtgggaatc actgaatctaatgaaaacgagtcagagattccagttgactcatcatcagtagcaagtttatggactatgatagga agcattttttcctttcaatctgagaagaaacaagagacatcttggggtttaactgaaatcaatgcattcaaaaat atgcagtcaaaggttgttcctctagacaatattttcagagtatgcaaatctcaacctcctagtatatataacgcg tcagcaacctctgtttttcataaacactgtgccattcatgtatttccatgggaccaggaatattttgatgtagag cccagctttactgtgacatatggaaagctagttaagctactttctccaaagcaacagcaaagtaaaacaaaacaa aatgtgttatcacctgaaaaagagaagcagatgtcagagccactagatcaaaaaaaaattaggtcagatcataat gaagaagatgagaaggcctgtgtgctacaagtagtctggaatggacttgaagaattgaacaatgccatcaaatat accaaaaatgtagaagttctccatcttgggaaagtctggattccagatgacctgaggaagagactaaatatagaa atgcatgccgtagtcaggataactccagtggaagttacccctaaaattccaagatctctaaagttacaacctaga gagaatttacctaaagacataagtgaagaagacataaaaactgtattttattcatggctacagcagtctactacc accatgcttcctttggtaatatcagaggaagaatttattaagctggaaactaaagatggactgaaggaattttct ctgagtatagttcattcttgggaaaaagaaaaagataaaaatatttttctgttgagtcccaatttgctgcagaag actacaatacaagtccttctagatcctatggtaaaagaagaaaacagtgaggaaattgactttattcttcctttt ttaaagctgagctctttgggaggagtgaattccttaggcgtatcctccttggagcacatcactcacagcctcctg ggacgccctttgtctcggcagctgatgtctcttgttgcaggacttaggaatggagctcttttactcacaggagga aagggaagtggaaaatcaactttagccaaagcaatctgtaaagaagcatttgacaaactggatgcccatgtggag agagttgactgtaaagctttacgaggaaaaaggcttgaaaacatacaaaaaaccctagaggtggctttctcagag gcagtgtggatgcagccatctgttgtcctgctggatgaccttgacctcattgctggactgcctgctgtcccggaa catgagcacagtcctgatgcggtgcagagccagcggcttgctcatgctttgaatgatatgataaaagagtttatc tccatgggaagtttggttgcactgattgccacaagtcagtctcagcaatctctacatcctttacttgtttctgct caaggagttcacatatttcagtgcgtccaacacattcagcctcctaatcaggaacaaagatgtgaaattctgtgt aatgtaataaaaaataaattggactgtgatataaacaagttcaccgatcttgacctgcagcatgtagctaaagaa actggcgggtttgtggctagagattttacagtacttgtggatcgagccatacattctcgactctctcgtcagagt atatccaccagagaaaaattagttttaacaacattggacttccaaaaggctctccgcggatttcttcctgcgtct ttgcgaagtgtcaacctgcataaacctagagacctgggttgggacaagattgatgggttacatgaagttaggcag atactcatggatactatccagttacctgccaagtatccagaattatttgcaaacttgcccatacgacaaagaaca ggaatactgttgtatggtccgcctggaacaggaaaaaccttactagctggggtaattgcacgagagagtagaatg aattttataagtgtcaaggggccagagttactcagcaaatacattggagcaagtgaacaagctgttcgggatatt 132 / 149B1195.70208WO00#15198909v2tttattagagcacaggctgcaaagccctgcattcttttctttgatgaatttgaatccattgctcctcggcggggt catgataatacaggagttacagaccgagtagttaaccagttgctgactcagttggatggagtagaaggcttacag ggtgtttatgtattggctgctactagtcgccctgacttgattgaccctgccctgcttaggcctggtcgactagat aaatgtgtatactgtcctcctcctgatcaggtgtcacgtcttgaaattttaaatgtcctcagtgactctctacct ctggcagatgatgttgaccttcagcatgtagcatcagtaactgactcctttactggagctgatctgaaagcttta ctttacaatgcccaattggaggccttacatggaatgctgctctcgagtggactccaggatggaagttccagctct gatagtgacctaagtctgtcttcaatggtctttcttaaccatagcagtggctctgacgattcagctggagatgga gaatgtggcttagatcagtcccttgtttctttagagatgtccgagatccttccagatgaatcaaaattcaatatg taccggctctactttggaagctcttatgaatcagaacttggaaatggaacctcttctgatttgagctcacaatgt ctctctgcaccaagctccatgactcaggatttgcctggagttcctgggaaagaccagttgttttcacagcctcca gtgttaaggacagcttcacaagagggttgccaagaacttacacaagaacaaagagatcaactgagggcagatatc agtattatcaaaggcagataccggagccaaagtggagaggacgaatccatgaaccaaccaggaccaatcaaaacc agactggctattagtcagtcacatttaatgactgcacttggtcacacaagaccatccattagtgaagatgactgg aagaattttgctgagctatatgaaagctttcaaaatccaaagaggagaaaaaatcaaagtggaacaatgtttcga cctggacagaaagtaactttagcataa (SEQ ID NO: 128 )Mouse PEX1 wildtype amino acid sequenceNCBI Reference Sequence: NP_001280735. 1. peroxisomal ATPase PEX1 isoform 1 [Mus msculus].MWSSDRLAGAGSGGAWTVAFTNARDCFLHLPRRLVAQLHLLQNQAIEVASDHQPTYLSWVEGRHFNDQSENVAE INRQVGQKLGLSSGDQVFLRPCSHWSCQQVEVEPLSADDWEILELHAISLEQHLLDQIRIVFPKAWPIWVDQQ TYIFIQIVTLMPAAP YGRLETNTKLLIQPKTRQAKESTFPKEGDAHGQVHS YGREQKGLSKELQTRQLHTNSEGI TASNGRDPKVPGGPLKPSWWAVLGSMLSFGPDSKQESAWGSLELGAFKNMQSQAAPLEGTFRVCQVQPPSARTTT ATSVFHKHCTAHVFPWDQEYFDVEPSFTVTYGKLVKLHSPKQQQDKSKQGVLLPDKEKQLSKSPDHKQISSNRSE EAAEACVLKWWNGLEELKNATEFTESLELLHRGKVWIPDDLRKRLNIEMHAWRITPLETTPKIPRSLKLQPRE NLPKDVNEETIKTVFSSWVQQSATTMLPLVISKEERIKLEIKDGLREFSLSTVHSQEKEKEEGKTVFVLSSILLQ KISVQVLLEPMIKEEQSAEIDFLLPSLTLSSLGGVSALGASAMEHITHSLLGRPLSRQLMALVAGLRNGALLITG GKGSGKSTFAKAICKEAQDTLDARVETVDCKALRGKRLESIQKALEVAFSEAAWRQPSVILLDDLDLIAGLPSVP EQEHSPEAVQSQRLAHALNDMIKEFVSTGSLVALIATSQLQQSLHPSLVSAQGIHTFQCVQHLQPPNPEQRCEIL HSWKNKLGCDISNFPDLDLQCIAKDTEAFVARDFTVLVDRAIHSSLSRQHSSSREDLTLTTSDFQKALRGFLPA SLRNVNLHKPRDLGWDKIGGLHEVRQILMDTIQLPAKYPELFANLPIRQRTGILLYGPPGTGKTLLAGWARESG MNFISIKGPELLSKYIGASEQAVRDVFIRAQAAKPCILFFDEFESIAPRRGHDNTGVTDRWNQLLTQLDGVEGL QGVYVLAATSRPDLIDPALLRPGRLDKCVYCPPPDQVSRLEILTVLSKSLALADDVDLQHVASVTDSFTGADLKA LLYNAQLEALQGRLLPSGLPDGGSSSDSDLSLSSMVFLNHSSGSDDSAGDGECGLEQSLLSLEMSEILPDESKFN MYRLYFGSSYESELGNGTPSDLSSHCLSAPSSVTQDLPAAPGKDPLFTQHPVFRTPSQEGCQDLTQEQRDQLRAE ISIIKGRYRSQSGEDESLNQPGPIKTTFAISQAHLMTALAHTRPSISEDEGKEFAELYENFQNPKKRKNQSGTVF RTGQKVTLA (SEQ ID NO: 125)Mouse PEX1 wildtype nucleotide sequenceNCBI Reference Sequence: NM_001293806. 1. Mus musculus peroxisomal biogenesis factor 1 (Pexl ), transcript variant 1, mRNA. ctggatgccatcttgccggctctagtcccccgcgccagaacaacatccgccagccgcgctcctctgagtccaata agagagcaggatggaccaggcgtgctaggattggctgaaggatcgaccccatcgacgatcatctcctgagagcga gaattcgacgagcgacgtgccgccccctagagcttcggaggtggcccgagggtgacagcggccgggcgtgggaag aggggggcgggcctgatcgatgttctcgggttccgacgctctcacctgacgagaagccggtggactccgctctcc ggtgagagttgaaccttgggacaatgtggagcagcgatcgcttagcgggtgcggggtctggtggggcggtcgtga cggtggccttcacgaatgctcgggactgcttcctgcatctgccgcggcgcctcgtggcccagcttcacctgctgc agaatcaagctatagaagtggccagcgatcaccagcctacctacctgagctgggtggaaggcaggcattttaatg atcaaagtgaaaatgtggcagaaattaatagacaagttggccagaaacttggactctcaagcggagatcaggtgt ttctcaggccttgttcccatgtggtatcttgccaacaggttgaagtggagcctctctcagcagatgactgggaaa tactggagctgcacgccatttcccttgaacagcatcttctggatcagattcgaatagttttccccaaagctgttg ttcccatctgggttgaccagcagacctacatatttatccagatcgtcactctgatgccagctgccccttatggaa ggctagaaactaacaccaaactccttattcagccaaagacacgccaagccaaagagagcacatttccaaaagaag gagatgcacacggacaagttcatagttatgggcgagaacagaaaggattgtcaaaggaattacaaaccaggcagc ttcatacgaactcagagggtatcactgcatccaatggaagagacccaaaagtcccaggtggcccgttgaagccaa gctggtgggctgtgctcggaagcatgctttcctttgggcctgacagtaaacaggagtcagcctggggctcgttgg aactcggtgctttcaaaaacatgcagtcacaggctgcccctctggaaggtactttcagagtatgccaagtccagc cacctagtgcgcgtaccaccaccgctacctctgtgtttcacaaacactgcaccgcccacgtatttccttgggacc133 / 149B1195.70208WO00#15198909v2aagaatactttgatgtggagcccagctttactgtgacctatggaaaactagttaagctacattctccaaaacaac agcaagacaaaagtaagcagggtgtcctgttgcctgacaaagagaagcagctgtccaagtctccagatcataagc agatcagctccaaccgcagtgaggaggctgctgaggcctgtgtgctgaaggtagtctggaatggactcgaggagt tgaagaatgccacagagttcaccgaaagtctagagcttctccaccgtgggaaagtctggattccagatgacctga gaaagagactaaatatagaaatgcatgcagtagtcagaataactccactggaaaccacgcctaaaatcccaagat ctctgaaattacaacctagagagaacttacctaaagacgtcaatgaagaaactataaaaacagtgttctcatctt gggtacagcagtccgctaccacgatgcttcctttggtaatatcaaaggaagagcgtattaagctggaaattaaag atgggctgagagagttctctctgagtacagttcattctcaggaaaaagaaaaggaagaaggaaaaactgtgtttg tgttgagttccatcctgctgcagaagatctcagtacaagtccttctagagcccatgataaaagaagaacagagtg cggaaatcgactttcttcttccctctttaacgctgagctctttggggggagtgagtgccttaggtgcatctgcaa tggagcacatcactcacagtctcctgggacgcccgttgtctaggcagctgatggccctcgttgcaggacttagga atggcgctcttttgatcactggaggaaagggaagcgggaagtcaacattcgcgaaagccatctgcaaggaagcac aggacactctggatgcccgtgtggagacagtcgactgcaaggctttacgaggaaaaaggcttgaaagcatacaaa aagcgctagaggtggctttctcagaggccgcctggaggcagccatctgtcattctgctggatgacctggacctca ttgccggactgccaagtgtccccgagcaggagcacagccctgaagcggtgcagagccagcggcttgcacatgctt tgaacgatatgatcaaagagtttgtttccacgggaagcttggtggcactcatcgccacgagccagctccagcagt ctctgcacccttcccttgtgtctgctcaaggaatccacacgtttcaatgtgtccagcaccttcagcctcccaatc cggaacagagatgtgaaattctgcacagtgttgtgaagaataaactgggctgtgatataagcaatttccctgact tggacctgcagtgcatagctaaagacacagaagcgtttgtggctcgtgactttacagttcttgtggaccgagcca tacactcttctctctctcgccagcatagctcctctagggaagacttgactttaacaacatcagacttccaaaagg ctctccgtggattccttcctgcttctctgcgaaatgtcaacttgcataaacctagagacctgggctgggacaaga ttggtggattacatgaagttcggcagatcctcatggatactatccagttaccagccaagtacccagaattatttg caaacttacccatacgacagaggacaggaatactgctttatggtcctccagggacaggaaaaactttacttgctg gggtagttgcaagagagagtggaatgaattttattagtattaagggaccagagttactcagcaaatatattggcg caagtgagcaagctgttcgagatgttttcatcagagcacaggctgcaaagccctgcattcttttctttgatgagt ttgagtccatcgctcctcgaagaggccatgacaacacaggggttacagaccgagtagtcaaccagttgctgacac agttagacggagtagaaggcttacagggagtttatgtgctggctgctactagtcgccctgacttgatcgaccctg ccctgttgcggcctggcagactggataaatgtgtatactgccctcctccagatcaggtgtcccgtcttgagattt taactgtcctcagcaagtctctagctctggcagatgacgtggaccttcagcacgtggcgtcggtcaccgactcgt tcactggagcggatctgaaagctctgctgtacaacgctcagctggaggccttgcagggacggctgctgcccagtg ggcttcccgatggaggctccagctctgacagtgacctgagtctgtcttcaatggtctttcttaaccacagcagtg gttccgacgactccgctggagatggagaatgtggcttagagcaatccctgctttctctcgagatgtctgagatcc ttccagacgaatcaaaattcaatatgtaccggctctactttggaagctcgtatgaatcggagcttggaaatggga ccccttctgacttgagctcacactgtctgtctgcaccaagctccgtgactcaggatttacctgcagctcctggga aagacccgttatttacacaacatcctgtgttcaggacaccttcccaagaaggctgccaagacctcacccaggagc agagagatcagctgagggcagagatcagcatcatcaaaggcagataccggagccaaagtggagaggatgaatccc ttaaccagcctggaccaatcaaaaccacttttgctattagccaggcacatttaatgactgcacttgcccacacaa gaccgtctattagtgaagatgaagggaaggaatttgctgagctgtatgagaactttcaaaatccaaagaagagaa aaaatcaaagtggaacagtgtttcgaactggacagaaagtaactttagcataaaatacacttctgattttctaga tgtgtttgttttaatggtctgtccctaagttgtaactataaaaatgatgtaaaaattttttaatttaataaattt ggttaatctataaaatcacagactggaaagtgctgtgattctgctcaggactacctgagattaacagtgcaggct aaaggaagtgatttgtaacagatcgtttattttattcccaagtctgtattaaatccttaatgatattacgtcaat ggtggacctcatttgttttcttttagaggcactcacagacccagagtcactgattttctggcttttggcagattg tatgccttgtaacttcttgattgttttgggaaaagatacattctattatcgtc (SEQ ID NO: 129)Mouse PEX1-P. G844D (c.2531G> A) variant amino acid sequenceNCBI Reference Sequence: NP_001280735. 1:p. Gly844Asp. peroxisomal ATPase PEX1 isoform 1 [Mus musculus].MWSSDRLAGAGSGGAWTVAFTNARDCFLHLPRRLVAQLHLLQNQAIEVASDHQPTYLSWVEGRHFNDQSENVAE INRQVGQKLGLSSGDQVFLRPCSHWSCQQVEVEPLSADDWEILELHAISLEQHLLDQIRIVFPKAWPIWVDQQ TYIFIQIVTLMPAAP YGRLETNTKLLIQPKTRQAKESTFPKEGDAHGQVHS YGREQKGLSKELQTRQLHTNSEGI TASNGRDPKVPGGPLKPSWWAVLGSMLSFGPDSKQESAWGSLELGAFKNMQSQAAPLEGTFRVCQVQPPSARTTT ATSVFHKHCTAHVFPWDQEYFDVEPSFTVTYGKLVKLHSPKQQQDKSKQGVLLPDKEKQLSKSPDHKQISSNRSE EAAEACVLKWWNGLEELKNATEFTESLELLHRGKVWIPDDLRKRLNIEMHAWRITPLETTPKIPRSLKLQPRE NLPKDVNEETIKTVFSSWVQQSATTMLPLVISKEERIKLEIKDGLREFSLSTVHSQEKEKEEGKTVFVLSSILLQ KISVQVLLEPMIKEEQSAEIDFLLPSLTLSSLGGVSALGASAMEHITHSLLGRPLSRQLMALVAGLRNGALLITG GKGSGKSTFAKAICKEAQDTLDARVETVDCKALRGKRLESIQKALEVAFSEAAWRQPSVILLDDLDLIAGLPSVP EQEHSPEAVQSQRLAHALNDMIKEFVSTGSLVALIATSQLQQSLHPSLVSAQGIHTFQCVQHLQPPNPEQRCEIL134 / 149B1195.70208WO00#15198909v2HS WKNKLGCDI SNFPDLDLQCIAKDTEAFVARDFTVLVD RATHS SLSRQHSSSREDLTLTTSDFQKALRGFLPA SLRNVNLHKPRDLGWDKIDGLHEVRQILMDTIQLPAKYPELFANLPIRQRTGILLYGPPGTGKTLLAGWARESG MNFISIKGPELLSKYIGASEQAVRDVFIRAQAAKPCILFFDEFESIAPRRGHDNTGVTDRWNQLLTQLDGVEGL QGVYVLAATSRPDLIDPALLRPGRLDKCVYCPPPDQVSRLEILTVLSKSLALADDVDLQHVASVTDSFTGADLKA LLYNAQLEALQGRLLPSGLPDGGSSSDSDLSLSSMVFLNHSSGSDDSAGDGECGLEQSLLSLEMSEILPDESKFN MYRLYFGSSYESELGNGTPSDLSSHCLSAPSSVTQDLPAAPGKDPLFTQHPVFRTPSQEGCQDLTQEQRDQLRAE ISIIKGRYRSQSGEDESLNQPGPIKTTFAISQAHLMTALAHTRPSISEDEGKEFAELYENFQNPKKRKNQSGTVF RTGQKVTLA (SEQ ID NO: 126)Mouse PEX1-P. G844D (c.2531G> A) variant nucleotide sequenceNCBI Reference Sequence: NM_001293806. 1.:p. Gly844Asp Mus musculus peroxisomal biogenesis factor 1 (Pexl ), transcript variant 1, mRNA. ctggatgccatcttgccggctctagtcccccgcgccagaacaacatccgccagccgcgctcctctgagtccaata agagagcaggatggaccaggcgtgctaggattggctgaaggatcgaccccatcgacgatcatctcctgagagcga gaattcgacgagcgacgtgccgccccctagagcttcggaggtggcccgagggtgacagcggccgggcgtgggaag aggggggcgggcctgatcgatgttctcgggttccgacgctctcacctgacgagaagccggtggactccgctctcc ggtgagagttgaaccttgggacaatgtggagcagcgatcgcttagcgggtgcggggtctggtggggcggtcgtga cggtggccttcacgaatgctcgggactgcttcctgcatctgccgcggcgcctcgtggcccagcttcacctgctgc agaatcaagctatagaagtggccagcgatcaccagcctacctacctgagctgggtggaaggcaggcattttaatg atcaaagtgaaaatgtggcagaaattaatagacaagttggccagaaacttggactctcaagcggagatcaggtgt ttctcaggccttgttcccatgtggtatcttgccaacaggttgaagtggagcctctctcagcagatgactgggaaa tactggagctgcacgccatttcccttgaacagcatcttctggatcagattcgaatagttttccccaaagctgttg ttcccatctgggttgaccagcagacctacatatttatccagatcgtcactctgatgccagctgccccttatggaa ggctagaaactaacaccaaactccttattcagccaaagacacgccaagccaaagagagcacatttccaaaagaag gagatgcacacggacaagttcatagttatgggcgagaacagaaaggattgtcaaaggaattacaaaccaggcagc ttcatacgaactcagagggtatcactgcatccaatggaagagacccaaaagtcccaggtggcccgttgaagccaa gctggtgggctgtgctcggaagcatgctttcctttgggcctgacagtaaacaggagtcagcctggggctcgttgg aactcggtgctttcaaaaacatgcagtcacaggctgcccctctggaaggtactttcagagtatgccaagtccagc cacctagtgcgcgtaccaccaccgctacctctgtgtttcacaaacactgcaccgcccacgtatttccttgggacc aagaatactttgatgtggagcccagctttactgtgacctatggaaaactagttaagctacattctccaaaacaac agcaagacaaaagtaagcagggtgtcctgttgcctgacaaagagaagcagctgtccaagtctccagatcataagc agatcagctccaaccgcagtgaggaggctgctgaggcctgtgtgctgaaggtagtctggaatggactcgaggagt tgaagaatgccacagagttcaccgaaagtctagagcttctccaccgtgggaaagtctggattccagatgacctga gaaagagactaaatatagaaatgcatgcagtagtcagaataactccactggaaaccacgcctaaaatcccaagat ctctgaaattacaacctagagagaacttacctaaagacgtcaatgaagaaactataaaaacagtgttctcatctt gggtacagcagtccgctaccacgatgcttcctttggtaatatcaaaggaagagcgtattaagctggaaattaaag atgggctgagagagttctctctgagtacagttcattctcaggaaaaagaaaaggaagaaggaaaaactgtgtttg tgttgagttccatcctgctgcagaagatctcagtacaagtccttctagagcccatgataaaagaagaacagagtg cggaaatcgactttcttcttccctctttaacgctgagctctttggggggagtgagtgccttaggtgcatctgcaa tggagcacatcactcacagtctcctgggacgcccgttgtctaggcagctgatggccctcgttgcaggacttagga atggcgctcttttgatcactggaggaaagggaagcgggaagtcaacattcgcgaaagccatctgcaaggaagcac aggacactctggatgcccgtgtggagacagtcgactgcaaggctttacgaggaaaaaggcttgaaagcatacaaa aagcgctagaggtggctttctcagaggccgcctggaggcagccatctgtcattctgctggatgacctggacctca ttgccggactgccaagtgtccccgagcaggagcacagccctgaagcggtgcagagccagcggcttgcacatgctt tgaacgatatgatcaaagagtttgtttccacgggaagcttggtggcactcatcgccacgagccagctccagcagt ctctgcacccttcccttgtgtctgctcaaggaatccacacgtttcaatgtgtccagcaccttcagcctcccaatc cggaacagagatgtgaaattctgcacagtgttgtgaagaataaactgggctgtgatataagcaatttccctgact tggacctgcagtgcatagctaaagacacagaagcgtttgtggctcgtgactttacagttcttgtggaccgagcca tacactcttctctctctcgccagcatagctcctctagggaagacttgactttaacaacatcagacttccaaaagg ctctccgtggattccttcctgcttctctgcgaaatgtcaacttgcataaacctagagacctgggctgggacaaga ttgatggattacatgaagttcggcagatcctcatggatactatccagttaccagccaagtacccagaattatttg caaacttacccatacgacagaggacaggaatactgctttatggtcctccagggacaggaaaaactttacttgctg gggtagttgcaagagagagtggaatgaattttattagtattaagggaccagagttactcagcaaatatattggcg caagtgagcaagctgttcgagatgttttcatcagagcacaggctgcaaagccctgcattcttttctttgatgagt ttgagtccatcgctcctcgaagaggccatgacaacacaggggttacagaccgagtagtcaaccagttgctgacac agttagacggagtagaaggcttacagggagtttatgtgctggctgctactagtcgccctgacttgatcgaccctg ccctgttgcggcctggcagactggataaatgtgtatactgccctcctccagatcaggtgtcccgtcttgagattt taactgtcctcagcaagtctctagctctggcagatgacgtggaccttcagcacgtggcgtcggtcaccgactcgt tcactggagcggatctgaaagctctgctgtacaacgctcagctggaggccttgcagggacggctgctgcccagtg ggcttcccgatggaggctccagctctgacagtgacctgagtctgtcttcaatggtctttcttaaccacagcagtg 135 / 149B1195.70208WO00#15198909v2gttccgacgactccgctggagatggagaatgtggcttagagcaatccctgctttctctcgagatgtctgagatcc ttccagacgaatcaaaattcaatatgtaccggctctactttggaagctcgtatgaatcggagcttggaaatggga ccccttctgacttgagctcacactgtctgtctgcaccaagctccgtgactcaggatttacctgcagctcctggga aagacccgttatttacacaacatcctgtgttcaggacaccttcccaagaaggctgccaagacctcacccaggagc agagagatcagctgagggcagagatcagcatcatcaaaggcagataccggagccaaagtggagaggatgaatccc ttaaccagcctggaccaatcaaaaccacttttgctattagccaggcacatttaatgactgcacttgcccacacaa gaccgtctattagtgaagatgaagggaaggaatttgctgagctgtatgagaactttcaaaatccaaagaagagaa aaaatcaaagtggaacagtgtttcgaactggacagaaagtaactttagcataaaatacacttctgattttctaga tgtgtttgttttaatggtctgtccctaagttgtaactataaaaatgatgtaaaaattttttaatttaataaattt ggttaatctataaaatcacagactggaaagtgctgtgattctgctcaggactacctgagattaacagtgcaggct aaaggaagtgatttgtaacagatcgtttattttattcccaagtctgtattaaatccttaatgatattacgtcaat ggtggacctcatttgttttcttttagaggcactcacagacccagagtcactgattttctggcttttggcagattg tatgccttgtaacttcttgattgttttgggaaaagatacattctattatcgtc (SEQ ID NO: 130 ) Human sequence targeting guide5' -GTTGATGGGTTACATGAAGTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGG CACCGAGTCGGTGCTTTTTT-3' (SEQ ID NO: 131 )Mouse sequence targeting guide5' -GTGATGGATTACATGAAGTTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGC ACCGAGTCGGTGCTTTTTTT-3' (SEQ ID NO: 132)Split AAV9 constructNpu-N imei.n TGCCTGTCCTACGAGACAGAGATCCTGACAGTGGAGTATGGCCTGCTGCCAATCGGCAAGATCGTGGAGAAGAGGATCGAGTG TACCGTGTACTCTGTGGATAACAATGGCAACATCTATACACAGCCCGTGGCACAGTGGCACGATAGGGGAGAGCAGGAGGTGT TCGAGTATTGCCTGGAGGACGGCAGCCTGATCAGGGCAACCAAGGACCACAAGTTCATGACAGTGGATGGCCAGATGCTGCCC ATCGACGAGATTTTCGAGCGGGAGCTGGACCTGATGAGAGTGGATAACCTGCCTAAT (SEQ ID NO: 133) Npu-C imei.n ATCAAGATTGCTACACGGAAATACCTGGGAAAGCAGAACGTGTACGACATCGGCGTGGAGCGGGATCACAACTTCGCCCTGAA GAATGGCTTTATCGCCAGCAAT (SEQ ID NO: 134 )N-terminus AAV9 constructKEY:S' ITRCbh promoterABE8e-V106WSpCas9-CNpu-N3' ITRU6-sgRNA ctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctt ggt.cgcccggcctca gtgagcgagagagcgagaagagagggagtggaaaaat ccaticiad s. aggggt*Lcc!jtg(:: g g c c t c t a g a t c a g g g t a cc:gttacataacttacggtaaatxggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaatagta a cgccaa t a ggga c t t tccattgacgtcaatgggt gga gtattta c ggtaaactgcccacttggcagt a c at caa gt gt at cat a gccaagt a cgcccccta 11 ga cg caat ga cggtaaa t ggcccgcctggca ttgt gccca gt a c a tgacctt a t ggga ctttcctactt ggcagt a ca tcta cgt att agt ca t cgcta tta cca t ggt cgaggt gag c c cac gt t ct get tcactctccc at ct c c c c cccctccccacccccaat t t t gt atttat t t a ttttttaatt a ttttgtgcagcgatgggggcggggggggggggggggcgcgcgccaggcggggcggggcggggcgaggggcggggc ggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgc ccgaaagtttccttt tatggcgaggcgg136 / 149B1195.70208WO00#15198909v2cggcggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgacgctgccttcgccccgtgcc ccgctccgccgccgcctcgcgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcgggcggga cggcccttctcctccgggctgtaattagctgagcaagaggtaagggtttaagggatggttggttggtggggtatt aa tgtttaat tacctggagcacctgcctgaaatcactttttt t caggttggaocggtgccaccatgaaacggaca gccgacggaagcgagttcgagtcaccaaagaagaagcggaaagtctctgagg ggagttttcccacgagtactgg- a t ga ga ca t gacct ga ccct ggccaa ga gggca. cggga t ga. ga ggga ggt gaat. gfc ggga gccgt gat ggt get CO* fi CAt x* x4 <9 x C3t xTJ'C! x xX X* x X*x < F x* x A Z xTxZ*YfY^ w^ x* Z MY 9 <9 Cw- fJY CA? ZYX *r*’< X*X’« iA^ x f X*^xZ XxYfZYFZ X^*Z x'*’^ **x’ *A C3 f w^Z OYFzC^A **’<*X,Z *x** K^A» C3 w < Z xrfY x**’<*X,Z X**^X» f <" ZY'Z O^*Z X^ xT^AIA »A < X* xX Z OYfZ X^*’ X*’**x’^ xx' xx Ciy fYtx% Zx^*x C^ ZxZTZ O*Yf4 *O**fYZ OYFZ x^' X*’^ X' r xC X* xvxiAXJ C3CA O* X* C X 1A C3 X * ZTX CSf X xx xx C3 i X^,Z OYFZ X^' X*’x CA9 Xx x X Z OYF^ X*x C^f X ^A Xx Z XxY* C< A^ O*CA x>> X Z X*x*Z x*xY^ C3> ZYZ O^*Z X^'^ x-’ tgagt a gtgagaaggagaaa ga aaaa a aggataggaagag gg gtttggatggagaaat ataaaaga ggcgca a ggctaaatg t aaagtgct aact ccaagga t aatcacc a tcg a ttacaga a tc ct ggca ga t gaa t gt gccgccct get gt gega 111 ct a t agga t gcat a ga ca ggt gt t caa t get ca gaa gaa g gcccagagrctccatcaactctggaggatctagcggaggatcctctggcagcgagacaccaggaacaagcgagtca g c a aca c c a g a g a g c a g t gg c g c a g c a g c gg c g g c a g cgacaagaagtacagcatcggcctggccatcggcacc aactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaacacc gac.cggcac gcatcaagaagaacctgatcggagc.cctgctgttcgacagc.ggcgaaac.agccgaggccacccgg c t g a a g a g a a c c g c c a g a a g a a g a t a c a c c a g a c g g a a g a a c c g g a t c t g c t a t c t g c a a g a g a t c 11 c a g c a a c gagatggccaaggtggacgacagcttcttccacagactggaagagtccttcctggtggaagaggataagaagcac gagcggcaccccatcttcggcaacatcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacctg agaaagaaactggtggacagcaccgacaaggccgacctgcggctgatctatctggccctggcccacatgatcaag ttccggggccacttc.ctga cgagggcgacc.tgaaccccgacaacagcgacgtggacaagctgttca ccagctg gtgcagacctacaaccagctgttcgaggaaaaccccat caacgccagcggcgtggacgccaaggccatcctgtct gccagactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttc gg a aac c t g a 11 g c c. c t g a g c c t ggg c c t g c c c cca a c.11 c a a g a g c a a c 11 c g a c c t gg c c. g a gga t g c. c a a a ctgcagctgagcaaggacacctacgacgacgacctggacaacctgctggcccagatcggcgaccagtacgccgac ctgtttctggc.cgccaagaacctgtcc.gacgccatcctgctgagcgacatc.ctgagagtgaacaccgagatcacc aaggcccccctgagcgcctctatgat caagagat acgacgagcaccaccaggacctgaccctgctgaaagctct c g t g c gg c a g c a g c t g c c t g a g a a gt a c. a a a g a g a 1111 c 11 c g a c c a g a g c. a a g a a c g c t a c g c c gg c t a c a 11 gacggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaa ctgctcgtgaagctgaacagagaggacctgctgcggaagcagcggacct tcgacaacggcagcatcccccaccag atccacc.tgggagagctgcacgccattctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaa aagat cgagaagat cctgaccttccgcat cccctact acgtgggccctct gccaggggaaacagcagattcgcc tggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggtggacaagggcgcttccgcc c a g a g c 11 c a t c g a g c gg a t g a c. c a a c 11 c g a t a a g a a c. c t g c c c a a c g a g a a g. g c t g c c c. a a g c a c a g c c t g ctgtacgagtact tcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgcc ttc.ctgagcggcgagcagaaaaaggcc.atcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcag ctgaaagaggactactt caagaaaat cga.gtgcctgtcctacgagacagagatcctgacagtggagtatggcctg ctgccaatcggcaagatcgtggagaagaggatcgagtgtaccgtgtactctgtggataacaatggcaacatctat acacagcccgtggcacagtggcacgataggggagagcaggaggtgttcgagtattgcctggaggacggcagcctg atcagggcaaccaaggaccacaagttcatga cagtgga tggccaga tgctgcccatcgacgagattttcgagcgg gagctggacctgatgagagtggataacctgcctaatagcggaggcagtaaaagaacagcagacgggagtgagttt gagcccaagaaaaagagaaaggtgt aagat ctgat atcaacctctggattacaaaatttgtgaaagattgactg gtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgctt cccgtatggctttcattttctcctccttgtataaatcctggttagttcttgccacggcggaactcatcgccgcct gccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgcgactgtgccttctagttg ccagcca ctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccact cccactgt cctttcct a at aaaatgaggaaattgcatcgcattgtctgagt aggtgtcattctatt ctggggggtggggtggggcaggacag caagggggaggattgggaagacaatagcaggcatgctggggatgcggtgggctctatggctcgagaaaaaaagga X- AA Xx X Xx ' OF X* n XX *x XV Xx * x* > X Xr* X CA W X X* n C Xx X C w OF xfl C X Xx *A Xx t* <x* - X- CA r*. X * CA CA C* r*. x Xx C x* >> C* X < X C O' O* X* X C* C xC C CA O* CA W cttcatgtaatccatcacggtgtttcgtcctttccacaagatafcataaagccaagaaatcgaaatacfcttcaagt tacggtaagcatatgatagtccattttaaaacataattttaaaactgcaaactacccaagaaattatfcactttct acgtoacg^at ttij actaa atctttgtgtttacagtcaaatt aattctaattatctct ctaacagccttgta tcgtatatgcaaatatgaaggaatcatgggaaataggccctcttcctgcccgaccttgcggccgcagga ccgct CA *AvJ" Mrls CaA f X"" rylfysAi CAvJ O" + O• X. Jm XJr X** X** A \x O r*r*r ***i** * M X Mrl **nM*r **f x <*W’t Xx’ c,*Mr1 **i O" r x**f z X**’*t’ Cn’». C3* X***i" r VyIa CSC z XYXzycn,»r Xn*»r\r4m X-*rr VYI *^w*z XYX^ n» w C-X CA r Va4rr XXrt X*’w cx,» r***r Vw* X**f XY^ XX f Xr’WcXr? J cccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagc cttaattaacctaattcactggccgtcgt tttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatccccctttc ccag c ggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgc gccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccct a g c g c c c g c t c c 111 c g c 111 c 11 c c c 11 c c 111 c t c gccac g 11 c g c c g c 111 c c c c g t c a a g c t c t a a a t c g ggggctccctttagggt tccgatttagtgctttacggcacctcgaccccaaaaaact tgattagggtgatggt tc acg gtgggcc tcgccc g tagacggtttttcgccctttgacgttggagtccacgt ctttaatagtggact cttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttc 137 / 149B1195.70208WO00#15198909v2ggcct attggttaaaaaatgagctgattt aacaaaaatttaacgcgaattttaacaaa tattaacgttt ataat ttcaggtggcatctttcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgta t c c g c t c t g a g a c a a t a a c c c t g t a a a t g c 11 c a a t a a t a t 1 g a a a a a gg a a g a g t a t g a g t a t tea a c a 111 ccgtgtcgcccttattccctt ttttgcggcattttgccttcctgt ttttgctcacccagaaacgctggtgaaagt aaaagatgctgaagatcagttgggtgcacgagtgggtt c tcgaactggatctc acagcggt agatccttga gagttttcgccccgaagaacgtttt ccaatgat agcacttttaaagtt ctgctatgtggcgcggt attatcccg tattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagt c a c a g a a a a g c a t c 11 a c gg a t gg c a t g a c a gt a a g a g a a 11 a t g c a gt g c t g cca t a a c c a t g a g t g t a a c a c tgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatca tgt actcgccttgatcgttgggaaccggagctgaatgaagcc taccaaacgacgagcgtgacacc cgatgcc tgtagt aat ggt aacaacgtt cgcaaact att aact gcgaact act tact ctagcttcccggcaacaattaat agactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctga taaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtat cgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctc actgatt agcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaacttcattttta atttaaaaggatctaggtgaagatcctttttgat aatctcatgaccaaaatcccttaacgtgagttttcgttcca ctgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgctt gcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggt aactggcttcagcagagcgcagataccaaatactgtccttctagtgtagccgtagttaggccaccacttcaagaa ctctgt gcaccgcctacat cct eget etget aat cctgtt ccagtggctgctgccagtggcgat agtcgtg tcttaccgggttggactcaagacgatagtt ccggat aaggcgcagcggtcgggctgaacggggggttcgtgcac a c a g c c c a g c 11 gg a g c g a a c g a c c t a c a c c g a a c t g a g a t a c c t a c a g c g t g a g c t a t g a g a a a g c g c c a c g c t tcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttcc agggggaaacgcctggtatct ttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatg ctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctgcgg ttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgcctttgagtgagctga t a c c g c t c g c c g c a g c c g a a c g a c c g a g c g c a g c g a g t c a g t g a g c g a g g a a g c g g a a g a g c g c c c a a t a c g c a a accgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaagcgggcag tgagcgcaacgcaattaatgtgagt tagctcactcattaggcaccccaggctttacactttatgcttccggctcg tatgttgtgtggaattgtgagcggat acaatttcacacaggaaac gct tgaccatgattacgccagatttaa ttaagg (SEQ ID NO: 135 )C-terminus A4 V9 constructKEY:5’ITRCbh promoterNpu-CSpCas9-C3' ITRU6-sgRNA ct.gagcgctcgatcgctcaatgaggcagcccgggaaaagcccgggcgtcgggcgacct.t.tggt.cgcaaggcctca gtgagcg gcgagcgcsgciciL a a g ciL z. gcsc2cLciLCi z.c! C! 'tLC!ciLCi z.ag g 't.‘Lcc!jtc](:: g g c c t c t. a g a t c a g g g t a cccgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgt caatagta a cgccaa t a ggga c t t tccattgacgtcaatgggt gga gtattta c ggtaaactgcccacttggcagt a c at caa gt gt at cat a gccaagt a cgcccccta 11 ga cg caat ga cggtaaa t ggcccgcctggca ttgt gccca gt a c a tgacctt a t ggga ctttcctactt ggcagt a ca tcta cgt att agt ca t cgcta tta cca t ggt cgaggt gag c c cac gt t ct get tcactctccc at ct c c c c cccctccccacccccaat t t t gt att tat t t a ttttttaatt a ttttgtgcagcgatgggggcggggggggggggggggcgcgcgccaggcggggcggggcggggcgaggggcggggc ggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgct ccgaaagtttccttt tatggegaggegg cggcggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgacgctgccttcgccccgtgcc ccgct ccgccgccgcct cgcgccgcccgccccggct etga ctgaccgcgt t act ceca caggt gagcgggcggga cggcccttctcctccgggctgtaattagctgagcaagaggtaagggtttaagggatggttggttggtggggtatt aatgtttaat tacctggagcacctgcctgaaatcactttttt t caggttggaccggtgccaccatgaaacggaca g c c g a c gg a a g c g a g 11 c g a g c a c c a a a g a a g a a g c gg a a a g t catcaagattgctacacggaaatac c tggga aagcagaacgtgtacgacatcggcgtggagcgggatcacaac tcgccctgaagaatggctttatcgccagcaat t cttcgact ccgtggaaatctccggcgtggaagatcggtt caacgcct ccctgggcacataccacgatctgctg138 / 149B1195.70208WO00#15198909v2139 / 149B1195.70208WO00#15198909v2ttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccat accaaa cgacgagcgtgacaccacgatgcctgtagtaatggtaacaacgttgcgcaaactattaactggcgaactacttac tctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggccct tccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggg gccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaat g acagatcgctgagataggtgcctcactgattaagcattggt aact gtcagaccaagtt tact cat at at act tt a g a 11 g a 111 a a a a c 11 c a 11111 a a 111 a a a a gg a t c t a gg t g a a g a t c c 11111 g a t a a t c tea t g a c c a a a a t cccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatccttt t tttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggt ttgtttgccggatcaaga gctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagcc gtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggc tgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtc gggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcg tgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaac aggagagcgcacgagggagcttccagggggaaacgcctggt tctttat gtcctgtcgggtttcgccacctctg acttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggccttttt acggttcctggccttttgctgcggttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccg t a 11 a c c g c c 111 g a g t g a g c t g a t a c c g c t c g c c g c a g c c g a a c g a c c g a g c g c a g c g a g t c a g t g a g c g a g g a agcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacag gtttcccgactggaaagcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggc tttacactttatgcttccggctcgtatgttgtgtggaattgtgagcggataacaatttcacacaggaaacagcta tgaccatgattacgccagatttaattaagg (SEQ ID NO: 136 )EQUIVALENTS AND SCOPE

[0228] In the articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Embodiments or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

[0229] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claims that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is / are referred to as comprising particular elements and / or features, certain embodiments of the disclosure or aspects of the disclosure consist, or consist essentially of, such elements and / or features. For purposes of simplicity, those140 / 149B1195.70208WO00#15198909v2embodiments have not been specifically set forth in haec verba herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[0230] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the embodiments. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any embodiment, for any reason, whether or not related to the existence of prior art.

[0231] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended embodiments. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following embodiments.141 / 149B1195.70208WO00#15198909v2

Claims

CLAIMSWhat is claimed is:

1. A method of correcting a PPX / -G843D (c.2528G> A) mutant allele in a PEX1 gene comprising contacting the PPX / -G843D (c.2528G> A) mutant allele with an adenine base editor and a gRNA targeting the adenine base editor to the PEX7-G843D (c.2528G> A) mutant allele, thereby converting an A T base pair to a G-C base pair to produce a corrected PEX1 allele, wherein the adenine base editor is ABE7.10, ABE8e, or ABE8e-V106W and the gRNA comprises a spacer sequence of 5’-GUUGAUGGGUUACAUGAAGUU-3’ (SEQ ID NO: 114).

2. The method of claim 1, wherein the human PEX1 gene comprises the nucleotide sequence of SEQ ID NO: 127.

3. The method of claim 1 or 2, wherein the human PEX1 gene encodes an amino acid sequence of SEQ ID NO: 123.

4. The method of any one of claims 1-3, wherein the PEX7-G843D (c.2528G> A) mutant allele comprises a nucleotide sequence of SEQ ID NO: 128.

5. The method of any one of claims 1-4, wherein the PEX7-G843D (c.2528G> A) mutant allele encodes the PPX / -G843D variant comprising an amino acid sequence of SEQ ID NO: 124.

6. The method of any one of claims 1-5, wherein the adenine base editor is ABE7.0 comprising the sequence of SEQ ID NO: 108.

7. The method of any one of claims 1-5, wherein the adenine base editor is ABE8e comprising the sequence of SEQ ID NO: 101.

8. The method of any one of claims 1-5, wherein the adenine base editor is ABE8e-V106W comprising the sequence of SEQ ID NO: 102.142 / 149B1195.70208WO00#15198909v29. The method of any one of claims 1-8, wherein the adenine base editor is a split adenine base editor comprising an N-terminal portion and a C-terminal portion.

10. The method of claim 9, wherein the N-terminal portion comprises an N-intein.

11. The method of claim 9, wherein the C-terminal portion comprises a C-intein.

12. The method of claim 9, wherein the split adenine base editor is a split ABE7.10.

13. The method of claim 9, wherein the split adenine base editor is a split ABE8e.

14. The method of claim 9, wherein the split adenine base editor is a split ABE8e- V106W.

15. The method of claim 10, wherein the N-intein comprises a nucleotide sequence of SEQ ID NO: 133.

16. The method of claim 11, wherein the C-intein comprises a nucleotide sequence of SEQ ID NO: 134.

17. The method of any one of claims 1-16, wherein the adenine base editor and the gRNA are encoded on one or more polynucleotides.

18. The method of claim 17, wherein the one or more polynucleotides are delivered in one or more delivery systems.

19. The method of claim 18, wherein the delivery system is a viral vector or a non-viral vector.

20. The method of claim 19, wherein the viral vector is an AAV vector or lenti virus vector.143 / 149B1195.70208WO00#15198909v221. The method of claim 19, wherein the non-viral vector is a virus-like particle (VLP).

22. The method of claim 19, wherein the non-viral vector is a nanoparticle.

23. The method of claim 22, wherein the nanoparticle is a lipid nanoparticle (LNP), polymeric nanoparticle, inorganic nanoparticle, liposome, or a nano structured lipid carrier.

24. The method of any one of claims 1-23, wherein the method results in the treatment of Zellweger spectrum disorder or at least one symptom or condition associated with a PEX1 mutant allele in a subject.

25. The method of claim 24, wherein the at least one symptom or condition associated with the PEX1 mutant allele comprises a liver abnormality, intellectual disability, peroxisome dysfunction, vision loss, hearing loss, toxic bile acid intermediate accumulation, and / or increased body weight.

26. The method of any one of claims 1-25, wherein the method results in correction of at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% of the PEX1 mutant allele.

27. The method of any one of claims 1-26, wherein the step of contacting is performed in a cell.

28. The method of any one of claims 1-27, wherein the step of contacting is performed ex vivo in a cell.

29. The method of any one of claims 1-27, wherein the step of contacting is performed in vivo in a subject.

30. The method of claim 29, wherein the subject is a human.

31. A complex for correcting a PEX7-G843D (c.2528G> A) mutant allele in a PEX1 gene, said complex comprising an adenine base editor and a gRNA targeting the adenine base144 / 149B1195.70208WO00#15198909v2editor to the PPX / -G843D (c.2528G> A) mutant allele, wherein the adenine base editor is ABE7.10, ABE8e, or ABE8e-V106W and the gRNA comprises a spacer sequence of 5’-GUUGAUGGGUUACAUGAAGUU-3’ (SEQ ID NO: 114).

32. The complex of claim 31, wherein the complex is capable of converting an A T base pair to a G C base pair in the PEX7-G843D (c.2528G> A) mutant allele to produce a corrected PEX1 allele.

33. The complex of claim 31, wherein the adenine base editor is ABE7.10.

34. The complex of claim 31, wherein the adenine base editor is ABE8e.

35. The complex of claim 31, wherein the adenine base editor is ABE8e-V106W.

36. The complex of claim 31, wherein the adenine base editor is a split adenine base editor comprising an N-terminal portion and a C-terminal protein.

37. The complex of claim 36, wherein the N-terminal portion comprises an N-intein, and the C-terminal portion comprises a C-intein.

38. The complex of claim 36, wherein the split adenine base editor is a split ABE7.10.

39. The complex of claim 36, wherein the split adenine base editor is a split ABE8e.

40. The complex of claim 36, wherein the split adenine base editor is a split ABE8e-V106W.

41. The complex of claim 37, wherein the N-intein is encoded by a nucleotide sequence of SEQ ID NO: 133.

42. The complex of claim 37, wherein the C-intein is encoded by a nucleotide sequence of SEQ ID NO: 134.145 / 149B1195.70208WO00#15198909v243. The complex of any one of claims 31-42, wherein the adenine base editor and the gRNA are encoded on one or more polynucleotides.

44. The complex of claim 43, wherein the one or more polynucleotides are delivered in one or more delivery systems.

45. The complex of claim 44, wherein the delivery system is a viral vector or a non- viral vector.

46. The complex of claim 45, wherein the viral vector is an AAV vector or lentivirus vector.

47. The complex of claim 45, wherein the non- viral vector is a virus-like particle (VLP).

48. The complex of claim 45, wherein the non- viral vector is a nanoparticle.

49. The complex of claim 48, wherein the nanoparticle is a lipid nanoparticle (LNP), polymeric nanoparticle, inorganic nanoparticle, liposome, or a nano structured lipid carrier.

50. The complex of any one of claims 31-49, wherein administration of the complex results in the treatment of Zellweger spectrum disorder or at least one symptom or condition associated with a PEX1 mutant allele in a subject.

51. The complex of claim 50, wherein the at least one symptom or condition associated with the PEX1 mutant allele comprises a liver abnormality, intellectual disability, peroxisome dysfunction, vision loss, hearing loss, toxic bile acid intermediate accumulation, and / or increased body weight.

52. A guide RNA (gRNA) comprising a spacer sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the sequence 5’-GUUGAUGGGUUACAUGAAGUU-3’ (SEQ ID NO: 114) or a spacer sequence comprising one, two, three, four, or five nucleotide substitutions relative to the sequence 5 ’-GUUGAUGGGUUACAUGAAGUU-3’ (SEQ ID NO: 114).146 / 149B1195.70208WO00#15198909v253. A polynucleotide encoding the gRNA of claim 52.

54. One or more polynucleotides encoding the complex of any one of claims 31-51.

55. A vector comprising the polynucleotide of claim 53 or the one or more polynucleotides of claim 54.

56. One or more delivery vehicles comprising the polynucleotide of claim 53, the one or more polynucleotides of claim 54, or the vector of claim 55.

57. The one more delivery vehicles of claim 56, wherein the one of more delivery vehicles comprise one or more AAVs comprising the polynucleotide of claim 54, and wherein the adenine base editor of the complex of any one of claims 31-51 is a split adenine base editor.

58. A pharmaceutical composition comprising the complex of any one of claims 31-51, the gRNA of claim 52, the polynucleotide of claim 53, the one or more polynucleotides of claim 54, the vector of claim 55, or the one or more delivery vehicles of claims 56-57, or any combinations thereof, and at least one pharmaceutically acceptable excipient.

59. A cell comprising the complex of any one of claims 31-51, the gRNA of claim 52, the polynucleotide of claim 53, the one or more polynucleotides of claim 54, the vector of claim 55, or the one or more delivery vehicles of claims 56-57, or any combinations thereof, and at least one pharmaceutically acceptable excipient.

60. A kit comprising the complex of any one of claims 31-51, the gRNA of claim 52, the polynucleotide of claim 53, the one or more polynucleotides of claim 54, the vector of claim 55, or the one or more delivery vehicles of claims 56-57, or any combinations thereof.

61. Use of the complex of any one of claims 31-51, the gRNA of claim 52, the polynucleotide of claim 53, the one or more polynucleotides of claim 54, the vector of claim 55, or the one or more delivery vehicles of claims 56-57, or any combinations thereof, in the147 / 149B1195.70208WO00#15198909v2manufacture of a medicament for the treatment of Zellweger spectrum disorder or at least one symptom or condition associated with a PEX1 mutant allele in a subject.

62. The use of claim 61, wherein the at least one symptom or condition associated with the PEX1 mutant allele comprises a liver abnormality, intellectual disability, vision loss, and / or hearing loss.

63. The use of claim 61, wherein the at least one symptom or condition associated with the PEX1 mutant allele comprises peroxisome dysfunction, toxic bile acid intermediate accumulation, liver pathology, and / or increased body weight.

64. The complex of any one of claims 31-51, the gRNA of claim 52, the polynucleotide of claim 53, the one or more polynucleotides of claim 54, the vector of claim 55, or the one or more delivery vehicles of claims 56-57, or any combinations thereof, for use in the treatment of Zellweger spectrum disorder or at least one symptom or condition associated with a PEX1 mutant allele in a subject.

65. The complex of claim 64, wherein the at least one symptom or condition associated with the PEX1 mutant allele comprises a liver abnormality, intellectual disability, vision loss, and / or hearing loss.

66. The complex of claim 64, wherein the at least one symptom or condition associated with the PEX1 mutant allele comprises peroxisome dysfunction, toxic bile acid intermediate accumulation, liver pathology, and / or increased body weight.148 / 149B1195.70208WO00#15198909v2